Farnesoid X receptor antagonists

ABSTRACT

Provided herein are Famesoid X receptor (FXR) antagonists having the structure of formula (I), and pharmaceutical compositions comprising the compound of formula (I) and a pharmaceutically acceptable excipient. Also provided are methods of antagonizing FXR, and methods of treating metabolic disease in a subject in need thereof, comprising administering an effective amount of the FXR antagonists of formula (I) to a subject.

CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a division application of U.S. patent applicationSer. No. 15/214,282, filed Jul. 19, 2016, which is a continuationapplication of PCT Application No. PCT/US2015/013596, filed Jan. 29,2015, which claims the benefit of U.S. Provisional Patent ApplicationNo. 61/933,095, filed Jan. 29, 2014, all of which are incorporatedherein by reference in their entireties and for all purposes.

BACKGROUND OF THE INVENTION

Famesoid X receptor (FXR, NRIH4),¹ a member of the bile acid nuclearhormone receptor superfamily, is a ligand-dependent transcription factorthat regulates gene networks involved in regulating lipid andcholesterol homeostasis.² FXR is expressed primarily in tissues exposedto high concentrations of bile acids, such as the intestine, kidney,adrenal gland, and liver.³ Consistent with the role of FXR, bile acidsare the primary activating endogenous ligands of FXR.³⁻⁴ As the bileacid sensor, FXR regulates the expression of transporters andbiosynthetic enzymes crucial for the physiological maintenance of bileacid homeostasis.

BRIEF SUMMARY OF THE INVENTION

In a first aspect is a compound of formula (I):

In formula (I), X is —CH₂— or —C(O)— or —CY(OH)—. Y is hydrogen,halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OR^(9A), —NHR^(9A),—COOR^(9A), —CONHR^(9A), —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂,—OCH₃, —NHC(O)NHNH₂, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. L¹ isindependently a bond, —C(O)—, —O—, —S—, —NR^(9B)—, —C(O)NR^(9B)—,—S(O)_(n)—, —S(O)NR^(9B)—, substituted or unsubstituted alkylene,substituted or unsubstituted heteroalkylene, substituted orunsubstituted cycloalkylene, substituted or unsubstitutedheterocycloalkylene, substituted or unsubstituted arylene, orsubstituted or unsubstituted heteroarylene. L² is independently a bond,—C(O)—, —O—, —S—, —NR^(9C)—, —C(O)NR^(9C)—, —S(O)_(n)—, —S(O)NR^(9C)—,substituted or unsubstituted alkylene, substituted or unsubstitutedheteroalkylene, substituted or unsubstituted cycloalkylene, substitutedor unsubstituted heterocycloalkylene, substituted or unsubstitutedarylene, or substituted or unsubstituted heteroarylene. R¹ and R² areindependently substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. R³ ishydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(3A),—NR^(3B)R^(3C), —COOR^(3A), —C(O)NR^(3B)R^(3C), —NO₂, —SR^(3D),—S(O)_(n3)R^(3B), —S(O)_(n3)OR^(3B), —S(O)_(n3)NR^(3B)R^(3C),—NHNR^(3B)R^(3C), —ONR^(3B)R^(3C), —NHC(O)NHNR^(3B)R^(3C), orsubstituted or unsubstituted alkyl. R⁵ is hydrogen or substituted orunsubstituted alkyl. R⁶ is halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN,—CHO, —OR^(6A), —NR^(6B)R^(6C), —COOR^(6A), —CONR^(6B)R^(6C), —NO₂,—SR^(6D), —SO_(n6)R^(6B), —SO_(n6)OR^(6B), —SO_(n6)NR^(6B)R^(6C),—NHNR^(6B)R^(6C), —ONR^(6B)R^(6C), —NHC(O)NHNR^(6B)R^(6C), substitutedor unsubstituted alkyl, or substituted or unsubstituted heteroalkyl. R⁷is independently hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN,—CHO, —OR^(7A), —NR^(7B)R^(7C), —COOR^(7A), —C(O)NR^(7B)R^(7C), —NO₂,—SR^(7D), —S(O)_(n7)R^(7B), —S(O)_(n7)OR^(7B), —S(O)_(n7)NR^(7B)R^(7C),—NHNR^(7B)R^(7C), —ONR^(7B)R^(7D), —NHC(O)NHNR^(7B)R^(7C), substitutedor unsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl. R⁸ is independently hydrogen, halogen, —N₃,—CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(8A), —NR^(8B)R^(8C),—COOR^(8A), —C(O)NR^(8B)R^(8C), —NO₂, —SR^(8D), —S(O)_(n8)R^(8B),—S(O)_(n8)OR^(8B), —S(O)_(n8)NR^(8B)R^(8C), —NHNR^(8B)R^(8C),—ONR^(8B)R^(8C), —NHC(O)NHNR^(8B)R^(8C), substituted or unsubstitutedalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl. R^(9A), R^(9B), R^(9C) are independently hydrogen, halogen,—N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂, —COOH, —CONH₂, —SH,—SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂, substitutedor unsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl. R^(3A), R^(6A), R^(7A), and R^(8A) areindependently hydrogen or unsubstituted alkyl. R^(3B), R^(6B), R^(7B),R^(8B)R^(3C), R^(6C), R^(7C), R^(8C), R^(3D), R^(6D), R^(7D), and R^(8D)are independently hydrogen, substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted aryl, or substituted or unsubstituted heteroaryl. Thesymbol z1 is 1, 2, 3, 4, 5 or 6. The symbol z2 is 1, 2, 3, 4, 5, 6, 7 or8. The symbols n, n3, n6, n7, and n8 are independently 1 or 2. Inembodiments, if X is —C(O)— and -L¹-R¹ is unsubstituted phenyl, then-L²-R² is not methyl, p-substituted or unsubstituted phenyl, orunsubstituted pyridine.

In another aspect a pharmaceutical composition is provided. Thepharmaceutical composition includes a pharmaceutically acceptableexcipient and a compound having formula:

X is —C(R^(4A))(R^(4B))—, —C(O)—, —CY(OH)—. Y is hydrogen, halogen, —N₃,—NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OR^(9A), —NHR^(9A), —COOR^(9A),—CONHR^(9A), —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. L¹ isindependently a bond, —C(O)—, —O—, —S—, —NR^(9B)—, —C(O)NR^(9B)—,—S(O)_(n)—, —S(O)NR^(9B)—, substituted or unsubstituted alkylene,substituted or unsubstituted heteroalkylene, substituted orunsubstituted cycloalkylene, substituted or unsubstitutedheterocycloalkylene, substituted or unsubstituted arylene, orsubstituted or unsubstituted heteroarylene. L² are independently a bond,—C(O)—, —O—, —S—, —NR^(9C)—, —C(O)NR^(9C)—, —S(O)_(n)—, —S(O)NR^(9C)—,substituted or unsubstituted alkylene, substituted or unsubstitutedheteroalkylene, substituted or unsubstituted cycloalkylene, substitutedor unsubstituted heterocycloalkylene, substituted or unsubstitutedarylene, or substituted or unsubstituted heteroarylene. R¹, R², R³,R^(4A), R^(4B), R⁵, R⁶, R⁷, and R⁸ are independently hydrogen, halogen,—N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(11A), —NR^(11B)R^(11C),—COOR^(11A), —C(O)NR^(11B)R^(11C), —NO₂, —SR^(11D), —S(O)_(n11)R^(11B),—S(O)_(n11)OR^(11B), —S(O)_(n111)NR^(11B)R^(11C), —NHNR^(11B)R^(11C),—ONR^(11B)R^(11C), —NHC(O)NHNR^(11B)R^(11C), substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl. R^(9A), R^(9B), R^(9C) are independentlyhydrogen, halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. Thesymbol n and n11 are independently 1 or 2. The symbol z1 is 1, 2, 3, 4,5, or 6. The symbol z2 is 1, 2, 3, 4, 5, 6, 7, or 8. R^(11A), R^(11B),R^(11C), and R^(11D) are independently hydrogen, substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl. The pharmaceutical compositions contemplatedherein include pharmaceutically acceptable salts thereof, as describedherein, including embodiments thereof.

In another aspect is a method of treating metabolic disease in a subjectin need thereof. The method includes administering to the subject inneed thereof, a compound of formula (I), (II), or (III), includingembodiments thereof.

In another aspect is provided a method of antagonizing an FXR receptorprotein. The method includes contacting an FXR receptor protein with acompound disclosed herein (e.g. formula (I), (II), or (III)), therebyantagonizing the FXR receptor protein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: Chemical structures of compounds synthesized herein.

FIG. 2: FXR binding activities of GW4064, Z26476908, and lithocholicacid in an FXR TR-FRET binding assay (2A). FXR agonistic activities(GW4064, Z26476908, or lithocholic acid alone) and antagonisticactivities (Z26476908 and lithocholic acid in the presence of 400 nMGW4064) in a cell-based FXR transactivation assay (2B). GW4064 andlithocholic acid were used as agonistic and antagonistic control,respectively.

FIG. 3: The retro-analysis of 1,3,4-trisubsttituted pyrazolecarboxamides.

FIG. 4: A focused two-component small array of pyrazoles designed foroptimization.

FIG. 5: Initial exploration of pyrazole core via Vilsmeier-Haackreaction to introduce R₁ as substituted1,3-diphenylpyrazole-4-carboxylic acids 4 in the N¹-position ofpyrazole.

FIG. 6: Alternative exploration of the pyrazole core to introduce R¹ andR² as substituted N¹—C3-substituted pyrazoles of 4f-4s.

FIG. 7: N-methyl examination and amide reduction of 4f, 4m, and 4o gavecorresponding compounds 8 and 9.

FIG. 8: FXR binding activities of Z26476908 and 4j in a FXR TR-FRETbinding assay; Agonistic (Z26476908 and DY268 [4j]) and antagonisticactivities (Z26476908 and DY268 [4j] in an FXR cell-basedtransactivation assay.

FIG. 9: Cholesterol metabolites act as signaling molecules regulatingtranscriptional activity of FXR. Bile acids exemplified by CDCA actingat FXR is represented. Hypothetical binding mode of designed FXRantagonist 4j acting at FXR is represented.

DETAILED DESCRIPTION OF THE INVENTION

The abbreviations used herein have their conventional meaning within thechemical and biological arts. The chemical structures and formulae setforth herein are constructed according to the standard rules of chemicalvalency known in the chemical arts.

Where substituent groups are specified by their conventional chemicalformulae, written from left to right, they equally encompass thechemically identical substituents that would result from writing thestructure from right to left, e.g., —CH₂O— is equivalent to —OCH₂—.

The term “alkyl,” by itself or as part of another substituent, means,unless otherwise stated, a straight (i.e., unbranched) or branchedcarbon chain (or carbon), or combination thereof, which may be fullysaturated, mono- or polyunsaturated and can include mono-, di- andmultivalent radicals, having the number of carbon atoms designated(i.e., C₁-C₁₀ means one to ten carbons). Alkyl is an uncyclized chain.Examples of saturated hydrocarbon radicals include, but are not limitedto, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl,isobutyl, sec-butyl, (cyclohexyl)methyl, homologs and isomers of, forexample, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. Anunsaturated alkyl group is one having one or more double bonds or triplebonds. Examples of unsaturated alkyl groups include, but are not limitedto, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl),2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl,3-butynyl, and the higher homologs and isomers. An alkoxy is an alkylattached to the remainder of the molecule via an oxygen linker (—O—).

The term “alkylene,” by itself or as part of another substituent, means,unless otherwise stated, a divalent radical derived from an alkyl, asexemplified, but not limited by, —CH₂CH₂CH₂CH₂—. Typically, an alkyl (oralkylene) group will have from 1 to 24 carbon atoms, with those groupshaving 10 or fewer carbon atoms being preferred in the presentinvention. A “lower alkyl” or “lower alkylene” is a shorter chain alkylor alkylene group, generally having eight or fewer carbon atoms. Theterm “alkenylene,” by itself or as part of another substituent, means,unless otherwise stated, a divalent radical derived from an alkene.

The term “heteroalkyl,” by itself or in combination with another term,means, unless otherwise stated, a stable straight or branched chain, orcombinations thereof, including at least one carbon atom and at leastone heteroatom selected from the group consisting of O, N, P, Si, and S,and wherein the nitrogen and sulfur atoms may optionally be oxidized,and the nitrogen heteroatom may optionally be quaternized. Theheteroatom(s) O, N, P, S, B, As, and Si may be placed at any interiorposition of the heteroalkyl group or at the position at which the alkylgroup is attached to the remainder of the molecule. Heteroalkyl is anuncyclized chain. Examples include, but are not limited to:—CH₂—CH₂—O—CH₃, —CH₂—CH₂—NH—CH₃, —CH₂—CH₂—N(CH₃)—CH₃, —CH₂—S—CH₂—CH₃,—CH₂—CH₂, —S(O)—CH₃, —CH₂—CH₂—S(O)₂—CH₃, —CH═CH—O—CH₃, —Si(CH₃)₃,—CH₂—CH═N—OCH₃, —CH═CH—N(CH₃)—CH₃, —O—CH₃, —O—CH₂—CH₃, and —CN. Up totwo or three heteroatoms may be consecutive, such as, for example,—CH₂—NH—OCH₃ and —CH₂—O—Si(CH₃)₃.

Similarly, the term “heteroalkylene,” by itself or as part of anothersubstituent, means, unless otherwise stated, a divalent radical derivedfrom heteroalkyl, as exemplified, but not limited by,—CH₂—CH₂—S—CH₂—CH₂— and —CH₂—S—CH₂—CH₂—NH—CH₂—. For heteroalkylenegroups, heteroatoms can also occupy either or both of the chain termini(e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, andthe like). Still further, for alkylene and heteroalkylene linkinggroups, no orientation of the linking group is implied by the directionin which the formula of the linking group is written. For example, theformula —C(O)₂R′— represents both —C(O)₂R′— and —R′C(O)₂—. As describedabove, heteroalkyl groups, as used herein, include those groups that areattached to the remainder of the molecule through a heteroatom, such as—C(O)R′, —C(O)NR′, —NR′R″, —OR′, —SR′, and/or —SO₂R′. Where“heteroalkyl” is recited, followed by recitations of specificheteroalkyl groups, such as —NR′R″ or the like, it will be understoodthat the terms heteroalkyl and —NR′R″ are not redundant or mutuallyexclusive. Rather, the specific heteroalkyl groups are recited to addclarity. Thus, the term “heteroalkyl” should not be interpreted hereinas excluding specific heteroalkyl groups, such as —NR′R″ or the like.

The terms “cycloalkyl” and “heterocycloalkyl,” by themselves or incombination with other terms, mean, unless otherwise stated, cyclicversions of “alkyl” and “heteroalkyl,” respectively. Cycloalkyl andheteroalkyl are not aromatic. Additionally, for heterocycloalkyl, aheteroatom can occupy the position at which the heterocycle is attachedto the remainder of the molecule. Examples of cycloalkyl include, butare not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples ofheterocycloalkyl include, but are not limited to,1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl,3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl,tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl,1-piperazinyl, 2-piperazinyl, and the like. A “cycloalkylene” and a“heterocycloalkylene,” alone or as part of another substituent, means adivalent radical derived from a cycloalkyl and heterocycloalkyl,respectively.

The terms “halo” or “halogen,” by themselves or as part of anothersubstituent, mean, unless otherwise stated, a fluorine, chlorine,bromine, or iodine atom. Additionally, terms such as “haloalkyl” aremeant to include monohaloalkyl and polyhaloalkyl. For example, the term“halo(C₁-C₄)alkyl” includes, but is not limited to, fluoromethyl,difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl,3-bromopropyl, and the like.

The term “acyl” means, unless otherwise stated, —C(O)R where R is asubstituted or unsubstituted alkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl.

The term “aryl” means, unless otherwise stated, a polyunsaturated,aromatic, hydrocarbon substituent, which can be a single ring ormultiple rings (preferably from 1 to 3 rings) that are fused together(i.e., a fused ring aryl) or linked covalently. A fused ring aryl refersto multiple rings fused together wherein at least one of the fused ringsis an aryl ring. The term “heteroaryl” refers to aryl groups (or rings)that contain at least one heteroatom such as N, O, or S, wherein thenitrogen and sulfur atoms are optionally oxidized, and the nitrogenatom(s) are optionally quaternized. Thus, the term “heteroaryl” includesfused ring heteroaryl groups (i.e., multiple rings fused togetherwherein at least one of the fused rings is a heteroaromatic ring). A5,6-fused ring heteroarylene refers to two rings fused together, whereinone ring has 5 members and the other ring has 6 members, and wherein atleast one ring is a heteroaryl ring. Likewise, a 6,6-fused ringheteroarylene refers to two rings fused together, wherein one ring has 6members and the other ring has 6 members, and wherein at least one ringis a heteroaryl ring. And a 6,5-fused ring heteroarylene refers to tworings fused together, wherein one ring has 6 members and the other ringhas 5 members, and wherein at least one ring is a heteroaryl ring. Aheteroaryl group can be attached to the remainder of the moleculethrough a carbon or heteroatom. Non-limiting examples of aryl andheteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl,1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl,4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl,5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl,4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl,2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl,5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl,5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and6-quinolyl. Substituents for each of the above noted aryl and heteroarylring systems are selected from the group of acceptable substituentsdescribed below. An “arylene” and a “heteroarylene,” alone or as part ofanother substituent, mean a divalent radical derived from an aryl andheteroaryl, respectively. A heteroaryl group substituent may be a —O—bonded to a ring heteroatom nitrogen.

A “fused ring aryl-heterocycloalkyl” is an aryl fused to aheterocycloalkyl. A “fused ring heteroaryl-heterocycloalkyl” is aheteroaryl fused to a heterocycloalkyl. A “fused ringheterocycloalkyl-cycloalkyl” is a heterocycloalkyl fused to acycloalkyl. A “fused ring heterocycloalkyl-heterocycloalkyl” is aheterocycloalkyl fused to another heterocycloalkyl. Fused ringaryl-heterocycloalkyl, fused ring heteroaryl-heterocycloalkyl, fusedring heterocycloalkyl-cycloalkyl, or fused ringheterocycloalkyl-heterocycloalkyl may each independently beunsubstituted or substituted with one or more of the substituentsdescribed herein. Fused ring aryl-heterocycloalkyl, fused ringheteroaryl-heterocycloalkyl, fused ring heterocycloalkyl-cycloalkyl, orfused ring heterocycloalkyl-heterocycloalkyl may each independently benamed according to the size of each of the fused rings. Thus, forexample, 6,5 aryl-heterocycloalkyl fused ring describes a 6 memberedaryl moiety fused to a 5 membered heterocycloalkyl. Spirocyclic ringsare two or more rings wherein adjacent rings are attached through asingle atom. The individual rings within spirocyclic rings may beidentical or different. Individual rings in spirocyclic rings may besubstituted or unsubstituted and may have different substituents fromother individual rings within a set of spirocyclic rings. Possiblesubstituents for individual rings within spirocyclic rings are thepossible substituents for the same ring when not part of spirocyclicrings (e.g. substituents for cycloalkyl or heterocycloalkyl rings).Spirocylic rings may be substituted or unsubstituted cycloalkyl,substituted or unsubstituted cycloalkylene, substituted or unsubstitutedheterocycloalkyl or substituted or unsubstituted heterocycloalkylene andindividual rings within a spirocyclic ring group may be any of theimmediately previous list, including having all rings of one type (e.g.all rings being substituted heterocycloalkylene wherein each ring may bethe same or different substituted heterocycloalkylene). When referringto a spirocyclic ring system, heterocyclic spirocyclic rings means aspirocyclic rings wherein at least one ring is a heterocyclic ring andwherein each ring may be a different ring. When referring to aspirocyclic ring system, substituted spirocyclic rings means that atleast one ring is substituted and each substituent may optionally bedifferent.

The term “oxo,” as used herein, means an oxygen that is double bonded toa carbon atom.

The term “thio,” as used herein, means a sulfur that is single bonded tocarbon or to another sulfur.

Each of the above terms (e.g., “alkyl,” “heteroalkyl,” “aryl,” and“heteroaryl”) includes both substituted and unsubstituted forms of theindicated radical. Preferred substituents for each type of radical areprovided below.

Substituents for the alkyl and heteroalkyl radicals (including thosegroups often referred to as alkylene, alkenyl, heteroalkylene,heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, andheterocycloalkenyl) can be one or more of a variety of groups selectedfrom, but not limited to, —OR′, ═O, ═NR′, ═N—OR′, —NR′R″, —SR′,-halogen, —SiR′R″R″′, —OC(O)R′, —C(O)R′, —CO₂R′, —CONR′R″, —OC(O)NR′R″,—NR″C(O)R′, —NR′—C(O)NR″R″′, —NR″C(O)₂R′, —NR—C(NR′R″R″′)═NR″″,—NR—C(NR′R″)═NR″′, —S(O)R′, —S(O)₂R′, —S(O)₂NR′R″, —NRSO₂R′, —NR′NR″R″′,—ONR′R″, —NR′C═(O)NR″NR″′R″″, —CN, —NO₂, —NR′SO₂R″, —NR′C═(O)R″,—NR′C(O)—OR″, —NR′OR″, in a number ranging from zero to (2m′+1), wherem′ is the total number of carbon atoms in such radical. R, R′, R″, R″′,and R″″ each preferably independently refer to hydrogen, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl (e.g., aryl substituted with 1-3 halogens),substituted or unsubstituted heteroaryl, substituted or unsubstitutedalkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups. When acompound of the invention includes more than one R group, for example,each of the R groups is independently selected as are each R′, R″, R″′,and R″″ group when more than one of these groups is present. When R′ andR″ are attached to the same nitrogen atom, they can be combined with thenitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example,—NR′R″ includes, but is not limited to, 1-pyrrolidinyl and4-morpholinyl. From the above discussion of substituents, one of skillin the art will understand that the term “alkyl” is meant to includegroups including carbon atoms bound to groups other than hydrogengroups, such as haloalkyl (e.g., —CF₃ and —CH₂CF₃) and acyl (e.g.,—C(O)CH₃, —C(O)CF₃, —C(O)CH₂OCH₃, and the like).

Similar to the substituents described for the alkyl radical,substituents for the aryl and heteroaryl groups are varied and areselected from, for example: —OR′, —NR′R″, —SR′, -halogen, —SiR′R″R″′,—OC(O)R′, —C(O)R′, —CO₂R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′,—NR′—C(O)NR″R″′, —NR″C(O)₂R′, —NR—C(NR′R″R″′)═NR″″, —NR—C(NR′R″)═NR″′,—S(O)R′, —S(O)₂R′, —S(O)₂NR′R″, —NRSO₂R′, —NR′NR″R″′, —ONR′R″,—NR′C═(O)NR″NR″′R″″, —CN, —NO₂, —R′, —N₃, —CH(Ph)₂, fluoro(C₁-C₄)alkoxy,and fluoro(C₁-C₄)alkyl, —NR′SO₂R″, —NR′C═(O)R″, —NR′C(O)—OR″, —NR′OR″,in a number ranging from zero to the total number of open valences onthe aromatic ring system; and where R, R′, R″, R″′, and R″″ arepreferably independently selected from hydrogen, substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, and substituted orunsubstituted heteroaryl. When a compound of the invention includes morethan one R group, for example, each of the R groups is independentlyselected as are each R′, R″, R″′, and R″″ groups when more than one ofthese groups is present.

Substituents for rings (e.g. cycloalkyl, heterocycloalkyl, aryl,heteroaryl, cycloalkylene, heterocycloalkylene, arylene, orheteroarylene) may be depicted as substituents on the ring rather thanon a specific atom of a ring (commonly referred to as a floatingsubstituent). In such a case, the substituent may be attached to any ofthe ring atoms (obeying the rules of chemical valency) and in the caseof fused rings or spirocyclic rings, a substituent depicted asassociated with one member of the fused rings or spirocyclic rings (afloating substituent on a single ring), may be a substituent on any ofthe fused rings or spirocyclic rings (a floating substituent on multiplerings). When a substituent is attached to a ring, but not a specificatom (a floating substituent), and a subscript for the substituent is aninteger greater than one, the multiple substituents may be on the sameatom, same ring, different atoms, different fused rings, differentspirocyclic rings, and each substituent may optionally be different.Where a point of attachment of a ring to the remainder of a molecule isnot limited to a single atom (a floating substituent), the attachmentpoint may be any atom of the ring and in the case of a fused ring orspirocyclic ring, any atom of any of the fused rings or spirocyclicrings while obeying the rules of chemical valency. Where a ring, fusedrings, or spirocyclic rings contain one or more ring heteroatoms and thering, fused rings, or spirocyclic rings are shown with one more floatingsubstituents (including, but not limited to, points of attachment to theremainder of the molecule), the floating substituents may be bonded tothe heteroatoms. Where the ring heteroatoms are shown bound to one ormore hydrogens (e.g. a ring nitrogen with two bonds to ring atoms and athird bond to a hydrogen) in the structure or formula with the floatingsubstituent, when the heteroatom is bonded to the floating substituent,the substituent will be understood to replace the hydrogen, whileobeying the rules of chemical valency.

Two or more substituents may optionally be joined to form aryl,heteroaryl, cycloalkyl, or heterocycloalkyl groups. Such so-calledring-forming substituents are typically, though not necessarily, foundattached to a cyclic base structure. In one embodiment, the ring-formingsubstituents are attached to adjacent members of the base structure. Forexample, two ring-forming substituents attached to adjacent members of acyclic base structure create a fused ring structure. In anotherembodiment, the ring-forming substituents are attached to a singlemember of the base structure. For example, two ring-forming substituentsattached to a single member of a cyclic base structure create aspirocyclic structure. In yet another embodiment, the ring-formingsubstituents are attached to non-adjacent members of the base structure.

Two of the substituents on adjacent atoms of the aryl or heteroaryl ringmay optionally form a ring of the formula -T-C(O)—(CRR′)_(q)—U—, whereinT and U are independently —NR—, —O—, —CRR′—, or a single bond, and q isan integer of from 0 to 3. Alternatively, two of the substituents onadjacent atoms of the aryl or heteroaryl ring may optionally be replacedwith a substituent of the formula -A-(CH₂)_(r)—B—, wherein A and B areindependently —CRR′—, —O—, —NR—, —S—, —S(O)—, —S(O)₂—, —S(O)₂NR′—, or asingle bond, and r is an integer of from 1 to 4. One of the single bondsof the new ring so formed may optionally be replaced with a double bond.Alternatively, two of the substituents on adjacent atoms of the aryl orheteroaryl ring may optionally be replaced with a substituent of theformula —(CRR′)_(s)—X′—(C″R″R″′)_(d)—, where s and d are independentlyintegers of from 0 to 3, and X′ is —O—, —NR′—, —S—, —S(O)—, —S(O)₂—, or—S(O)₂NR′—. The substituents R, R′, R″, and R″′ are preferablyindependently selected from hydrogen, substituted or unsubstitutedalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,substituted or unsubstituted aryl, and substituted or unsubstitutedheteroaryl.

As used herein, the terms “heteroatom” or “ring heteroatom” are meant toinclude, oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), Boron(B), Arsenic (As), and silicon (Si).

A “substituent group,” as used herein, means a group selected from thefollowing moieties:

-   -   (A) oxo, halogen, —CF₃, —CN, —OH, —NH₂, —COOH, —CONH₂, —NO₂,        —SH, —SO₂Cl, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂,        —NHC═(O)NHNH₂, —NHC═(O) NH₂, —NHSO₂H, —NHC═(O)H, —NHC(O)—OH,        —NHOH, —OCF₃, —OCHF₂, unsubstituted alkyl, unsubstituted        heteroalkyl, unsubstituted cycloalkyl, unsubstituted        heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl,        and    -   (B) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and        heteroaryl, substituted with at least one substituent selected        from:        -   (i) oxo, halogen, —CF₃, —CN, —OH, —NH₂, —COOH, —CONH₂, —NO₂,            —SH, —SO₂Cl, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂,            —NHC═(O)NHNH₂, —NHC═(O) NH₂, —NHSO₂H, —NHC═(O)H, —NHC(O)—OH,            —NHOH, —OCF₃, —OCHF₂, unsubstituted alkyl, unsubstituted            heteroalkyl, unsubstituted cycloalkyl, unsubstituted            heterocycloalkyl, unsubstituted aryl, unsubstituted            heteroaryl, and        -   (ii) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl,            and heteroaryl, substituted with at least one substituent            selected from:            -   (a) oxo, halogen, —CF₃, —CN, —OH, —NH₂, —COOH, —CONH₂,                —NO₂, —SH, —SO₂Cl, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂,                —NHC═(O)NHNH₂, —NHC═(O) NH₂, —NHSO₂H, —NHC═(O)H,                —NHC(O)—OH, —NHOH, —OCF₃, —OCHF₂, unsubstituted alkyl,                unsubstituted heteroalkyl, unsubstituted cycloalkyl,                unsubstituted heterocycloalkyl, unsubstituted aryl,                unsubstituted heteroaryl, and            -   (b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl,                aryl, or heteroaryl, substituted with at least one                substituent selected from: oxo, halogen, —CF₃, —CN, —OH,                —NH₂, —COOH, —CONH₂, —NO₂, —SH, —SO₂Cl, —SO₃H, —SO₄H,                —SO₂NH₂, —NHNH₂, —ONH₂, —NHC═(O)NHNH₂, —NHC═(O) NH₂,                —NHSO₂H, —NHC═(O)H, —NHC(O)—OH, —NHOH, —OCF₃, —OCHF₂,                unsubstituted alkyl, unsubstituted heteroalkyl,                unsubstituted cycloalkyl, unsubstituted                heterocycloalkyl, unsubstituted aryl, and unsubstituted                heteroaryl.

A “size-limited substituent” or “size-limited substituent group,” asused herein, means a group selected from all of the substituentsdescribed above for a “substituent group,” wherein each substituted orunsubstituted alkyl is a substituted or unsubstituted C₁-C₂₀ alkyl, eachsubstituted or unsubstituted heteroalkyl is a substituted orunsubstituted 2 to 20 membered heteroalkyl, each substituted orunsubstituted cycloalkyl is a substituted or unsubstituted C₃-C₈cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is asubstituted or unsubstituted 3 to 8 membered heterocycloalkyl, eachsubstituted or unsubstituted aryl is a substituted or unsubstitutedC₆-C₁₀ aryl, and each substituted or unsubstituted heteroaryl is asubstituted or unsubstituted 5 to 10 membered heteroaryl.

A “lower substituent” or “lower substituent group,” as used herein,means a group selected from all of the substituents described above fora “substituent group,” wherein each substituted or unsubstituted alkylis a substituted or unsubstituted C₁-C₈ alkyl, each substituted orunsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8membered heteroalkyl, each substituted or unsubstituted cycloalkyl is asubstituted or unsubstituted C₃-C₇ cycloalkyl, and each substituted orunsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7membered heterocycloalkyl, each substituted or unsubstituted aryl is asubstituted or unsubstituted C₆-C₁₀ aryl, and each substituted orunsubstituted heteroaryl is a substituted or unsubstituted 5 to 9membered heteroaryl.

In some embodiments, each substituted group described in the compoundsherein is substituted with at least one substituent group. Morespecifically, in some embodiments, each substituted alkyl, substitutedheteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl,substituted aryl, substituted heteroaryl, substituted alkylene,substituted heteroalkylene, substituted cycloalkylene, substitutedheterocycloalkylene, substituted arylene, and/or substitutedheteroarylene described in the compounds herein are substituted with atleast one substituent group. In other embodiments, at least one or allof these groups are substituted with at least one size-limitedsubstituent group. In other embodiments, at least one or all of thesegroups are substituted with at least one lower substituent group.

In other embodiments of the compounds herein, each substituted orunsubstituted alkyl may be a substituted or unsubstituted C₁-C₂₀ alkyl,each substituted or unsubstituted heteroalkyl is a substituted orunsubstituted 2 to 20 membered heteroalkyl, each substituted orunsubstituted cycloalkyl is a substituted or unsubstituted C₃-C₈cycloalkyl, and/or each substituted or unsubstituted heterocycloalkyl isa substituted or unsubstituted 3 to 8 membered heterocycloalkyl. In someembodiments of the compounds herein, each substituted or unsubstitutedalkylene is a substituted or unsubstituted C₁-C₂₀ alkylene, eachsubstituted or unsubstituted heteroalkylene is a substituted orunsubstituted 2 to 20 membered heteroalkylene, each substituted orunsubstituted cycloalkylene is a substituted or unsubstituted C₃-C₈cycloalkylene, substituted or unsubstituted heterocycloalkylene is asubstituted or unsubstituted 3 to 8 membered heterocycloalkylene, eachsubstituted or unsubstituted arylene is a substituted or unsubstitutedC₆-C₁₀ arylene, and/or each substituted or unsubstituted heteroaryleneis a substituted or unsubstituted 5 to 10 membered heteroarylene.

In some embodiments, each substituted or unsubstituted alkyl is asubstituted or unsubstituted C₁-C₈ alkyl, each substituted orunsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8membered heteroalkyl, each substituted or unsubstituted cycloalkyl is asubstituted or unsubstituted C₃-C₇ cycloalkyl, and/or each substitutedor unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to7 membered heterocycloalkyl. In some embodiments, each substituted orunsubstituted alkylene is a substituted or unsubstituted C₁-C₈ alkylene,each substituted or unsubstituted heteroalkylene is a substituted orunsubstituted 2 to 8 membered heteroalkylene, each substituted orunsubstituted cycloalkylene is a substituted or unsubstituted C₃-C₇cycloalkylene, each substituted or unsubstituted heterocycloalkylene isa substituted or unsubstituted 3 to 7 membered heterocycloalkylene, eachsubstituted or unsubstituted arylene is a substituted or unsubstitutedC₆-C₁₀ arylene, and/or each substituted or unsubstituted heteroaryleneis a substituted or unsubstituted 5 to 9 membered heteroarylene. In someembodiments, the compound is a chemical species set forth in theExamples section, figures, or tables below.

Certain compounds of the present invention possess asymmetric carbonatoms (optical or chiral centers) or double bonds; the enantiomers,racemates, diastereomers, tautomers, geometric isomers, stereoisometricforms that may be defined, in terms of absolute stereochemistry, as (R)-or (S)- or, as (D)- or (L)- for amino acids, and individual isomers areencompassed within the scope of the present invention. The compounds ofthe present invention do not include those which are known in art to betoo unstable to synthesize and/or isolate. The present invention ismeant to include compounds in racemic and optically pure forms.Optically active (R)- and (S)-, or (D)- and (L)-isomers may be preparedusing chiral synthons or chiral reagents, or resolved using conventionaltechniques. When the compounds described herein contain olefinic bondsor other centers of geometric asymmetry, and unless specified otherwise,it is intended that the compounds include both E and Z geometricisomers.

As used herein, the term “isomers” refers to compounds having the samenumber and kind of atoms, and hence the same molecular weight, butdiffering in respect to the structural arrangement or configuration ofthe atoms.

The term “tautomer,” as used herein, refers to one of two or morestructural isomers which exist in equilibrium and which are readilyconverted from one isomeric form to another.

It will be apparent to one skilled in the art that certain compounds ofthis invention may exist in tautomeric forms, all such tautomeric formsof the compounds being within the scope of the invention.

Unless otherwise stated, structures depicted herein are also meant toinclude all stereochemical forms of the structure; i.e., the R and Sconfigurations for each asymmetric center. Therefore, singlestereochemical isomers as well as enantiomeric and diastereomericmixtures of the present compounds, generally recognized as stable bythose skilled in the art, are within the scope of the invention.

Unless otherwise stated, structures depicted herein are also meant toinclude compounds which differ only in the presence of one or moreisotopically enriched atoms. For example, compounds having the presentstructures except for the replacement of a hydrogen by a deuterium ortritium, or the replacement of a carbon by ¹³C- or ¹⁴C-enriched carbonare within the scope of this invention.

The compounds of the present invention may also contain unnaturalproportions of atomic isotopes at one or more of the atoms thatconstitute such compounds. For example, the compounds may beradiolabeled with radioactive isotopes, such as for example tritium(³H), iodine-125 (¹²⁵I), or carbon-14 (¹⁴C). All isotopic variations ofthe compounds of the present invention, whether radioactive or not, areencompassed within the scope of the present invention.

The symbol “

” denotes the point of attachment of a chemical moiety to the remainderof a molecule or chemical formula.

The terms “a” or “an,” as used in herein means one or more. In addition,the phrase “substituted with a[n],” as used herein, means the specifiedgroup may be substituted with one or more of any or all of the namedsubstituents. For example, where a group, such as an alkyl or heteroarylgroup, is “substituted with an unsubstituted C₁-C₂₀ alkyl, orunsubstituted 2 to 20 membered heteroalkyl,” the group may contain oneor more unsubstituted C₁-C₂₀ alkyls, and/or one or more unsubstituted 2to 20 membered heteroalkyls.

Moreover, where a moiety is substituted with an R substituent, the groupmay be referred to as “R-substituted.” Where a moiety is R-substituted,the moiety is substituted with at least one R substituent and each Rsubstituent is optionally different. Where a particular R group ispresent in the description of a chemical genus (such as Formula (I)), aRoman alphabetic symbol may be used to distinguish each appearance ofthat particular R group. For example, where multiple R¹³ substituentsare present, each R¹³ substituent may be distinguished as R^(13A),R^(13B), R^(13C), R^(13D), etc., wherein each of R^(13A), R^(13B),R^(13C), R^(13D), etc. is defined within the scope of the definition ofR¹³ and optionally differently.

Description of compounds of the present invention is limited byprinciples of chemical bonding known to those skilled in the art.Accordingly, where a group may be substituted by one or more of a numberof substituents, such substitutions are selected so as to comply withprinciples of chemical bonding and to give compounds which are notinherently unstable and/or would be known to one of ordinary skill inthe art as likely to be unstable under ambient conditions, such asaqueous, neutral, and several known physiological conditions. Forexample, a heterocycloalkyl or heteroaryl is attached to the remainderof the molecule via a ring heteroatom in compliance with principles ofchemical bonding known to those skilled in the art thereby avoidinginherently unstable compounds.

The term “pharmaceutically acceptable salts” is meant to include saltsof the active compounds that are prepared with relatively nontoxic acidsor bases, depending on the particular substituents found on thecompounds described herein. When compounds of the present inventioncontain relatively acidic functionalities, base addition salts can beobtained by contacting the neutral form of such compounds with asufficient amount of the desired base, either neat or in a suitableinert solvent. Examples of pharmaceutically acceptable base additionsalts include sodium, potassium, calcium, ammonium, organic amino, ormagnesium salt, or a similar salt. When compounds of the presentinvention contain relatively basic functionalities, acid addition saltscan be obtained by contacting the neutral form of such compounds with asufficient amount of the desired acid, either neat or in a suitableinert solvent. Examples of pharmaceutically acceptable acid additionsalts include those derived from inorganic acids like hydrochloric,hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric,monohydrogenphosphoric, dihydrogenphosphoric, sulfuric,monohydrogensulfuric, hydriodic, or phosphorous acids and the like, aswell as the salts derived from relatively nontoxic organic acids likeacetic, propionic, isobutyric, maleic, malonic, benzoic, succinic,suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic,p-tolylsulfonic, citric, tartaric, oxalic, methanesulfonic, and thelike. Also included are salts of amino acids such as arginate and thelike, and salts of organic acids like glucuronic or galactunoric acidsand the like (see, for example, Berge et al., “Pharmaceutical Salts”,Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specificcompounds of the present invention contain both basic and acidicfunctionalities that allow the compounds to be converted into eitherbase or acid addition salts.

Thus, the compounds of the present invention may exist as salts, such aswith pharmaceutically acceptable acids. The present invention includessuch salts. Examples of such salts include hydrochlorides,hydrobromides, sulfates, methanesulfonates, nitrates, maleates,acetates, citrates, fumarates, tartrates (e.g., (+)-tartrates,(−)-tartrates, or mixtures thereof including racemic mixtures),succinates, benzoates, and salts with amino acids such as glutamic acid.These salts may be prepared by methods known to those skilled in theart.

The neutral forms of the compounds are preferably regenerated bycontacting the salt with a base or acid and isolating the parentcompound in the conventional manner. The parent form of the compounddiffers from the various salt forms in certain physical properties, suchas solubility in polar solvents.

In addition to salt forms, the present invention provides compounds,which are in a prodrug form. Prodrugs of the compounds described hereininclude those compounds that readily undergo chemical changes underphysiological conditions to provide the compounds of the presentinvention. Additionally, prodrugs can be converted to the compounds ofthe present invention by chemical or biochemical methods in an ex vivoenvironment. For example, prodrugs can be slowly converted to thecompounds of the present invention when placed in a transdermal patchreservoir with a suitable enzyme or chemical reagent.

Certain compounds of the present invention can exist in unsolvated formsas well as solvated forms, including hydrated forms. In general, thesolvated forms are equivalent to unsolvated forms and are encompassedwithin the scope of the present invention. Certain compounds of thepresent invention may exist in multiple crystalline or amorphous forms.In general, all physical forms are equivalent for the uses contemplatedby the present invention and are intended to be within the scope of thepresent invention.

As used herein, the term “salt” refers to acid or base salts of thecompounds used in the methods of the present invention. Illustrativeexamples of acceptable salts are mineral acid (hydrochloric acid,hydrobromic acid, phosphoric acid, and the like) salts, organic acid(acetic acid, propionic acid, glutamic acid, citric acid and the like)salts, quatemary ammonium (methyl iodide, ethyl iodide, and the like)salts.

The terms “treating”, or “treatment” refers to any indicia of success inthe treatment or amelioration of an injury, disease, pathology orcondition, including any objective or subjective parameter such asabatement; remission; diminishing of symptoms or making the injury,pathology or condition more tolerable to the patient; slowing in therate of degeneration or decline; making the final point of degenerationless debilitating; improving a patient's physical or mental well-being.The treatment or amelioration of symptoms can be based on objective orsubjective parameters; including the results of a physical examination,neuropsychiatric exams, and/or a psychiatric evaluation. The term“treating” and conjugations thereof, include prevention of an injury,pathology, condition, or disease.

A “therapeutically effective amount” or “effective amount” is an amountsufficient for a compound to accomplish a stated purpose relative to theabsence of the compound (e.g. achieve the effect for which it isadministered, treat a disease, reduce enzyme activity, increase enzymeactivity, reduce a signaling pathway, or reduce one or more symptoms ofa disease or condition). An example of an “effective amount” is anamount sufficient to contribute to the treatment, prevention, orreduction of a symptom or symptoms of a disease, which could also bereferred to as a “therapeutically effective amount.” A “reduction” of asymptom or symptoms (and grammatical equivalents of this phrase) meansdecreasing of the severity or frequency of the symptom(s), orelimination of the symptom(s). The exact amounts will depend on thepurpose of the treatment, and will be ascertainable by one skilled inthe art using known techniques (see, e.g., Lieberman, PharmaceuticalDosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technologyof Pharmaceutical Compounding (1999); Pickar, Dosage Calculations(1999); and Remington: The Science and Practice of Pharmacy, 20thEdition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).

“Control” or “control experiment” is used in accordance with its plainordinary meaning and refers to an experiment in which the subjects orreagents of the experiment are treated as in a parallel experimentexcept for omission of a procedure, reagent, or variable of theexperiment. In some instances, the control is used as a standard ofcomparison in evaluating experimental effects. In some embodiments, acontrol is the measurement of the activity of a protein in the absenceof a compound as described herein (including embodiments and examples).

As defined herein, the term “inhibition”, “inhibit”, “inhibiting” andthe like in reference to a protein-inhibitor interaction meansnegatively affecting (e.g. decreasing) the activity or function of theprotein relative to the activity or function of the protein in theabsence of the inhibitor. In some embodiments inhibition refers toreduction of a disease or symptoms of disease. In some embodiments,inhibition refers to a reduction in the activity of a particular proteinor nucleic acid target. Thus, inhibition includes, at least in part,partially or totally blocking stimulation, decreasing, preventing, ordelaying activation, or inactivating, desensitizing, or down-regulatingsignal transduction or enzymatic activity or the amount of a protein.

“Contacting” is used in accordance with its plain ordinary meaning andrefers to the process of allowing at least two distinct species (e.g.chemical compounds including biomolecules or cells) to becomesufficiently proximal to react, interact or physically touch. It shouldbe appreciated; however, the resulting reaction product can be produceddirectly from a reaction between the added reagents or from anintermediate from one or more of the added reagents which can beproduced in the reaction mixture.

The term “contacting” may include allowing two species to react,interact, or physically touch, wherein the two species may be a compoundas described herein and a protein or enzyme. In some embodimentscontacting includes allowing a compound described herein to interactwith a protein or enzyme that is involved in a signaling pathway.

“Patient,” “subject,” “patient in need thereof,” and “subject in needthereof” are herein used interchangeabley and refer to a living organismsuffering from or prone to a disease or condition that can be treated byadministration of a pharmaceutical composition as provided herein.Non-limiting examples include humans, other mammals, bovines, rats,mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammaliananimals. In some embodiments, a patient is human.

“Disease” or “condition” refer to a state of being or health status of apatient or subject capable of being treated with the compounds ormethods provided herein.

“Pharmaceutically acceptable excipient” and “pharmaceutically acceptablecarrier” refer to a substance that aids the administration of an activeagent to and absorption by a subject and can be included in thecompositions of the present invention without causing a significantadverse toxicological effect on the patient. Non-limiting examples ofpharmaceutically acceptable excipients include water, NaCl, normalsaline solutions, lactated Ringer's, normal sucrose, normal glucose,binders, fillers, disintegrants, lubricants, coatings, sweeteners,flavors, salt solutions (such as Ringer's solution), alcohols, oils,gelatins, carbohydrates such as lactose, amylose or starch, fatty acidesters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, andthe like. Such preparations can be sterilized and, if desired, mixedwith auxiliary agents such as lubricants, preservatives, stabilizers,wetting agents, emulsifiers, salts for influencing osmotic pressure,buffers, coloring, and/or aromatic substances and the like that do notdeleteriously react with the compounds of the invention. One of skill inthe art will recognize that other pharmaceutical excipients are usefulin the present invention.

The term “preparation” is intended to include the formulation of theactive compound with encapsulating material as a carrier providing acapsule in which the active component with or without other carriers, issurrounded by a carrier, which is thus in association with it.Similarly, cachets and lozenges are included. Tablets, powders,capsules, pills, cachets, and lozenges can be used as solid dosage formssuitable for oral administration.

As used herein, the term “administering” means oral administration,administration as a suppository, topical contact, intravenous,parenteral, intraperitoneal, intramuscular, intralesional, intrathecal,intranasal or subcutaneous administration, or the implantation of aslow-release device, e.g., a mini-osmotic pump, to a subject.Administration is by any route, including parenteral and transmucosal(e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, ortransdermal). Parenteral administration includes, e.g., intravenous,intramuscular, intra-arteriole, intradermal, subcutaneous,intraperitoneal, intraventricular, and intracranial. Other modes ofdelivery include, but are not limited to, the use of liposomalformulations, intravenous infusion, transdermal patches, etc.

By “co-administer” it is meant that a composition described herein isadministered at the same time, just prior to, or just after theadministration of one or more additional therapies. The compound of theinvention can be administered alone or can be co-administered to thepatient. Co-administration is meant to include simultaneous orsequential administration of the compound individually or in combination(more than one compound or agent). Thus, the preparations can also becombined, when desired, with other active substances (e.g. to reducemetabolic degradation).

The compositions disclosed herein can be delivered by transdermally, bya topical route, formulated as applicator sticks, solutions,suspensions, emulsions, gels, creams, ointments, pastes, jellies,paints, powders, and aerosols. Oral preparations include tablets, pills,powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups,slurries, suspensions, etc., suitable for ingestion by the patient.Solid form preparations include powders, tablets, pills, capsules,cachets, suppositories, and dispersible granules. Liquid formpreparations include solutions, suspensions, and emulsions, for example,water or water/propylene glycol solutions. The compositions of thepresent invention may additionally include components to providesustained release and/or comfort. Such components include high molecularweight, anionic mucomimetic polymers, gelling polysaccharides andfinely-divided drug carrier substrates. These components are discussedin greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and4,861,760. The entire contents of these patents are incorporated hereinby reference in their entirety for all purposes. The compositionsdisclosed herein can also be delivered as microspheres for slow releasein the body. For example, microspheres can be administered viaintradermal injection of drug-containing microspheres, which slowlyrelease subcutaneously (see Rao, J. Biomater Sci. Polym. Ed. 7:623-645,1995; as biodegradable and injectable gel formulations (see, e.g., GaoPharm. Res. 12:857-863, 1995); or, as microspheres for oraladministration (see, e.g., Eyles, J Pharm. Pharmacol. 49:669-674, 1997).In another embodiment, the formulations of the compositions of thepresent invention can be delivered by the use of liposomes which fusewith the cellular membrane or are endocytosed, i.e., by employingreceptor ligands attached to the liposome, that bind to surface membraneprotein receptors of the cell resulting in endocytosis. By usingliposomes, particularly where the liposome surface carries receptorligands specific for target cells, or are otherwise preferentiallydirected to a specific organ, one can focus the delivery of thecompositions of the present invention into the target cells in vivo.(See, e.g., Al-Muhammed, J. Microencapsul. 13:293-306, 1996; Chonn,Curr. Opin. Biotechnol. 6:698-708, 1995; Ostro, Am. J. Hosp. Pharm.46:1576-1587, 1989). The compositions can also be delivered asnanoparticles.

Pharmaceutical compositions may include compositions wherein the activeingredient (e.g. compounds described herein, including embodiments orexamples) is contained in a therapeutically effective amount, i.e., inan amount effective to achieve its intended purpose. The actual amounteffective for a particular application will depend, inter alia, on thecondition being treated. When administered in methods to treat adisease, such compositions will contain an amount of active ingredienteffective to achieve the desired result, e.g., modulating the activityof a target molecule, and/or reducing, eliminating, or slowing theprogression of disease symptoms.

The dosage and frequency (single or multiple doses) administered to amammal can vary depending upon a variety of factors, for example,whether the mammal suffers from another disease, and its route ofadministration; size, age, sex, health, body weight, body mass index,and diet of the recipient; nature and extent of symptoms of the diseasebeing treated, kind of concurrent treatment, complications from thedisease being treated or other health-related problems. Othertherapeutic regimens or agents can be used in conjunction with themethods and compounds of Applicants' invention. Adjustment andmanipulation of established dosages (e.g., frequency and duration) arewell within the ability of those skilled in the art.

For any compound described herein, the therapeutically effective amountcan be initially determined from cell culture assays. Targetconcentrations will be those concentrations of active compound(s) thatare capable of achieving the methods described herein, as measured usingthe methods described herein or known in the art.

As is well known in the art, therapeutically effective amounts for usein humans can also be determined from animal models. For example, a dosefor humans can be formulated to achieve a concentration that has beenfound to be effective in animals. The dosage in humans can be adjustedby monitoring compounds effectiveness and adjusting the dosage upwardsor downwards, as described above. Adjusting the dose to achieve maximalefficacy in humans based on the methods described above and othermethods is well within the capabilities of the ordinarily skilledartisan.

Dosages may be varied depending upon the requirements of the patient andthe compound being employed. The dose administered to a patient, in thecontext of the present invention should be sufficient to effect abeneficial therapeutic response in the patient over time. The size ofthe dose also will be determined by the existence, nature, and extent ofany adverse side-effects. Determination of the proper dosage for aparticular situation is within the skill of the practitioner. Generally,treatment is initiated with smaller dosages which are less than theoptimum dose of the compound. Thereafter, the dosage is increased bysmall increments until the optimum effect under circumstances isreached. Dosage amounts and intervals can be adjusted individually toprovide levels of the administered compound effective for the particularclinical indication being treated. This will provide a therapeuticregimen that is commensurate with the severity of the individual'sdisease state.

The term “associated” or “associated with” in the context of a substanceor substance activity or function associated with a disease means thatthe disease is caused by (in whole or in part), a symptom of the diseaseis caused by (in whole or inpart) the substance or substance activity orfunction, or a side-effect of the compound (e.g. toxicity) is caused by(in whole or inpart) the substance or substance activity or function.

The term “metabolic syndrome” as used herein refers to a group ofconditions including, but not limited to, dyslipidemia (e.g.hyperlipidemia), insulin-resistance, increased blood pressure, visceralobesity and hypercoagubility, where at least two of the conditions occursimultaneously. The term “cholestasis” refers to a conditioncharacterized by elevated levels of bile acid in the liver. The term“hypertriglyceridemia” refers to a condition characterized by elevatedlevels of triglycerides in the blood.

Farmesoid X Receptor or “FXR” refers to a nuclear hormone receptor foundin the liver, intestines, adrenal glands, and kidneys. FXR is involvedin regulation of lipid and carbohydrate metabolism and trigyceridehomeostasis. FXR also regulates bile acid synthesis (e.g. throughinduced expression of small heterodimer partner (SHP) protein).

An “agonist,” as used herein, refers to a compound capable of detectablyincreasing the expression or activity of a given protein or receptor.The agonist can increase expression or activity 10%, 20%, 30%, 40%, 50%,60%, 70%, 80%, 90%, 100% or more in comparison to a control in theabsence of the agonist. In embodiments, expression or activity is1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or more higher thanthe expression or activity in the absence of the agonist. An “FXRagonist” is a compound which increases FXR activity. In embodiments, theincreased FXR activity indirectly represses synthesis of bile acid. Inembodiments the increased FXR activity reduces triglyceride levels inhypertriglyceridemic subjects.

The term “antagonist” refers to a substance capable of detectablylowering expression or activity of a given protein. The antagonist caninhibit expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%,90%, 100% or less in comparison to a control in the absence of theantagonist. In embodiments, the inhibition is 1.5-fold, 2-fold, 3-fold,4-fold, 5-fold, 10-fold, or more than the expression or activity in theabsence of the antagonist. An “FXR antagonist” is a compound whichdecreases FXR activity. In embodiments, decreased FXR activity increasesconversion of cholesterol to bile acids. The increased conversion maydecrease low density lipoprotein (LDL) levels in hyperlipidemicsubjects. In embodiments decreased FXR activity reduces the amount ofbile acid returning to the liver

In a first aspect is a compound of formula (I):

In formula (I), X is —CH₂— or —C(O)— or —CY(OH)—. Y is hydrogen,halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OR^(9A), —NHR^(9A),—COOR^(9A), —CONHR^(9A), —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂,—OCH₃, —NHC(O)NHNH₂, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. L¹ isindependently a bond, —C(O)—, —C(O)O—, —O—, —S—, —NR^(9B)—,—C(O)NR^(9B)—, —S(O)_(n)—, —S(O)NR^(9B)—, substituted or unsubstitutedalkylene, substituted or unsubstituted heteroalkylene, substituted orunsubstituted cycloalkylene, substituted or unsubstitutedheterocycloalkylene, substituted or unsubstituted arylene, orsubstituted or unsubstituted heteroarylene. L² is independently a bond,—C(O)—, —C(O)O—, —O—, —S—, —NR^(9C)—, —C(O)NR^(9C)—, —S(O)_(n)—,—S(O)NR^(9C)—, substituted or unsubstituted alkylene, substituted orunsubstituted heteroalkylene, substituted or unsubstitutedcycloalkylene, substituted or unsubstituted heterocycloalkylene,substituted or unsubstituted arylene, or substituted or unsubstitutedheteroarylene. R¹ and R² are independently substituted or unsubstitutedalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl. R³ is hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN,—CHO, —OR^(3A), —NR^(3B)R^(3C), —COOR^(3A), —C(O)NR^(3B)R^(3C), —NO₂,—SR^(3D), —S(O)_(n3)R^(3B), —S(O)_(n3)OR^(3B), —S(O)_(n3)NR^(3B)R^(3C),—NHNR^(3B)R^(3C), —ONR^(3B)R^(3C), —NHC(O)NHNR^(3B)R^(3C), orsubstituted or unsubstituted alkyl. R⁵ is hydrogen or substituted orunsubstituted alkyl. R⁶ is halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN,—CHO, —OR^(6A), —NR^(6B)R^(6C), —COOR^(6A), —CONR^(6B)R^(6C), —NO₂,—SR^(6D), —SO_(n6)R^(6B), —SO_(n6)OR^(6B), —SO_(n6)NR^(6B)R^(6C),—NHNR^(6B)R^(6C), —ONR^(6B)R^(6C), —NHC(O)NHNR^(6B)R^(6C), substitutedor unsubstituted alkyl, or substituted or unsubstituted heteroalkyl. R⁷is independently hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN,—CHO, —OR^(7A), —NR^(7B)R^(7C), —COOR^(7A), —C(O)NR^(7B)R^(7C), —NO₂,—SR^(7D), —S(O)_(n7)R^(7B), —S(O)_(n7)OR^(7B), —S(O)_(n7)NR^(7B)R^(7C),—NHNR^(7B)R^(7C), —ONR^(7B)R^(7D), —NHC(O)NHNR^(7B)R^(7C), substitutedor unsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl. R⁸ is independently hydrogen, halogen, —N₃,—CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(8A), —NR^(8B)R^(8C),—COOR^(8A), C(O)NRBR^(8C), —NO₂, —SR^(8D), —S(O)_(n8)R^(8B),—S(O)_(n8)OR^(8B), —S(O)_(n8)NR^(8B)R^(8C), —NHNR^(8B)R^(8C),—ONR^(8B)R^(8C), —NHC(O)NHNR^(8B)R^(8C), substituted or unsubstitutedalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl. R^(9A), R^(9B), and R^(9C) are independently hydrogen,halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂, —COOH,—CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂,substituted or unsubstituted alkyl, substituted or unsubstitutedheteroalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl. R^(3A), R^(6A), R^(7A), andR^(8A) are independently hydrogen or unsubstituted alkyl. R^(3B),R^(6B), R^(7B), R^(8B), R^(3C), R^(6C), R^(7C), R^(8C), R^(3D),R^(6D)R^(7D), and R^(8D) are independently hydrogen, substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl. The symbol z1 is 1, 2, 3, 4, 5 or 6. Thesymbol z2 is 1, 2, 3, 4, 5, 6, 7 or 8. The symbols n, n3, n6, n7, and n8are independently 1 or 2. In embodiments, if X is —C(O)— and -L¹-R¹ isunsubstituted phenyl, then -L²-R² is not methyl, p-substituted orunsubstituted phenyl, or unsubstituted pyridine.

X may be —CH₂—. X may be —C(O)—. X may be —CY(OH)—. In embodiments, Y ishydrogen or substituted or unsubstituted alkyl. Y may be hydrogen (e.g.X is —C(H)OH—). Y may be substituted or unsubstituted C₁-C₁₀ alkyl. Ymay be substituted or unsubstituted C₁-C₁₀ alkyl. In embodiments, Y ismethyl. In embodiments, Y is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃,—CI₃, —CN, —OR^(9A), —NHR^(9A), —COOR^(9A), —CONHR^(9A), —SH, —SO₃H,—SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂. Y may be halogen,—N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OR⁹A —NHR^(9A), —COOH, or—CONH₂. Y may be halogen, —OR^(9A), —NHR^(9A), —COOR^(9A), —CONHR^(9A).R^(9A) may be hydrogen or C₁-C₅ substituted or unsubstituted alkyl (e.g.methyl). In embodiments, Y is substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl. Y may be substituted or unsubstitutedheteroalkyl (e.g. 2 to 10 membered or 2 to 6 membered heteroalkyl). Ymay be substituted or unsubstituted cycloalkyl (e.g. 3 to 10 membered or3 to 6 membered cycloalkyl). Y may be substituted or unsubstitutedheterocycloalkyl (e.g. 3 to 10 membered or 3 to 6 memberedheterocycloalkyl). Y may be substituted or unsubstituted aryl (e.g. 6membered aryl). Y may be substituted or unsubstituted heteroaryl (e.g. 5or 6 membered heteroaryl).

L¹ may independently be a bond, —C(O)—, —O—, —S—, —NR^(9B)—, —C(O)NR⁹B—,—S(O)_(n)—, —S(O)NR^(9B-). L¹ may independently be a bond, —C(O)—, —O—.L¹ may independently be a bond, —C(O)—, —O—, substituted orunsubstituted alkylene, substituted or unsubstituted heteroalkylene,substituted or unsubstituted cycloalkylene, substituted or unsubstitutedheterocycloalkylene, substituted or unsubstituted arylene, orsubstituted or unsubstituted heteroarylene. L¹ may independently be abond, —C(O)—, substituted or unsubstituted alkylene, substituted orunsubstituted heteroarylene, or substituted or unsubstituted arylene. L¹may independently be a bond. L¹ may independently be substituted orunsubstituted alkylene (e.g. substituted or unsubstituted C₁ to C₁₀alkyl). L¹ may independently be substituted or unsubstitutedheteroarylene (e.g. substituted or unsubstituted 6 membered arylene). L¹may independently be substituted or unsubstituted heteroarylene (e.g.substituted or unsubstituted 5 or 6 membered heteroarylene). Inembodiments L¹ may independently be substituted or unsubstituted fusedring arylene or substituted or unsubstituted fused ring heteroaryl. L¹may independently be a bond. L² may independently be a bond, —C(O)—,—O—, —S—, —NR^(9C)—, —C(O)NR^(9C)—, —S(O)_(n)—, —S(O)NR^(9C-). L² mayindependently be a bond, —C(O)—, —O—. L² may independently be a bond,—C(O)—, —O—, substituted or unsubstituted alkylene, substituted orunsubstituted heteroalkylene, substituted or unsubstitutedcycloalkylene, substituted or unsubstituted heterocycloalkylene,substituted or unsubstituted arylene, or substituted or unsubstitutedheteroarylene. L² may independently be a bond, —C(O)—, substituted orunsubstituted alkylene, substituted or unsubstituted heteroarylene, orsubstituted or unsubstituted arylene. L² may independently be a bond. L²may independently be substituted or unsubstituted alkylene (e.g.substituted or unsubstituted C₁ to C₁₀ alkyl). L² may independently besubstituted or unsubstituted heteroarylene (e.g. substituted orunsubstituted 6 membered arylene). L² may independently be substitutedor unsubstituted heteroarylene (e.g. substituted or unsubstituted 5 or 6membered heteroarylene). In embodiments L² may independently besubstituted or unsubstituted fused ring arylene or substituted orunsubstituted fused ring heteroaryl. L² may independently be a bond. L¹and L² may independently be a bond.

L¹ may independently be substituted or unsubstituted alkylene. L¹ mayindependently be substituted or unsubstituted C₁-C₁₀ alkylene. L¹ mayindependently be substituted or unsubstituted C₁-C₅ alkylene. L¹ mayindependently be R^(12A)-substituted or unsubstituted alkylene. L¹ mayindependently be R^(12A)-substituted or unsubstituted C₁-C₁₀ alkylene.L¹ may independently be R^(12A)-substituted or unsubstituted C₁-C₅alkylene. L² may independently be substituted or unsubstituted alkylene.L² may independently be substituted or unsubstituted C₁-C₁₀ alkylene. L²may independently be substituted or unsubstituted C₁-C₅ alkylene. L² mayindependently be R^(12B)-substituted or unsubstituted alkylene. L² mayindependently be R^(12B-)substituted or unsubstituted C₁-C₁₀ alkylene.L² may independently be R^(12B)-substituted or unsubstituted C₁-C₅alkylene.

L¹ may independently be substituted or unsubstituted heteroalkylene. L¹may independently be substituted or unsubstituted 2 to 10 memberedheteroalkylene. L¹ may independently be substituted or unsubstituted 2to 6 membered heteroalkylene. L¹ may independently beR^(12A)-substituted or unsubstituted heteroalkylene. L¹ mayindependently be R^(12A)-substituted or unsubstituted 2 to 10 memberedheteroalkylene. L¹ may independently be R^(12A)-substituted orunsubstituted 2 to 6 membered heteroalkylene. L² may independently besubstituted or unsubstituted heteroalkylene. L² may independently besubstituted or unsubstituted 2 to 10 membered heteroalkylene. L² mayindependently be substituted or unsubstituted 2 to 6 memberedheteroalkylene. L² may independently be R^(12B)-substituted orunsubstituted heteroalkylene. L² may independently beR^(12B)-substituted or unsubstituted 2 to 10 membered heteroalkylene. L²may independently be R^(12B)-substituted or unsubstituted 2 to 6membered heteroalkylene.

L¹ may independently be substituted or unsubstituted cycloalkylene. L¹may independently be R^(12A)-substituted or unsubstituted cycloalkylene.L¹ may independently be substituted or unsubstitutedheterocycloalkylene. L¹ may independently be R^(12A)-substituted orunsubstituted heterocycloalkylene. L¹ may independently be a substitutedor unsubstituted arylene. L¹ may independently be a R^(12A)-substitutedor unsubstituted arylene. L¹ may independently be a substituted orunsubstituted heteroarylene. L¹ may independently be aR^(12A)-substituted or unsubstituted heteroarylene. L² may independentlybe substituted or unsubstituted cycloalkylene. L² may independently beR^(12B)-substituted or unsubstituted cycloalkylene. L² may independentlybe substituted or unsubstituted heterocycloalkylene. L² mayindependently be R^(12B)-substituted or unsubstitutedheterocycloalkylene. L² may independently be a substituted orunsubstituted arylene. L² may independently be a R^(12B)-substituted orunsubstituted arylene. L² may independently be a substituted orunsubstituted heteroarylene. L² may independently be aR^(12B)-substituted or unsubstituted heteroarylene.

In embodiments, X is —C(O)— and at least one of L¹ and L² is a bond. Inembodiments, X is —C(O)— and L¹ and L² are a bond. X may be —C(O)— andL¹ may be a bond, substituted or unsubstituted alkylene, or substitutedor unsubstituted heteroarylene. In embodiments, X is —C(O)—, L¹ issubstituted or unsubstituted alkylene, and L² is a bond. In embodiments,X is —C(O)—, and L¹ and L² are substituted or unsubstituted alkylene. Inembodiments, X is —CH₂—, and L¹ and L² are independently a bond orsubstituted or unsubstituted alkylene. In embodiments, X is —CH₂—, andL¹ and L² are independently a bond or substituted or unsubstitutedalkylene. In embodiments, X is —CY(OH)—, and L¹ and L² are independentlya bond or substituted or unsubstituted alkylene. In embodiments, X is—CY(OH)—, and L¹ and L² are independently a bond or substituted orunsubstituted alkylene.

R¹² is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, unsubstituted alkyl, unsubstituted heteroalkyl,unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstitutedaryl, or unsubstituted heteroaryl. R¹² may be halogen, —CF₃, —OH, —COOH,or unsubstituted alkyl. R^(12A) is halogen, —N₃, —NO₂, —CF₃, —CCl₃,—CBr₃, —CI₃, —CN, —OH, —NH₂, —COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂,—NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂, unsubstituted alkyl, unsubstitutedheteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl,unsubstituted aryl, or unsubstituted heteroaryl. R^(12A) may be halogen,—CF₃, —OH, —COOH, or unsubstituted alkyl. R^(12B) is halogen, —N₃, —NO₂,—CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂, —COOH, —CONH₂, —SH, —SO₃H,—SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂, unsubstituted alkyl,unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstitutedheterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl.R^(12B) may be halogen, —CF₃, —OH, —COOH, or unsubstituted alkyl.

R¹ may be substituted or unsubstituted alkyl. R¹ may be unsubstitutedalkyl. R¹ may be R¹⁰-substituted or unsubstituted alkyl. R¹ may besubstituted or unsubstituted alkyl. R¹ may be substituted orunsubstituted C₁-C₂₀ alkyl. R¹ may be R¹⁰-substituted or unsubstitutedC₁-C₂₀ alkyl. R¹ may be substituted or unsubstituted C₁-C₁₀ alkyl. R¹may be R¹⁰-substituted or unsubstituted C₁-C₁₀ alkyl. R¹ may besubstituted or unsubstituted C₁-C₅ alkyl. R¹ may be R^(° 0)-substitutedor unsubstituted C₁-C₅ alkyl. R¹ may be unsubstituted C₁-C₃ alkyl.

R¹ may be substituted or unsubstituted heteroalkyl. R¹ may beunsubstituted heteroalkyl. R¹ may be substituted or unsubstituted 2 to20 membered heteroalkyl. R¹ may be R¹⁰-substituted or unsubstituted 2 to20 membered heteroalkyl. R¹ may be substituted or unsubstituted 2 to 10membered heteroalkyl. R¹ may be R¹⁰-substituted or unsubstituted 2 to 10membered heteroalkyl. R¹ may be substituted or unsubstituted 2 to 6membered heteroalkyl. R¹ may be R¹⁰-substituted or unsubstituted 2 to 6membered heteroalkyl.

R¹ may be substituted or unsubstituted cycloalkyl. R¹ may beunsubstituted cycloalkyl. R¹ may be R¹⁰-substituted or unsubstituted 3to 20 membered cycloalkyl. R¹ may be substituted or unsubstituted 3 to20 membered cycloalkyl. R¹ may be substituted or unsubstituted 3 to 10membered cycloalkyl. R¹ may be R¹⁰-substituted or unsubstituted 3 to 10membered cycloalkyl. R¹ may be substituted or unsubstituted 3 to 6membered cycloalkyl. R¹ may be R¹⁰-substituted or unsubstituted 3 to 6membered cycloalkyl.

R¹ may be substituted or unsubstituted heterocycloalkyl. R¹ may beunsubstituted heterocycloalkyl. R¹ may be substituted or unsubstituted 3to 20 membered heterocycloalkyl. R¹ may be R¹⁰-substituted orunsubstituted 3 to 20 membered heterocycloalkyl. R¹ may be substitutedor unsubstituted 3 to 10 membered heterocycloalkyl. R¹ may beR¹⁰-substituted or unsubstituted 3 to 10 membered heterocycloalkyl. R¹may be substituted or unsubstituted 3 to 6 membered heterocycloalkyl. R¹may be R¹⁰-substituted or unsubstituted 3 to 6 memberedheterocycloalkyl.

R¹ may be substituted or unsubstituted aryl. R¹ may be unsubstitutedaryl. R¹ may be substituted or unsubstituted 5 to 10 membered aryl. R¹may be R¹⁰-substituted or unsubstituted 5 to 10 membered aryl. R¹ may besubstituted or unsubstituted 5 to 8 membered aryl. R¹ may beR¹⁰-substituted or unsubstituted 5 to 8 membered aryl. R¹ may besubstituted or unsubstituted 6 membered aryl. R¹ may be R¹⁰-substitutedor unsubstituted 6 membered aryl.

R¹ may be substituted or unsubstituted fused ring aryl (e.g. a 5,6-;6,5-; or 6,6-fused ring aryl). R¹ may be R¹⁰-substituted orunsubstituted fused ring aryl (e.g. a 5,6-; 6,5-; or 6,6-fused ringaryl). R¹ may be substituted or unsubstituted 5,6-fused ring aryl. R¹may be R¹⁰-substituted or unsubstituted 5,6-fused ring aryl. R¹ may beR¹⁰-substituted or unsubstituted 6,5-fused ring aryl. R¹ may beR¹⁰-substituted or unsubstituted 6,5-fused ring aryl. R¹ may beR¹⁰-substituted or unsubstituted 6,6-fused ring aryl. R¹ may beR¹⁰-substituted or unsubstituted 6,6-fused ring aryl.

R¹ may be substituted or unsubstituted heteroaryl. R¹ may beunsubstituted heteroaryl. R¹ may be substituted or unsubstituted 5 to 10membered heteroaryl. R¹ may be R¹⁰-substituted or unsubstituted 5 to 10membered heteroaryl. R¹ may be substituted or unsubstituted 5 to 8membered heteroaryl. R¹ may be R¹⁰-substituted or unsubstituted 5 to 8membered heteroaryl. R¹ may be substituted or unsubstituted 5 or 6membered heteroaryl. R¹ may be R¹⁰-substituted or unsubstituted 5 or 6membered heteroaryl.

R¹ may be substituted or unsubstituted fused ring heteroaryl (e.g. a5,6-; 6,5-; or 6,6-fused ring heteroaryl). R¹ may be R¹⁰-substituted orunsubstituted fused ring heteroaryl (e.g. a 5,6-; 6,5-; or 6,6-fusedring heteroaryl). R¹ may be substituted or unsubstituted 5,6-fused ringheteroaryl. R¹ may be R¹⁰-substituted or unsubstituted 5,6-fused ringheteroaryl. R¹ may be R¹⁰-substituted or unsubstituted 6,5-fused ringheteroaryl. R¹ may be R¹⁰-substituted or unsubstituted 6,5-fused ringheteroaryl. R¹ may be R¹⁰-substituted or unsubstituted 6,6-fused ringheteroaryl. R¹ may be R¹⁰-substituted or unsubstituted 6,6-fused ringheteroaryl.

R¹⁰ is hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO,—OR^(10A), —NR^(10B)R^(10C), —COOR^(10A), —C(O)NR^(10B)R^(10C), —NO₂,—SR^(10D), —S(O)_(n10)R^(10B), —S(O)_(n10)OR^(10B),—S(O)_(n10)NR^(1B)R^(10C), —NHNR^(10B)R^(10C), —ONR^(10B)R^(10C),—NHC(O)NHNR^(1B)R^(10C), R¹³-substituted or unsubstituted alkyl,R¹³-substituted or unsubstituted heteroalkyl, R¹³-substituted orunsubstituted cycloalkyl, R¹³-substituted or unsubstitutedheterocycloalkyl, R¹³-substituted or unsubstituted aryl, orR¹³-substituted or unsubstituted heteroaryl. R¹⁰ may be halogen, —CF₃,—OR^(10A), —NR^(10B)R^(10C), —COOR^(10A), or R¹³-substituted orunsubstituted alkyl. R¹⁰ may be R¹³-substituted or unsubstituted alkyl,R¹³-substituted or unsubstituted heteroalkyl, R¹³-substituted orunsubstituted cycloalkyl, R¹³-substituted or unsubstitutedheterocycloalkyl, R¹³-substituted or unsubstituted aryl, orR¹³-substituted or unsubstituted heteroaryl.

R^(10A), R^(10B), R^(11C), and R^(10D) are independently hydrogen,substituted or unsubstituted alkyl, substituted or unsubstitutedheteroalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl. The symbol n10 is 1 or 2.R^(10A), R^(10B), R^(11C), and R^(10D) may independently be hydrogen orsubstituted or unsubstituted alkyl.

R¹³ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R¹⁴-substituted or unsubstituted alkyl, R¹⁴-substituted orunsubstituted heteroalkyl, R¹⁴-substituted or unsubstituted cycloalkyl,R¹⁴-substituted or unsubstituted heterocycloalkyl, R¹⁴-substituted orunsubstituted aryl, or R¹⁴-substituted or unsubstituted heteroaryl. R¹³may be halogen, —CF₃, —OH, —COOH, or unsubstituted alkyl. R¹³ may beR¹⁴-substituted or unsubstituted alkyl, R¹⁴-substituted or unsubstitutedheteroalkyl, R¹⁴-substituted or unsubstituted cycloalkyl,R¹⁴-substituted or unsubstituted heterocycloalkyl, R¹⁴-substituted orunsubstituted aryl, or R¹⁴⁻substituted or unsubstituted heteroaryl.

R¹⁴ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R¹⁵-substituted or unsubstituted alkyl, R¹⁵-substituted orunsubstituted heteroalkyl, R¹⁵-substituted or unsubstituted cycloalkyl,R¹⁵-substituted or unsubstituted heterocycloalkyl, R¹⁵-substituted orunsubstituted aryl, or R¹⁵-substituted or unsubstituted heteroaryl.

R¹⁵ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R¹⁶-substituted or unsubstituted alkyl, R¹⁶-substituted orunsubstituted heteroalkyl, R¹⁶-substituted or unsubstituted cycloalkyl,R¹⁶-substituted or unsubstituted heterocycloalkyl, R¹⁶-substituted orunsubstituted aryl, or R¹⁶-substituted or unsubstituted heteroaryl.

R¹⁶ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R¹⁴-substituted or unsubstituted alkyl, unsubstitutedheteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl,unsubstituted aryl, or unsubstituted heteroaryl.

R¹ may be unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, or substituted or unsubstituted aryl. In embodiments,R¹ is R¹⁰-substituted or unsubstituted alkyl, R¹⁰-substituted orunsubstituted cycloalkyl, or R¹⁰-substituted or unsubstituted aryl. R¹⁰may independently be halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO,—OR^(10A), —NR^(10B)R^(10C), —COOR^(10A), —C(O)NR^(10B)R^(10C), —NO₂,—SR^(10D), —S(O)_(n10)R^(10B), —S(O)_(n10)OR^(10B),—S(O)_(n10)NR^(10B)R^(10C), —NHNR^(10B)R^(10C), —ONR^(10B)R^(10C),—NHC(O)NHNR^(10B)R^(10C), substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted aryl, or substituted or unsubstituted heteroaryl. R¹⁰may be halogen, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. R¹⁰ maybe halogen, R¹³-substituted or unsubstituted alkyl, R¹³-substituted orunsubstituted heteroalkyl, R¹³-substituted or unsubstituted cycloalkyl,R¹³-substituted or unsubstituted heterocycloalkyl, R¹³-substituted orunsubstituted aryl, or R¹³-substituted or unsubstituted heteroaryl.

In embodiments, R¹ is R¹⁰-substituted or unsubstituted alkyl,unsubstituted cycloalkyl, or R¹⁰-substituted or unsubstituted aryl. R¹⁰may be halogen, CF₃, or —OR^(10A). R¹⁰ may be halogen. R¹⁰ may be CF₃.R¹⁰ may be —OR^(10A). R^(10A) may be hydrogen or unsubstituted C₁-C₅alkyl (e.g. methyl or ethyl).

R^(10A), R^(10B), R^(10C), and R^(10D) may independently be hydrogen.R^(10A), R^(10B), R^(10C), and R^(10D) may independently be substitutedor unsubstituted alkyl. R^(10A), R^(10B), R^(10C), and R^(10D) mayindependently be substituted or unsubstituted aryl. The symbol n10 maybe 1. The symbol n10 may be 2.

R² may be substituted or unsubstituted alkyl. R² may be unsubstitutedalkyl. R² may be R¹⁷-substituted or unsubstituted alkyl. R² may besubstituted or unsubstituted alkyl. R² may be substituted orunsubstituted C₁-C₂₀ alkyl. R² may be R¹⁷-substituted or unsubstitutedC₁-C₂₀ alkyl. R² may be substituted or unsubstituted C₁-C₁₀ alkyl. R²may be R¹⁷-substituted or unsubstituted C₁-C₁₀ alkyl. R² may besubstituted or unsubstituted C₁-C₅ alkyl. R² may be R¹⁷-substituted orunsubstituted C₁-C₅ alkyl.

R² may be substituted or unsubstituted heteroalkyl. R² may beunsubstituted heteroalkyl. R² may be substituted or unsubstituted 2 to20 membered heteroalkyl. R² may be R¹⁷-substituted or unsubstituted 2 to20 membered heteroalkyl. R² may be substituted or unsubstituted 2 to 10membered heteroalkyl. R² may be R¹⁷-substituted or unsubstituted 2 to 10membered heteroalkyl. R² may be substituted or unsubstituted 2 to 6membered heteroalkyl. R² may be R¹⁷-substituted or unsubstituted 2 to 6membered heteroalkyl.

R² may be substituted or unsubstituted cycloalkyl. R² may beunsubstituted cycloalkyl. R² may be R¹⁷-substituted or unsubstituted 3to 20 membered cycloalkyl. R² may be substituted or unsubstituted 3 to20 membered cycloalkyl. R² may be substituted or unsubstituted 3 to 10membered cycloalkyl. R² may be R¹⁷-substituted or unsubstituted 3 to 10membered cycloalkyl. R² may be substituted or unsubstituted 3 to 6membered cycloalkyl. R² may be R¹⁷-substituted or unsubstituted 3 to 6membered cycloalkyl.

R² may be substituted or unsubstituted heterocycloalkyl. R² may beunsubstituted heterocycloalkyl. R² may be substituted or unsubstituted 3to 20 membered heterocycloalkyl. R² may be R¹⁷-substituted orunsubstituted 3 to 20 membered heterocycloalkyl. R² may be substitutedor unsubstituted 3 to 10 membered heterocycloalkyl. R² may beR¹⁷-substituted or unsubstituted 3 to 10 membered heterocycloalkyl. R²may be substituted or unsubstituted 3 to 6 membered heterocycloalkyl. R²may be R¹⁷-substituted or unsubstituted 3 to 6 memberedheterocycloalkyl.

R² may be substituted or unsubstituted aryl. R² may be unsubstitutedaryl. R² may be substituted or unsubstituted 5 to 10 membered aryl. R²may be R¹⁷-substituted or unsubstituted 5 to 10 membered aryl. R² may besubstituted or unsubstituted 5 to 8 membered aryl. R² may beR¹⁷-substituted or unsubstituted 5 to 8 membered aryl. R² may besubstituted or unsubstituted 6 membered aryl. R² may be R¹⁷-substitutedor unsubstituted 6 membered aryl.

R² may be substituted or unsubstituted heteroaryl. R² may beunsubstituted heteroaryl. R² may be substituted or unsubstituted 5 to 10membered heteroaryl. R² may be R¹⁷-substituted or unsubstituted 5 to 10membered heteroaryl. R² may be substituted or unsubstituted 5 to 8membered heteroaryl. R² may be R¹⁷-substituted or unsubstituted 5 to 8membered heteroaryl. R² may be substituted or unsubstituted 5 or 6membered heteroaryl. R² may be R¹⁷-substituted or unsubstituted 5 or 6membered heteroaryl.

R¹⁷ is independently halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO,—OR^(17A), —NR^(17B)R^(17C), —COOR^(17A), —C(O)NR^(17B)R^(17C), —NO₂,—SR^(17D), —S(O)_(n17)R^(17B), —S(O)_(n7)OR^(17B),—S(O)_(n17)NR^(17B)R^(17C), —NHNR^(17B)R^(17C), —ONR^(17B)R^(17C),—NHC(O)NHNR^(17B)R^(17C), R¹⁸-substituted or unsubstituted alkyl,R¹⁸-substituted or unsubstituted heteroalkyl, R¹⁸-substituted orunsubstituted cycloalkyl, R¹⁸-substituted or unsubstitutedheterocycloalkyl, R¹⁸-substituted or unsubstituted aryl, orR¹⁸-substituted or unsubstituted heteroaryl. R¹⁷ may be halogen, —CF₃,—OR^(17A)NR^(17B)R^(17C), —COOR^(17A), or R¹⁸-substituted orunsubstituted alkyl. R¹⁷ may be R¹⁸-substituted or unsubstituted alkyl,R¹⁸-substituted or unsubstituted heteroalkyl, R¹⁸-substituted orunsubstituted cycloalkyl, R¹⁸-substituted or unsubstitutedheterocycloalkyl, R¹⁸-substituted or unsubstituted aryl, orR¹⁸-substituted or unsubstituted heteroaryl.

R^(17A), R^(17B), R^(17C), and R^(17D) are independently hydrogen,substituted or unsubstituted alkyl, substituted or unsubstitutedheteroalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl. The symbol n17 is 1 or 2.R^(17A), R^(17B), R^(17C), and R^(17D) may independently be hydrogen orsubstituted or unsubstituted alkyl.

R^(17A), R^(17B), R^(17C), and R^(17D) may independently be hydrogen.R^(17A), R^(17B), R^(17C), and R^(17D) may independently be substitutedor unsubstituted alkyl. R^(17A), R^(17B), R^(17C), and R^(17D) mayindependently be substituted or unsubstituted aryl. The symbol n17 maybe 1. The symbol n17 may be 2.

R¹⁸ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R¹⁹-substituted or unsubstituted alkyl, R¹⁹-substituted orunsubstituted heteroalkyl, R¹⁹-substituted or unsubstituted cycloalkyl,R¹⁹-substituted or unsubstituted heterocycloalkyl, R¹⁹-substituted orunsubstituted aryl, or R¹⁹-substituted or unsubstituted heteroaryl. R¹⁸may be halogen, —CF₃, —OH, —COOH, or unsubstituted alkyl. R¹⁸ may beR¹⁹-substituted or unsubstituted alkyl, R¹⁹-substituted or unsubstitutedheteroalkyl, R¹⁹-substituted or unsubstituted cycloalkyl,R¹⁹-substituted or unsubstituted heterocycloalkyl, R¹⁹-substituted orunsubstituted aryl, or R¹⁹ substituted or unsubstituted heteroaryl.

R¹⁹ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R²⁰-substituted or unsubstituted alkyl, R²⁰-substituted orunsubstituted heteroalkyl, R²⁰-substituted or unsubstituted cycloalkyl,R²⁰-substituted or unsubstituted heterocycloalkyl, R²⁰-substituted orunsubstituted aryl, or R²⁰-substituted or unsubstituted heteroaryl.

R²⁰ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, unsubstituted alkyl, unsubstituted heteroalkyl,unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstitutedaryl, or unsubstituted heteroaryl.

In embodiments, R² is R¹⁷-substituted or unsubstituted alkyl orR¹⁷-substituted or unsubstituted aryl. R¹⁷ may be halogen, —CF₃,—OR^(17A). R¹⁷ may be halogen. R¹⁷ may be —CF₃. R¹⁷ may be —OR^(17A).R^(17A) may be hydrogen or unsubstituted C₁-C₅ alkyl. In embodiments, Xis —C(O)— and R² is R¹⁷-substituted or unsubstituted alkyl, orR¹⁷-substituted or unsubstituted aryl, where R¹⁷ is —CF₃, OR^(17A).R^(17A) may be hydrogen or unsubstituted C₁-C₅ alkyl. In embodiments, R²is R¹⁷-substituted or unsubstituted aryl, where R¹⁷ is R¹⁸-substitutedor unsubstituted alkyl (e.g. C₁-C₅ alkyl), —OR^(17A), or —CF₃. R^(17A)may be hydrogen or substituted or unsubstituted alkyl (e.g. C₁-C₅alkyl). R¹⁷ may be methyl. R^(17A) may be methyl.

In embodiments, R² is R¹⁷-substituted or unsubstituted alkyl orR¹⁷-substituted or unsubstituted aryl and R¹ is R¹⁰-substituted orunsubstituted alkyl, unsubstituted cycloalkyl, or R¹⁰-substituted orunsubstituted aryl. R¹⁷ and R¹⁰ are as described herein, includingembodiments thereof. L¹ and L² may independently be a bond, —C(O)—,substituted or unsubstituted alkylene, substituted or unsubstitutedheteroarylene, or substituted or unsubstituted arylene. In embodiments,L¹ and L² are a bond. L¹ and L² are substituted or unsubstitutedalkylene. In embodiments, L¹ is substituted or unsubstituted alkyleneand L² is a bond.

R³ may be hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO,—OR^(3A), —NR^(3B)R^(3C), —COOR^(3A), —C(O)NR^(3B)R³, —NO₂, —SR^(3D),—S(O)_(n3)R^(3B), —S(O)_(n3)OR^(3B), —S(O)_(n3)NR^(3B)R^(3C),—NHNR^(3B)R^(3C), —ONR^(3B)R^(3C), —NHC(O)NHNR^(3B)R^(3C). R³ may behydrogen or halogen. R³ may be hydrogen. R³ may be halogen. R³ may besubstituted or unsubstituted alkyl. R³ may be unsubstituted alkyl. R³may be R²¹-substituted or unsubstituted alkyl. R³ may be substituted orunsubstituted C₁-C₂₀ alkyl. R³ may be R²¹-substituted or unsubstitutedC₁-C₂₀ alkyl. R³ may be substituted or unsubstituted C₁-C₁₀ alkyl. R³may be R²¹-substituted or unsubstituted C₁-C₁₀ alkyl. R³ may besubstituted or unsubstituted C₁-C₅ alkyl. R³ may be R²¹-substituted orunsubstituted C₁-C₅ alkyl.

R²¹ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, unsubstituted alkyl, unsubstituted heteroalkyl,unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstitutedaryl, or unsubstituted heteroaryl.

R^(3A) may be hydrogen. R^(3A) may be unsubstituted alkyl. R^(3B),R^(3C), and R^(3D) may independently be hydrogen, substituted orunsubstituted alkyl, or substituted or unsubstituted aryl. R^(3B),R^(3C), and R^(3D) may independently be hydrogen or substituted orunsubstituted alkyl. R^(3B), R^(3C), and R^(3D) may independently behydrogen. R^(3B), R^(3C), and R^(3D) may independently be substituted orunsubstituted alkyl. R^(3B), R^(3C), and R^(3D) may independently besubstituted or unsubstituted heteroalkyl. R^(3B), R^(3C), and R^(3D) mayindependently be substituted or unsubstituted cycloalkyl. R^(3B),R^(3C), and R^(3D) may independently be substituted or unsubstitutedheterocycloalkyl R^(3B), R^(3C), and R^(3D) may independently besubstituted or unsubstituted aryl. R^(3B), R^(3C), and R^(3D) mayindependently be substituted or unsubstituted heteroaryl.

R⁵ may be hydrogen. R⁵ may be substituted or unsubstituted alkyl. R⁵ maybe unsubstituted alkyl. R⁵ may be R²²-substituted or unsubstitutedalkyl. R⁵ may be substituted or unsubstituted C₁-C₂₀ alkyl. R⁵ may beR²²-substituted or unsubstituted C₁-C₂₀ alkyl. R⁵ may be substituted orunsubstituted C₁-C₁₀ alkyl. R⁵ may be R²²-substituted or unsubstitutedC₁-C₁₀ alkyl. R⁵ may be substituted or unsubstituted C₁-C₅ alkyl. R⁵ maybe R²²-substituted or unsubstituted C₁-C₅ alkyl. R⁵ may be unsubstitutedC₁-C₃ alkyl.

R²² is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, unsubstituted alkyl, unsubstituted heteroalkyl,unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstitutedaryl, or unsubstituted heteroaryl.

R⁶ may be halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(6A),—NR^(6B)R^(6C), —COOR^(6A), —CONR^(6B)R^(6C), —NO₂, —SR^(6D),—SO_(n6)R^(6B), —SO_(n6)OR^(6B), —SO_(n6)NR^(6B)R⁶, —NHNR^(6B)R^(6C),—ONR^(6B)R^(6C), —NHC(O)NHNR^(6B)R^(6C). R⁶ may be halogen. R⁶ may besubstituted or unsubstituted alkyl. R⁶ may be unsubstituted alkyl. R⁶may be R²³-substituted or unsubstituted alkyl. R⁶ may be substituted orunsubstituted C₁-C₂₀ alkyl. R⁶ may be R²³-substituted or unsubstitutedC₁-C₂₀ alkyl. R⁶ may be substituted or unsubstituted C₁-C₁₀ alkyl. R⁶may be R²³-substituted or unsubstituted C₁-C₁₀ alkyl. R⁶ may besubstituted or unsubstituted C₁-C₅ alkyl. R⁶ may be R²³-substituted orunsubstituted C₁-C₅ alkyl. R⁶ may be methyl, ethyl or propyl. R⁶ may bemethyl. R⁶ may be ethyl (e.g. unsubstituted ethyl). R⁶ may be propyl(e.g. unsubstituted propyl).

R^(6A) may be hydrogen. R^(6A) may be unsubstituted alkyl. R^(6B),R^(6C), and R^(6D) may independently be hydrogen, substituted orunsubstituted alkyl, or substituted or unsubstituted aryl. R^(6B),R^(6C), and R^(6D) may independently be hydrogen or substituted orunsubstituted alkyl. R^(6B), R^(6C), and R^(6D) may independently behydrogen. R^(6B), R^(6C), and R^(6D) may independently be substituted orunsubstituted alkyl. R^(6B), R^(6C), and R^(6D) may independently besubstituted or unsubstituted heteroalkyl. R^(6B), R^(6C), and R^(6D) mayindependently be substituted or unsubstituted cycloalkyl. R^(6B),R^(6C), and R^(6D) may independently be substituted or unsubstitutedheterocycloalkyl R^(6B), R^(6C), and R^(6D) may independently besubstituted or unsubstituted aryl. R^(6B), R^(6C), and R^(6D) mayindependently be substituted or unsubstituted heteroaryl.

R²³ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R²⁴-substituted or unsubstituted alkyl, R²⁴-substituted orunsubstituted heteroalkyl, R²⁴-substituted or unsubstituted cycloalkyl,R²⁴-substituted or unsubstituted heterocycloalkyl, R²⁴-substituted orunsubstituted aryl, or R²⁴-substituted or unsubstituted heteroaryl.

R²⁴ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, unsubstituted alkyl, unsubstituted heteroalkyl,unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstitutedaryl, or unsubstituted heteroaryl.

R⁷ may independently be hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃,—CI₃, —CN, —CHO, —OR^(7A), —NR^(7B)R^(7C), —COOR^(7A),—C(O)NR^(7B)R^(7C), —NO₂, —SR^(7D), —S(O)_(n7)R^(7B), —S(O)_(n7)OR^(7B),—S(O)_(n7)NR^(7B)R^(7C), —NHNR^(7B)R^(7C), —ONR^(7B)R^(7D),—NHC(O)NHNR^(7B)R^(7C).

R⁷ may independently be hydrogen, halogen, —OR^(7A), —NO₂, or —CN. R¹may independently be hydrogen. R⁷ may independently be halogen. R⁷ mayindependently be hydrogen, halogen, substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted aryl, or substituted or unsubstituted heteroaryl. R⁷may independently be substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl.

R⁷ may independently be substituted or unsubstituted alkyl. R⁷ mayindependently be R²⁵-substituted or unsubstituted alkyl. R⁷ mayindependently be unsubstituted alkyl. R⁷ may independently besubstituted or unsubstituted C₁-C₂₀ alkyl. R⁷ may independently beR²⁵-substituted or unsubstituted C₁-C₂₀ alkyl. R⁷ may independently besubstituted or unsubstituted C₁-C₁₀ alkyl. R⁷ may independently beR²⁵-substituted or unsubstituted C₁-C₁₀ alkyl. R⁷ may independently besubstituted or unsubstituted C₁-C₅ alkyl. R⁷ may independently beR²⁵-substituted or unsubstituted C₁-C₅ alkyl.

R⁷ may independently be substituted or unsubstituted heteroalkyl. R⁷ mayindependently be unsubstituted heteroalkyl. R⁷ may independently besubstituted or unsubstituted 2 to 20 membered heteroalkyl. R⁷ mayindependently be R²⁵-substituted or unsubstituted 2 to 20 memberedheteroalkyl. R⁷ may independently be substituted or unsubstituted 2 to10 membered heteroalkyl. R⁷ may independently be R²⁵-substituted orunsubstituted 2 to 10 membered heteroalkyl. R⁷ may independently besubstituted or unsubstituted 2 to 6 membered heteroalkyl. R⁷ mayindependently be R²⁵-substituted or unsubstituted 2 to 6 memberedheteroalkyl.

R⁷ may independently be substituted or unsubstituted cycloalkyl. R⁷ mayindependently be unsubstituted cycloalkyl. R⁷ may independently beR²⁵-substituted or unsubstituted 3 to 20 membered cycloalkyl. R⁷ mayindependently be substituted or unsubstituted 3 to 20 memberedcycloalkyl. R⁷ may independently be substituted or unsubstituted 3 to 10membered cycloalkyl. R⁷ may independently be R²⁵-substituted orunsubstituted 3 to 10 membered cycloalkyl. R⁷ may independently besubstituted or unsubstituted 3 to 6 membered cycloalkyl. R⁷ mayindependently be R²⁵-substituted or unsubstituted 3 to 6 memberedcycloalkyl.

R⁷ may independently be substituted or unsubstituted heterocycloalkyl.R⁷ may independently be unsubstituted heterocycloalkyl. R⁷ mayindependently be substituted or unsubstituted 3 to 20 memberedheterocycloalkyl. R⁷ may independently be R²⁵-substituted orunsubstituted 3 to 20 membered heterocycloalkyl. R⁷ may independently besubstituted or unsubstituted 3 to 10 membered heterocycloalkyl. R⁷ mayindependently be R²⁵-substituted or unsubstituted 3 to 10 memberedheterocycloalkyl. R⁷ may independently be substituted or unsubstituted 3to 6 membered heterocycloalkyl. R⁷ may independently be R²⁵-substitutedor unsubstituted 3 to 6 membered heterocycloalkyl.

R⁷ may independently be substituted or unsubstituted aryl. R⁷ mayindependently be unsubstituted aryl. R⁷ may independently be substitutedor unsubstituted 5 to 10 membered aryl. R⁷ may independently beR²⁵-substituted or unsubstituted 5 to 10 membered aryl. R⁷ mayindependently be substituted or unsubstituted 5 to 8 membered aryl. R⁷may independently be R²⁵-substituted or unsubstituted 5 to 8 memberedaryl. R⁷ may independently be substituted or unsubstituted 6 memberedaryl. R⁷ may independently be R²⁵-substituted or unsubstituted 6membered aryl.

R⁷ may independently be substituted or unsubstituted heteroaryl. R⁷ mayindependently be unsubstituted heteroaryl. R⁷ may independently besubstituted or unsubstituted 5 to 10 membered heteroaryl. R⁷ mayindependently be R²⁵-substituted or unsubstituted 5 to 10 memberedheteroaryl. R⁷ may independently be substituted or unsubstituted 5 to 8membered heteroaryl. R⁷ may independently be R²⁵-substituted orunsubstituted 5 to 8 membered heteroaryl. R⁷ may independently besubstituted or unsubstituted 5 or 6 membered heteroaryl. R⁷ mayindependently be R²⁵-substituted or unsubstituted 5 or 6 memberedheteroaryl.

R^(7A) may independently be hydrogen. R^(7A) may independently beunsubstituted alkyl. R^(7B), R^(7C), and R^(7D) may independently behydrogen, substituted or unsubstituted alkyl, or substituted orunsubstituted aryl. R^(7B), R^(7C), and R^(7D) may independently behydrogen or substituted or unsubstituted alkyl. R^(7B), R^(7C), andR^(7D) may independently be hydrogen. R^(7B), R^(7C), and R^(7D) mayindependently be substituted or unsubstituted alkyl. R^(7B), R^(7C), andR^(7D) may independently be substituted or unsubstituted heteroalkyl.R^(7B), R^(7C), and R^(7D) may independently be substituted orunsubstituted cycloalkyl. R^(7B), R^(7C), and R^(7D) may independentlybe substituted or unsubstituted heterocycloalkyl R^(7B), R^(7C), andR^(7D) may independently be substituted or unsubstituted aryl. R^(7B),R^(7C), and R^(7D) may independently be substituted or unsubstitutedheteroaryl.

R²⁵ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R²⁶-substituted or unsubstituted alkyl, R²⁶-substituted orunsubstituted heteroalkyl, R²⁶-substituted or unsubstituted cycloalkyl,R²⁶-substituted or unsubstituted heterocycloalkyl, R²⁶-substituted orunsubstituted aryl, or R²⁶-substituted or unsubstituted heteroaryl.

R²⁶ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R²⁷-substituted or unsubstituted alkyl, R²⁷-substituted orunsubstituted heteroalkyl, R²⁷-substituted or unsubstituted cycloalkyl,R²⁷-substituted or unsubstituted heterocycloalkyl, R²⁷-substituted orunsubstituted aryl, or R²⁷-substituted or unsubstituted heteroaryl.

R²⁷ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R²⁸-substituted or unsubstituted alkyl, R²⁸-substituted orunsubstituted heteroalkyl, R²⁸-substituted or unsubstituted cycloalkyl,R²⁸-substituted or unsubstituted heterocycloalkyl, R²⁸-substituted orunsubstituted aryl, or R²⁸-substituted or unsubstituted heteroaryl.

R²⁸ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, unsubstituted alkyl, unsubstituted heteroalkyl,unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstitutedaryl, or unsubstituted heteroaryl.

The symbol z1 may be 1. The symbol z1 may be 2. The symbol z1 may be 3.The symbol z1 may be 4. The symbol z1 may be 5. The symbol z1 may be 6.

R⁸ may independently be hydrogen, halogen, —OR^(8A), —NO₂, or —CN. R⁸may independently be hydrogen. R⁸ may independently be halogen. R⁸ mayindependently be hydrogen, halogen, substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted aryl, or substituted or unsubstituted heteroaryl. R⁸may independently be substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl.

R⁸ may independently be substituted or unsubstituted alkyl. R⁸ mayindependently be R²⁹-substituted or unsubstituted alkyl. R⁸ mayindependently be unsubstituted alkyl. R⁸ may independently besubstituted or unsubstituted C₁-C₂₀ alkyl. R⁸ may independently beR²⁹-substituted or unsubstituted C₁-C₂₀ alkyl. R⁸ may independently besubstituted or unsubstituted C₁-C₁₀ alkyl. R⁸ may independently beR²⁹-substituted or unsubstituted C₁-C₁₀ alkyl. R⁸ may independently besubstituted or unsubstituted C₁-C₅ alkyl. R⁸ may independently beR²⁹-substituted or unsubstituted C₁-C₅ alkyl.

R⁸ may independently be substituted or unsubstituted heteroalkyl. R⁸ mayindependently be unsubstituted heteroalkyl. R⁸ may independently besubstituted or unsubstituted 2 to 20 membered heteroalkyl. R⁸ mayindependently be R²⁹-substituted or unsubstituted 2 to 20 memberedheteroalkyl. R⁸ may independently be substituted or unsubstituted 2 to10 membered heteroalkyl. R⁸ may independently be R²⁹-substituted orunsubstituted 2 to 10 membered heteroalkyl. R⁸ may independently besubstituted or unsubstituted 2 to 6 membered heteroalkyl. R⁸ mayindependently be R²⁹-substituted or unsubstituted 2 to 6 memberedheteroalkyl.

R⁸ may independently be substituted or unsubstituted cycloalkyl. R⁸ mayindependently be unsubstituted cycloalkyl. R⁸ may independently beR²⁹-substituted or unsubstituted 3 to 20 membered cycloalkyl. R⁸ mayindependently be substituted or unsubstituted 3 to 20 memberedcycloalkyl. R⁸ may independently be substituted or unsubstituted 3 to 10membered cycloalkyl. R⁸ may independently be R²⁹-substituted orunsubstituted 3 to 10 membered cycloalkyl. R⁸ may independently besubstituted or unsubstituted 3 to 6 membered cycloalkyl. R⁸ mayindependently be R²⁹-substituted or unsubstituted 3 to 6 memberedcycloalkyl.

R⁸ may independently be substituted or unsubstituted heterocycloalkyl.R⁸ may independently be unsubstituted heterocycloalkyl. R⁸ mayindependently be substituted or unsubstituted 3 to 20 memberedheterocycloalkyl. R⁸ may independently be R²⁹-substituted orunsubstituted 3 to 20 membered heterocycloalkyl. R⁸ may independently besubstituted or unsubstituted 3 to 10 membered heterocycloalkyl. R⁸ mayindependently be R²⁹-substituted or unsubstituted 3 to 10 memberedheterocycloalkyl. R⁸ may independently be substituted or unsubstituted 3to 6 membered heterocycloalkyl. R⁸ may independently be R²⁹-substitutedor unsubstituted 3 to 6 membered heterocycloalkyl.

R⁸ may independently be substituted or unsubstituted aryl. R⁸ mayindependently be unsubstituted aryl. R⁸ may independently be substitutedor unsubstituted 5 to 10 membered aryl. R⁸ may independently beR²⁹-substituted or unsubstituted 5 to 10 membered aryl. R⁸ mayindependently be substituted or unsubstituted 5 to 8 membered aryl. R⁸may independently be R²⁹-substituted or unsubstituted 5 to 8 memberedaryl. R⁸ may independently be substituted or unsubstituted 6 memberedaryl. R⁸ may independently be R²⁹-substituted or unsubstituted 6membered aryl.

R⁸ may independently be substituted or unsubstituted heteroaryl. R⁸ mayindependently be unsubstituted heteroaryl. R⁸ may independently besubstituted or unsubstituted 5 to 10 membered heteroaryl. R⁸ mayindependently be R²⁹-substituted or unsubstituted 5 to 10 memberedheteroaryl. R⁸ may independently be substituted or unsubstituted 5 to 8membered heteroaryl. R⁸ may independently be R²⁹-substituted orunsubstituted 5 to 8 membered heteroaryl. R⁸ may independently besubstituted or unsubstituted 5 or 6 membered heteroaryl. R⁸ mayindependently be R²⁹-substituted or unsubstituted 5 or 6 memberedheteroaryl.

R^(8A) may independently be hydrogen. R^(8A) may independently beunsubstituted alkyl. R^(8B), R^(8C), and R^(8D) may independently behydrogen, substituted or unsubstituted alkyl, or substituted orunsubstituted aryl. R^(8B), R^(8C), and R^(8D) may independently behydrogen or substituted or unsubstituted alkyl. R^(8B), R^(8C), andR^(8D) may independently be hydrogen. R^(8B), R^(8C), and R^(8D) mayindependently be substituted or unsubstituted alkyl. R^(8B), R^(8C), andR^(8D) may independently be substituted or unsubstituted heteroalkyl.R^(8B), R^(8C), and R^(8D) may independently be substituted orunsubstituted cycloalkyl. R^(8B), R^(8C), and R^(8D) may independentlybe substituted or unsubstituted heterocycloalkyl R^(8B), R^(8C), andR^(8D) may independently be substituted or unsubstituted aryl. R^(8B),R^(8C), and R^(8D) may independently be substituted or unsubstitutedheteroaryl.

R²⁹ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R³⁰-substituted or unsubstituted alkyl, R³⁰-substituted orunsubstituted heteroalkyl, R³⁰-substituted or unsubstituted cycloalkyl,R³⁰-substituted or unsubstituted heterocycloalkyl, R³⁰-substituted orunsubstituted aryl, or R³⁰-substituted or unsubstituted heteroaryl.

R³⁰ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R³¹-substituted or unsubstituted alkyl, R³¹-substituted orunsubstituted heteroalkyl, R³¹-substituted or unsubstituted cycloalkyl,R³¹-substituted or unsubstituted heterocycloalkyl, R³¹-substituted orunsubstituted aryl, or R³¹-substituted or unsubstituted heteroaryl.

R³¹ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R³²-substituted or unsubstituted alkyl, R³²-substituted orunsubstituted heteroalkyl, R³²-substituted or unsubstituted cycloalkyl,R³²-substituted or unsubstituted heterocycloalkyl, R³²-substituted orunsubstituted aryl, or R³²-substituted or unsubstituted heteroaryl.

R³² is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, unsubstituted alkyl, unsubstituted heteroalkyl,unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstitutedaryl, or unsubstituted heteroaryl.

The symbol z2 may be 1. The symbol z2 may be 2. The symbol z2 may be 3.The symbol z2 may be 4. The symbol z2 may be 5. The symbol z2 may be 6.The symbol z2 may be 7. The symbol z2 may be 8.

The symbols n, n3, n6, n7, and n8 may independently be 1. The symbols n,n3, n6, n7, and n8 may independently be 2.

In embodiments, X is —C(O)— and -L¹-R¹ is unsubstituted phenyl, and-L²-R² is not methyl, p-substituted or unsubstituted phenyl, orunsubstituted pyridine. In embodiments, X is —C(O)— and -L¹-R¹ isunsubstituted aryl, and -L²-R² is not methyl, p-substituted orunsubstituted phenyl, or unsubstituted pyridine. In embodiments, X is—C(O)— and -L¹-R¹ is unsubstituted aryl, and -L²-R² is not hydrogen,substituted or unsubstituted alkyl, substituted or unsubstituted aryl,or substituted or unsubstituted heteroaryl. In embodiments, X is —C(O)—and -L¹-R¹ is substituted or unsubstituted aryl, and -L²-R² is nothydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. Inembodiments, X is —C(O)— and -L¹-R¹ is hydrogen or substituted orunsubstituted aryl, and -L²-R² is not hydrogen, substituted orunsubstituted alkyl, substituted or unsubstituted aryl, or substitutedor unsubstituted heteroaryl.

In embodiments, X is —CH₂— and -L¹-R¹ is unsubstituted phenyl, and-L²-R² is not methyl, p-substituted or unsubstituted phenyl, orunsubstituted pyridine. In embodiments, X is —CH₂— and -L¹-R¹ isunsubstituted aryl, and -L²-R² is not methyl, p-substituted orunsubstituted phenyl, or unsubstituted pyridine. In embodiments, X is—CH₂— and -L¹-R¹ is unsubstituted aryl, and -L²-R² is not hydrogen,substituted or unsubstituted alkyl, substituted or unsubstituted aryl,or substituted or unsubstituted heteroaryl. In embodiments, X is —CH₂—and -L¹-R¹ is substituted or unsubstituted aryl, and -L²-R² is nothydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. Inembodiments, X is —CH₂— and -L¹-R¹ is hydrogen or substituted orunsubstituted aryl, and -L²-R² is not hydrogen, substituted orunsubstituted alkyl, substituted or unsubstituted aryl, or substitutedor unsubstituted heteroaryl.

The compound of formula (I) may have formula:

The compound of formula (I) may have formula:

In embodiments, R¹ of the compounds herein (e.g. formulas (I), (II), or(III)) is R¹⁰-substituted or unsubstituted alkyl, R¹⁰-substituted orunsubstituted cycloalkyl, or R¹⁰-substituted or unsubstituted aryl,wherein R¹⁰ is independently halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃,—CN, —CHO, —OR^(10A), —NR^(10B)R^(10C), —COOR^(10A),—C(O)NR^(10B)R^(10C), —NO₂, —SR^(10D), —S(O)_(n10)R^(10B),—S(O)_(n10)OR^(10B), —S(O)_(n10)NR^(10B)R^(10C), —NHNR^(10B)R^(10C),—ONR^(10B)R^(10C), —NHC(O)NHNR^(10B)R^(10C), substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl. R^(10A), R^(10B), R^(10C), R^(10D) and n10 areas described herein, including embodiments thereof. In embodiments, R¹of the compounds herein (e.g. formulas (I), (II), or (III)) isR¹⁰-substituted or unsubstituted alkyl, R¹⁰-substituted or unsubstitutedcycloalkyl, R¹⁰-substituted or unsubstituted aryl, or R¹⁰-substituted orunsubstituted heteroaryl.

In embodiments, R¹ is R¹⁰-substituted or unsubstituted 5,6-fused ringaryl, 5,6-fused ring heteroaryl, 6,5-fused ring aryl, 6,5-fused ringheteroaryl, 6,6-fused ring aryl, or 6,6-fused ring heteroaryl. Inembodiments, R¹ is R¹⁰-substituted or unsubstituted 5,6-fused ringheteroaryl. In embodiments, R¹ is R¹⁰-substituted or unsubstituted6,6-fused ring aryl.

In embodiments, R¹ of the compounds herein (e.g. formulas (I), (II), or(III)) is R¹⁰-substituted or unsubstituted alkyl, unsubstitutedcycloalkyl, or R¹⁰-substituted or unsubstituted aryl. R¹⁰ may hydrogen,halogen, —CF₃, —OR^(10A). R^(10A) may be hydrogen or unsubstituted C₁-C₅alkyl.

In embodiments, R² of the compounds herein (e.g. formulas (I), (II), or(III)) is R¹⁷-substituted or unsubstituted alkyl or R¹⁷-substituted orunsubstituted aryl. R¹⁷ may be halogen, —CF₃, —OR¹⁷A. R¹⁷ may behalogen. R¹⁷ may be —CF₃. R¹⁷ may be —OR¹⁷A. R^(17A) may be hydrogen orunsubstituted C₁-C₅ alkyl. In embodiments, X is —C(O)—. R² may beR¹⁷-substituted or unsubstituted alkyl, or R¹⁷-substituted orunsubstituted aryl, where R¹⁷ is —CF₃ or —OR^(17A)R^(17A) may behydrogen or unsubstituted C₁-C₅ alkyl. In embodiments, R² isR¹⁷-substituted or unsubstituted aryl, where R¹⁷ is R¹⁸-substituted orunsubstituted alkyl (e.g. C₁-C₅ alkyl), —OR^(17A), or —CF₃. R^(17A) maybe hydrogen or substituted or unsubstituted alkyl (e.g. C₁-C₅ alkyl).R¹⁷ may be methyl. R^(17A) may be methyl.

In embodiments, R² of the compounds herein (e.g. formulas (I), (II), or(III)) is R¹⁷-substituted or unsubstituted alkyl or R¹⁷-substituted orunsubstituted aryl and R¹ is R¹⁰-substituted or unsubstituted alkyl,unsubstituted cycloalkyl, or R¹⁰-substituted or unsubstituted aryl. R¹⁷and R¹⁰ are as described herein, including embodiments thereof. L¹ andL² may independently be a bond, —C(O)—, substituted or unsubstitutedalkylene, substituted or unsubstituted heteroarylene, or substituted orunsubstituted arylene. In embodiments, L¹ and L² are a bond. L¹ and L²are substituted or unsubstituted alkylene. In embodiments, L¹ issubstituted or unsubstituted alkylene and L² is a bond.

In embodiments, the compound of formula (I), (II), or (III) has formula:

In embodiments, the compound herein (e.g. formula (I), (II), or (III))has formula 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 4j, 4k, 4l, 4m, 4n, 4o,4p, 4q, 4r, 4s, 8-1, 8-2, 8-3, 9-1, 9-2, or 9-3. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula 4a. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula 4b. In embodiments, the compound herein (e.g. formula (I), (II),or (III)) has formula 4c. In embodiments, the compound herein (e.g.formula (I), (II), or (III)) has formula 4d. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula 4e. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula 4f. In embodiments, the compound herein (e.g. formula (I), (II),or (III)) has formula 4g. In embodiments, the compound herein (e.g.formula (I), (II), or (III)) has formula 4h. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula 4i. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula 4j. In embodiments, the compound herein (e.g. formula (I), (II),or (III)) has formula 4k. In embodiments, the compound herein (e.g.formula (I), (II), or (III)) has formula 4l. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula 4m. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula 4n. In embodiments, the compound herein (e.g. formula (I), (II),or (III)) has formula 4o. In embodiments, the compound herein (e.g.formula (I), (II), or (III)) has formula 4p. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula 4q. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula 4r. In embodiments, the compound herein (e.g. formula (I), (II),or (III)) has formula 4s. In embodiments, the compound herein (e.g.formula (I), (II), or (III)) has formula 8-1. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula 8-2. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula 8-3. In embodiments, the compound herein (e.g. formula (I),(II), or (III)) has formula 9-1. In embodiments, the compound herein(e.g. formula (I), (II), or (III)) has formula 9-2. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula 9-3.

In embodiments, the compound herein (e.g. formula (I), (II), or (III))is not a compound selected from 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 4j,4k, 4l, 4m, 4n, 4o, 4p, 4q, 4r, 4s, 8-1, 8-2, 8-3, 9-1, 9-2, 9-3, Z533,Z201, Z380, Z254, Z991, E7, Z993, Z990, Z098, Z992, Z047, Z873, orZ26476908. In embodiments, the compound herein (e.g. formula (I), (II),or (III)) is not 4a. In embodiments, the compound herein (e.g. formula(I), (II), or (III)) is not 4b. In embodiments, the compound herein(e.g. formula (I), (II), or (III)) is not 4c. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) is not 4d. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) isnot 4e. In embodiments, the compound herein (e.g. formula (I), (II), or(III)) is not 4f. In embodiments, the compound herein (e.g. formula (I),(II), or (III)) is not 4g. In embodiments, the compound herein (e.g.formula (I), (II), or (III)) is not 4h. In embodiments, the compoundherein (e.g. formula (I), (II), or (III)) is not 4i. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) is not 4j. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) isnot 4k. In embodiments, the compound herein (e.g. formula (I), (II), or(III)) is not 4l. In embodiments, the compound herein (e.g. formula (I),(II), or (III)) is not 4m. In embodiments, the compound herein (e.g.formula (I), (II), or (III)) is not 4n. In embodiments, the compoundherein (e.g. formula (I), (II), or (III)) is not 4o. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) is not 4p. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) isnot 4q. In embodiments, the compound herein (e.g. formula (I), (II), or(III)) is not 4r. In embodiments, the compound herein (e.g. formula (I),(II), or (III)) is not 4s. In embodiments, the compound herein (e.g.formula (I), (II), or (III)) is not 8-1. In embodiments, the compoundherein (e.g. formula (I), (II), or (III)) is not 8-2. In embodiments,the compound herein (e.g. formula (I), (II), or (III)) is not 8-3. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) isnot 9-1. In embodiments, the compound herein (e.g. formula (I), (II), or(III)) is not 9-2. In embodiments, the compound herein (e.g. formula(I), (II), or (III)) is not 9-3. In embodiments, the compound herein(e.g. formula (I), (II), or (III)) is not Z533. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) is not Z201. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) isnot Z380. In embodiments, the compound herein (e.g. formula (I), (II),or (III)) is not Z254. In embodiments, the compound herein (e.g. formula(I), (II), or (III)) is not Z991. In embodiments, the compound herein(e.g. formula (I), (II), or (III)) is not Z993. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) is not Z990. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) isnot Z098. In embodiments, the compound herein (e.g. formula (I), (II),or (III)) is not Z992. In embodiments, the compound herein (e.g. formula(I), (II), or (III)) is not Z047. In embodiments, the compound herein(e.g. formula (I), (II), or (III)) is not Z873. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) is not Z26476908. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) isnot E7. In embodiments, a compound is a compound described herein (e.g.,a compound described in another aspect or embodiment herein, forexample, in a pharmaceutical composition aspect or embodiment or in amethod aspect or embodiment).

In another aspect a pharmaceutical composition is provided. Thepharmaceutical composition includes a pharmaceutically acceptableexcipient and a compound described herein, including a compound havingformula:

X is —C(R^(4A))(R^(4B))—, —C(O)—, —CY(OH)—. Y is hydrogen, halogen, —N₃,—NO₂, —CF₃, —CCI₃, —CBr₃, —CI₃, —CN, —OR^(9A), —NHR^(9A), —COOR^(9A),—CONHR^(9A), —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. L¹ isindependently a bond, —C(O)—, —C(O)O—, —O—, —S—, —NR^(9B)—,—C(O)NR^(9B)—, —S(O)_(n)—, —S(O)NR^(9B)—, substituted or unsubstitutedalkylene, substituted or unsubstituted heteroalkylene, substituted orunsubstituted cycloalkylene, substituted or unsubstitutedheterocycloalkylene, substituted or unsubstituted arylene, orsubstituted or unsubstituted heteroarylene. L² is independently a bond,—C(O)—, —C(O)O—, —O—, —S—, —NR^(9C)—, —C(O)NR^(9C)—, —S(O)_(n)—,—S(O)NR^(9C)—, substituted or unsubstituted alkylene, substituted orunsubstituted heteroalkylene, substituted or unsubstitutedcycloalkylene, substituted or unsubstituted heterocycloalkylene,substituted or unsubstituted arylene, or substituted or unsubstitutedheteroarylene. R¹, R², R³, R^(4A), R^(4B), R⁵, R⁶, R⁷, and R⁸ areindependently hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN,—CHO, —OR^(11A), —NR^(11B)R^(11C), —COOR^(11A), —C(O)NR^(11B)R^(11C),—NO₂, —SR^(11D), —S(O)_(n11)R^(11B), —S(O)_(n11)OR^(11B),—S(O)_(n11)NR^(11B)R^(11C), —NHNR^(11B)R^(11C), —ONR^(11B)R^(11C),—NHC(O)NHNR^(11B)R^(11C), substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted aryl, or substituted or unsubstituted heteroaryl.R^(9A), R^(9B), and R^(9C) are independently hydrogen, halogen, —N₃,—NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂, —COOH, —CONH₂, —SH,—SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂, substitutedor unsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl. The symbol n and n11 are independently 1 or 2.The symbol z1 is 1, 2, 3, 4, 5, or 6. The symbol z2 is 1, 2, 3, 4, 5, 6,7, or 8. R^(11A), R^(11B), R^(11C), and R^(11D) are independentlyhydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. Thepharmaceutical compositions contemplated herein include pharmaceuticallyacceptable salts thereof, as described herein, including embodimentsthereof.

R¹ is as described herein, including embodiments thereof. R¹ of thepharmaceutical compositions herein may be hydrogen, halogen, —N₃, —CF₃,—CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(11A), —NR^(11B)R^(1C), —COOR^(11A),—C(O)NR^(11B)R^(1C), —NO₂, —SR^(11D), —S(O)_(n11)R^(11B),—S(O)_(n11)OR^(11B), —S(O)_(n11)NR^(11B)R^(11C), —NHNR^(11B)R^(11C),—ONR^(11B)R^(11C), —NHC(O)NHNR^(11B)R^(11C). R¹ of the pharmaceuticalcompositions herein may be hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃,—CI₃, —CN, —CHO, —OR^(11A), or —NO₂. R¹ of the pharmaceuticalcompositions herein may be hydrogen. R¹ of the pharmaceuticalcompositions herein may be halogen. R² of the pharmaceuticalcompositions herein may be —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO,—OR^(11A), or —NO₂. In embodiments, R¹ is not hydrogen. In embodiments,R¹ is not halogen. In embodiments, R¹ is not N₃, —CF₃, —CCl₃, —CBr₃,—CI₃, —CN, —CHO, —OR^(11A), or —NO₂.

R² is as described herein, including embodiments thereof. R² of thepharmaceutical compositions herein may be hydrogen, halogen, —N₃, —CF₃,—CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(11A), —NR^(11B)R^(11C), —COOR^(11A),—C(O)NR^(11B)R^(11C), —NO₂, —SR^(11D), —S(O)_(n11)R_(11B),—S(O)_(n11)OR^(11B), —S(O)_(n11)NR^(11B)R^(11C), —NHNR^(11B)R^(11C),—ONR^(11B)R^(11C), —NHC(O)NHNR^(11B)R^(11C). R² of the pharmaceuticalcompositions herein may be hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃,—CI₃, —CN, —CHO, —OR^(11A), or —NO₂. R² of the pharmaceuticalcompositions herein may be hydrogen. R² of the pharmaceuticalcompositions herein may be halogen. R² of the pharmaceuticalcompositions herein may be —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO,—OR^(11A), or —NO₂. In embodiments, R² is not hydrogen. In embodiment R²is not halogen. In embodiments, R² is not N₃, —CF₃, —CCl₃, —CBr₃, —CI₁₃,—CN, —CHO, —OR^(11A), or —NO₂.

R³ is as described herein, including embodiments thereof. R³ may behydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. R³ maybe hydrogen.

R³ may be substituted or unsubstituted alkyl. R³ may be R³³-substitutedor unsubstituted alkyl. R³ may be unsubstituted alkyl. R³ may besubstituted or unsubstituted C₁-C₂₀ alkyl. R³ may be R³³-substituted orunsubstituted C₁-C₂₀ alkyl. R³ may be substituted or unsubstitutedC₁-C₁₀ alkyl. R³ may be R³³-substituted or unsubstituted C₁-C₁₀ alkyl.R³ may be substituted or unsubstituted C₁-C₅ alkyl. R³ may beR³³-substituted or unsubstituted C₁-C₅ alkyl.

R³ may be substituted or unsubstituted heteroalkyl. R³ may beunsubstituted heteroalkyl. R³ may be substituted or unsubstituted 2 to20 membered heteroalkyl. R³ may be R³³-substituted or unsubstituted 2 to20 membered heteroalkyl. R³ may be substituted or unsubstituted 2 to 10membered heteroalkyl. R³ may be R³³-substituted or unsubstituted 2 to 10membered heteroalkyl. R³ may be substituted or unsubstituted 2 to 6membered heteroalkyl. R³ may be R³³-substituted or unsubstituted 2 to 6membered heteroalkyl.

R³ may be substituted or unsubstituted cycloalkyl. R³ may beunsubstituted cycloalkyl. R³ may be R³³-substituted or unsubstituted 3to 20 membered cycloalkyl. R³ may be substituted or unsubstituted 3 to20 membered cycloalkyl. R³ may be substituted or unsubstituted 3 to 10membered cycloalkyl. R³ may be R³³-substituted or unsubstituted 3 to 10membered cycloalkyl. R³ may be substituted or unsubstituted 3 to 6membered cycloalkyl. R³ may be R³³-substituted or unsubstituted 3 to 6membered cycloalkyl.

R³ may be substituted or unsubstituted heterocycloalkyl. R³ may beunsubstituted heterocycloalkyl. R³ may be substituted or unsubstituted 3to 20 membered heterocycloalkyl. R³ may be R³³-substituted orunsubstituted 3 to 20 membered heterocycloalkyl. R³ may be substitutedor unsubstituted 3 to 10 membered heterocycloalkyl. R³ may beR³³-substituted or unsubstituted 3 to 10 membered heterocycloalkyl. R³may be substituted or unsubstituted 3 to 6 membered heterocycloalkyl. R³may be R³³-substituted or unsubstituted 3 to 6 memberedheterocycloalkyl.

R³ may be substituted or unsubstituted aryl. R³ may be unsubstitutedaryl. R³ may be substituted or unsubstituted 5 to 10 membered aryl. R³may be R³³-substituted or unsubstituted 5 to 10 membered aryl. R³ may besubstituted or unsubstituted 5 to 3 membered aryl. R³ may beR³³-substituted or unsubstituted 5 to 3 membered aryl. R³ may besubstituted or unsubstituted 6 membered aryl. R³ may be R³³-substitutedor unsubstituted 6 membered aryl.

R³ may be substituted or unsubstituted heteroaryl. R³ may beunsubstituted heteroaryl. R³ may be substituted or unsubstituted 5 to 10membered heteroaryl. R³ may be R³³-substituted or unsubstituted 5 to 10membered heteroaryl. R³ may be substituted or unsubstituted 5 to 3membered heteroaryl. R³ may be R³³-substituted or unsubstituted 5 to 3membered heteroaryl. R³ may be substituted or unsubstituted 5 or 6membered heteroaryl. R³ may be R³³-substituted or unsubstituted 5 or 6membered heteroaryl.

R³³ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R³⁴-substituted or unsubstituted alkyl, R³⁴-substituted orunsubstituted heteroalkyl, R³⁴-substituted or unsubstituted cycloalkyl,R³⁴-substituted or unsubstituted heterocycloalkyl, R³⁴-substituted orunsubstituted aryl, or R³⁴-substituted or unsubstituted heteroaryl.

R³⁴ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R³⁵-substituted or unsubstituted alkyl, R³⁵-substituted orunsubstituted heteroalkyl, R³⁵-substituted or unsubstituted cycloalkyl,R³⁵-substituted or unsubstituted heterocycloalkyl, R³⁵-substituted orunsubstituted aryl, or R³⁵-substituted or unsubstituted heteroaryl.

R³⁵ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, unsubstituted alkyl, unsubstituted heteroalkyl,unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstitutedaryl, or unsubstituted heteroaryl.

R^(4A) and R^(4B) may independently be hydrogen, halogen, —N₃, —CF₃,—CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(11A), —NR^(11B)R^(11C), —COOR^(11A),—C(O)NR^(11B)R^(11C), —NO₂, —SR^(11D), —S(O)_(n111)R^(11B),—S(O)_(n10)R^(11B), —S(O)_(n11)NR^(11B)R^(11C), —NHNR^(11B)R^(11C),—ONR^(11B)R^(11C), —NHC(O)NHNR^(11B)R^(11C). R^(4A) and R^(4B) mayindependently be hydrogen, halogen, substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted aryl, or substituted or unsubstituted heteroaryl. Inembodiments, R^(4A) is not hydrogen.

R^(4A) and R^(4B) may independently be substituted or unsubstitutedalkyl. R^(4A) and R^(4B) may independently be R³⁶-substituted orunsubstituted alkyl. R^(4A) and R^(4B) may independently beunsubstituted alkyl. R^(4A) and R^(4B) may independently be substitutedor unsubstituted C₁-C₂₀ alkyl. R^(4A) and R^(4B) may independently beR³⁶-substituted or unsubstituted C₁-C₂₀ alkyl. R³ may independently besubstituted or unsubstituted C₁-C₁₀ alkyl. R^(4A) and R^(4B) mayindependently be R³⁶-substituted or unsubstituted C₁-C₁₀ alkyl. R^(4A)and R^(4B) may independently be substituted or unsubstituted C₁-C₅alkyl. R^(4A) and R^(4B) may independently be R³⁶-substituted orunsubstituted C₁-C₅ alkyl.

R^(4A) and R^(4B) may independently be substituted or unsubstitutedheteroalkyl. R³ may independently be unsubstituted heteroalkyl. R^(4A)and R^(4B) may independently be substituted or unsubstituted 2 to 20membered heteroalkyl. R^(4A) and R^(4B) may independently beR³⁶-substituted or unsubstituted 2 to 20 membered heteroalkyl. R^(4A)and R^(4B) may independently be substituted or unsubstituted 2 to 10membered heteroalkyl. R^(4A) and R^(4B) may independently beR³⁶-substituted or unsubstituted 2 to 10 membered heteroalkyl. R^(4A)and R^(4B) may independently be substituted or unsubstituted 2 to 6membered heteroalkyl. R^(4A) and R^(4B) may independently beR³⁶-substituted or unsubstituted 2 to 6 membered heteroalkyl.

R^(4A) and R^(4B) may independently be substituted or unsubstitutedcycloalkyl. R^(4A) and R^(4B) may independently be unsubstitutedcycloalkyl. R^(4A) and R^(4B) may independently be R³⁶-substituted orunsubstituted 3 to 20 membered cycloalkyl. R^(4A) and R^(4B) mayindependently be substituted or unsubstituted 3 to 20 memberedcycloalkyl. R^(4A) and R^(4B) may independently be substituted orunsubstituted 3 to 10 membered cycloalkyl. R^(4A) and R^(4B) mayindependently be R³⁶-substituted or unsubstituted 3 to 10 memberedcycloalkyl. R^(4A) and R^(4B) may independently be substituted orunsubstituted 3 to 6 membered cycloalkyl. R^(4A) and R^(4B) mayindependently be R³⁶-substituted or unsubstituted 3 to 6 memberedcycloalkyl.

R^(4A) and R^(4B) may independently be substituted or unsubstitutedheterocycloalkyl. R^(4A) and R^(4B) may independently be unsubstitutedheterocycloalkyl. R^(4A) and R^(4B) may independently be substituted orunsubstituted 3 to 20 membered heterocycloalkyl. R^(4A) and R^(4B) mayindependently be R³⁶-substituted or unsubstituted 3 to 20 memberedheterocycloalkyl. R^(4A) and R^(4B) may independently be substituted orunsubstituted 3 to 10 membered heterocycloalkyl. R^(4A) and R^(4B) mayindependently be R³⁶-substituted or unsubstituted 3 to 10 memberedheterocycloalkyl. R^(4A) and R^(4B) may independently be substituted orunsubstituted 3 to 6 membered heterocycloalkyl. R^(4A) and R^(4B) mayindependently be R³⁶-substituted or unsubstituted 3 to 6 memberedheterocycloalkyl.

R^(4A) and R^(4B) may independently be substituted or unsubstitutedaryl. R^(4A) and R^(4B) may independently be unsubstituted aryl. R^(4A)and R^(4B) may independently be substituted or unsubstituted 5 to 10membered aryl. R^(4A) and R^(4B) may independently be R³⁶-substituted orunsubstituted 5 to 10 membered aryl. R^(4A) and R^(4B) may independentlybe substituted or unsubstituted 5 to 3 membered aryl. R^(4A) and R^(4B)may independently be R³⁶-substituted or unsubstituted 5 to 3 memberedaryl. R^(4A) and R^(4B) may independently be substituted orunsubstituted 6 membered aryl. R^(4A) and R^(4B) may independently beR³⁶-substituted or unsubstituted 6 membered aryl.

R^(4A) and R^(4B) may independently be substituted or unsubstitutedheteroaryl. R^(4A) and R^(4B) may independently be unsubstitutedheteroaryl. R^(4A) and R^(4B) may independently be substituted orunsubstituted 5 to 10 membered heteroaryl. R^(4A) and R^(4B) mayindependently be R³⁶-substituted or unsubstituted 5 to 10 memberedheteroaryl. R^(4A) and R^(4B) may independently be substituted orunsubstituted 5 to 3 membered heteroaryl. R^(4A) and R^(4B) mayindependently be R³⁶-substituted or unsubstituted 5 to 3 memberedheteroaryl. R^(4A) and R^(4B) may independently be substituted orunsubstituted 5 or 6 membered heteroaryl. R^(4A) and R^(4B) mayindependently be R³⁶-substituted or unsubstituted 5 or 6 memberedheteroaryl.

R³⁶ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R³⁷-substituted or unsubstituted alkyl, R³⁷-substituted orunsubstituted heteroalkyl, R³⁷-substituted or unsubstituted cycloalkyl,R³⁷-substituted or unsubstituted heterocycloalkyl, R³⁷-substituted orunsubstituted aryl, or R³⁷-substituted or unsubstituted heteroaryl.

R³⁷ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R³⁸-substituted or unsubstituted alkyl, R³⁸-substituted orunsubstituted heteroalkyl, R³⁸-substituted or unsubstituted cycloalkyl,R³⁸-substituted or unsubstituted heterocycloalkyl, R³⁸-substituted orunsubstituted aryl, or R³⁸-substituted or unsubstituted heteroaryl.

R³⁸ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, unsubstituted alkyl, unsubstituted heteroalkyl,unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstitutedaryl, or unsubstituted heteroaryl.

R⁵ is as described herein, including embodiments thereof. R⁵ may behydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(11A),—NR^(11B)R^(11C), —COOR^(11A), —C(O)NR^(11B)R^(11C), —NO₂, —SR^(11D),—S(O)_(n11)R^(11B), —S(O)_(n11) OR^(11B), —S(O)_(n11)NR^(11B)R^(11C),—NHNR^(11B)R^(11C), —ONR^(11B)R^(11C), —NHC(O)NHNR^(11B)R^(11C). R⁵ maybe hydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. R⁵ maybe hydrogen. R⁵ may be substituted or unsubstituted alkyl, substitutedor unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl.

R⁵ may be substituted or unsubstituted alkyl. R⁵ may be R³⁹-substitutedor unsubstituted alkyl. R⁵ may be unsubstituted alkyl. R⁵ may besubstituted or unsubstituted C₁-C₂₀ alkyl. R⁵ may be R³⁹-substituted orunsubstituted C₁-C₂₀ alkyl. R⁵ may be substituted or unsubstitutedC₁-C₁₀ alkyl. R⁵ may be R³⁹-substituted or unsubstituted C₁-C₁₀ alkyl.R⁵ may be substituted or unsubstituted C₁-C₅ alkyl. R⁵ may beR³⁹-substituted or unsubstituted C₁-C₅ alkyl.

R⁵ may be substituted or unsubstituted heteroalkyl. R⁵ may beunsubstituted heteroalkyl. R⁵ may be substituted or unsubstituted 2 to20 membered heteroalkyl. R⁵ may be R³⁹-substituted or unsubstituted 2 to20 membered heteroalkyl. R⁵ may be substituted or unsubstituted 2 to 10membered heteroalkyl. R⁵ may be R³⁹-substituted or unsubstituted 2 to 10membered heteroalkyl. R⁵ may be substituted or unsubstituted 2 to 6membered heteroalkyl. R⁵ may be R³⁹-substituted or unsubstituted 2 to 6membered heteroalkyl.

R⁵ may be substituted or unsubstituted cycloalkyl. R⁵ may beunsubstituted cycloalkyl. R⁵ may be R³⁹-substituted or unsubstituted 3to 20 membered cycloalkyl. R⁵ may be substituted or unsubstituted 3 to20 membered cycloalkyl. R⁵ may be substituted or unsubstituted 3 to 10membered cycloalkyl. R⁵ may be R³⁹-substituted or unsubstituted 3 to 10membered cycloalkyl. R⁵ may be substituted or unsubstituted 3 to 6membered cycloalkyl. R⁵ may be R³⁹-substituted or unsubstituted 3 to 6membered cycloalkyl.

R⁵ may be substituted or unsubstituted heterocycloalkyl. R⁵ may beunsubstituted heterocycloalkyl. R⁵ may be substituted or unsubstituted 3to 20 membered heterocycloalkyl. R⁵ may be R³⁹-substituted orunsubstituted 3 to 20 membered heterocycloalkyl. R⁵ may be substitutedor unsubstituted 3 to 10 membered heterocycloalkyl. R⁵ may beR³⁹-substituted or unsubstituted 3 to 10 membered heterocycloalkyl. R⁵may be substituted or unsubstituted 3 to 6 membered heterocycloalkyl. R⁵may be R³⁹-substituted or unsubstituted 3 to 6 memberedheterocycloalkyl.

R⁵ may be substituted or unsubstituted aryl. R⁵ may be unsubstitutedaryl. R⁵ may be substituted or unsubstituted 5 to 10 membered aryl. R⁵may be R³⁹-substituted or unsubstituted 5 to 10 membered aryl. R⁵ may besubstituted or unsubstituted 5 to 5 membered aryl. R⁵ may beR³⁹-substituted or unsubstituted 5 to 3 membered aryl. R⁵ may besubstituted or unsubstituted 6 membered aryl. R⁵ may be R³⁹-substitutedor unsubstituted 6 membered aryl.

R⁵ may be substituted or unsubstituted heteroaryl. R⁵ may beunsubstituted heteroaryl. R⁵ may be substituted or unsubstituted 5 to 10membered heteroaryl. R⁵ may be R³⁹-substituted or unsubstituted 5 to 10membered heteroaryl. R⁵ may be substituted or unsubstituted 5 to 3membered heteroaryl. R⁵ may be R³⁹-substituted or unsubstituted 5 to 3membered heteroaryl. R⁵ may be substituted or unsubstituted 5 or 6membered heteroaryl. R⁵ may be R³⁹-substituted or unsubstituted 5 or 6membered heteroaryl.

R³⁹ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R⁴⁰-substituted or unsubstituted alkyl, R⁴⁰-substituted orunsubstituted heteroalkyl, R⁴⁰-substituted or unsubstituted cycloalkyl,R⁴⁰-substituted or unsubstituted heterocycloalkyl, R⁴⁰-substituted orunsubstituted aryl, or R⁴⁰-substituted or unsubstituted heteroaryl.

R⁴⁰ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, R⁴¹-substituted or unsubstituted alkyl, R⁴¹-substituted orunsubstituted heteroalkyl, R⁴¹-substituted or unsubstituted cycloalkyl,R⁴¹-substituted or unsubstituted heterocycloalkyl, R⁴¹-substituted orunsubstituted aryl, or R⁴¹-substituted or unsubstituted heteroaryl.

R⁴¹ is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂,—COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃,—NHC(O)NHNH₂, unsubstituted alkyl, unsubstituted heteroalkyl,unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstitutedaryl, or unsubstituted heteroaryl.

R⁶ is as described herein, including embodiments thereof. R⁶ may behydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. R⁶ maybe substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl.

R⁶ may be substituted or unsubstituted cycloalkyl. R⁶ may beunsubstituted cycloalkyl. R⁶ may be R²³-substituted or unsubstituted 3to 20 membered cycloalkyl. R⁶ may be substituted or unsubstituted 3 to20 membered cycloalkyl. R⁶ may be substituted or unsubstituted 3 to 10membered cycloalkyl. R⁶ may be R²³-substituted or unsubstituted 3 to 10membered cycloalkyl. R⁶ may be substituted or unsubstituted 3 to 6membered cycloalkyl. R⁶ may be R²³-substituted or unsubstituted 3 to 6membered cycloalkyl.

R⁶ may be substituted or unsubstituted heterocycloalkyl. R⁶ may beunsubstituted heterocycloalkyl. R⁶ may be substituted or unsubstituted 3to 20 membered heterocycloalkyl. R⁶ may be R²³-substituted orunsubstituted 3 to 20 membered heterocycloalkyl. R⁶ may be substitutedor unsubstituted 3 to 10 membered heterocycloalkyl. R⁶ may beR²³-substituted or unsubstituted 3 to 10 membered heterocycloalkyl. R⁶may be substituted or unsubstituted 3 to 6 membered heterocycloalkyl. R⁶may be R²³-substituted or unsubstituted 3 to 6 memberedheterocycloalkyl.

R⁶ may be substituted or unsubstituted aryl. R⁶ may be unsubstitutedaryl. R⁶ may be substituted or unsubstituted 5 to 10 membered aryl. R⁶may be R²³-substituted or unsubstituted 5 to 10 membered aryl. R⁶ may besubstituted or unsubstituted 5 to 5 membered aryl. R⁶ may beR²³-substituted or unsubstituted 5 to 3 membered aryl. R⁶ may besubstituted or unsubstituted 6 membered aryl. R⁶ may be R²³-substitutedor unsubstituted 6 membered aryl.

R⁶ may be substituted or unsubstituted heteroaryl. R⁶ may beunsubstituted heteroaryl. R⁶ may be substituted or unsubstituted 5 to 10membered heteroaryl. R⁶ may be R²³-substituted or unsubstituted 5 to 10membered heteroaryl. R⁶ may be substituted or unsubstituted 5 to 3membered heteroaryl. R⁶ may be R²³-substituted or unsubstituted 5 to 3membered heteroaryl. R⁶ may be substituted or unsubstituted 5 or 6membered heteroaryl. R⁶ may be R²³-substituted or unsubstituted 5 or 6membered heteroaryl.

R²³ is as described herein, including embodiments thereof.

R⁷, R⁸, R^(9A), R^(9B), and R^(9C), are as described herein, includingembodiments thereof.

The symbol n11 may be 1. The symbol n11 may be 2. The symbol z1 and z2are as described herein, including embodiments thereof. R^(11A),R^(11B), R¹¹, and R^(11D) may independently hydrogen, substituted orunsubstituted alkyl, or unsubstituted aryl. In embodiments, thepharmaceutical composition includes a compound of formula (I), (II), or(III), including embodiments thereof and optionally a pharmaceuticallyacceptable excipient as described herein. In embodiments, pharmaceuticalcomposition includes a compound as described herein (e.g., a compounddescribed in another aspect or embodiment herein, for example, in acompound aspect or embodiment or in a method aspect or embodiment),including embodiments thereof (e.g. formula (I), (II), or (III) orformula 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 4j, 4k, 4l, 4m, 4n, 4o, 4p,4q, 4r, 4s, 8-1, 8-2, 8-3, 9-1, 9-2, 9-3, Z533, Z201, Z380, Z254, Z991,E7, Z993, Z990, Z098, Z992, Z047, Z873, or Z26476908). Thepharmaceutical composition may optionally include a pharmaceuticallyacceptable excipient as described herein.

In another aspect is a method of treating metabolic disease in a subjectin need thereof. The method includes administering to the subject inneed thereof, a compound described herein, including for example acompound of formula:

including pharmaceutically acceptable salts and pharmaceuticallyacceptable compositions (as described herein, including all itsembodiments) thereof.

X, Y, L¹, L², z1, z2, n, n3, n6, n7, n8, n10, n11, R¹, R², R³, R^(4A),R^(4B), R⁵, R⁶, R, R⁸, R^(9A), R^(9B), R^(9C), R¹⁰, R^(10A), R^(10B),R^(10C), R^(10D), R¹¹, R^(11A), R^(11B), R^(11C), and R^(11D), are asdescribed herein, including embodiments thereof. In embodiments, themethod includes administering a pharmaceutically composition asdescribed herein, including embodiments thereof. In embodiments, acompound used in the method is a compound described herein (e.g., acompound described in another aspect or embodiment herein, for example,in a compound aspect or embodiment or a pharmaceutical compositionaspect or embodiment or in another method aspect or embodiment).

In embodiments, R¹ and R² are independently substituted or unsubstitutedalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl, X is —CH₂— or —C(O)—, and R⁵ is hydrogen or substituted orunsubstituted alkyl. In a further embodiment, R⁶ is substituted orunsubstituted C₁-C₅ alkyl as described herein, including embodimentsthereof.

The compound of the method of treating may have formula (II) asdescribed herein, including embodiments thereof. X, R¹, R², R³, R⁵, R⁶are as described herein, including embodiments thereof.

In embodiments, R¹ is R¹⁰-substituted or unsubstituted alkyl,R¹⁰-substituted or unsubstituted cycloalkyl, or R¹⁰-substituted orunsubstituted aryl, wherein R¹⁰ is independently halogen, —N₃, —CF₃,—CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(10A), —NR^(11B)R^(10C), —COOR^(10A),—C(O)NR^(10B)R^(10C), —NO₂, —SR^(10D), —S(O)_(n10)R^(10B),—S(O)_(n10)OR^(10B), —S(O)_(n10)NR^(10B)R^(10C), —NHNR^(10B)R^(10C),—ONR^(10B)R^(10C), —NHC(O)NHNR^(10B)R^(10C), substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl. R^(10A), R^(10B), R^(10C), R^(10D) and n10 areas described herein, including embodiments thereof.

In embodiments, R¹ is R¹⁰-substituted or unsubstituted alkyl,unsubstituted cycloalkyl, or R¹⁰-substituted or unsubstituted aryl. R¹⁰may hydrogen, halogen, CF₃, OR¹⁰A. R^(10A) may be hydrogen orunsubstituted C₁-C₅ alkyl.

In embodiments, R² is R¹⁷-substituted or unsubstituted alkyl orR¹⁷-substituted or unsubstituted aryl. R¹⁷ may be halogen, —CF₃,—OR^(17A). R¹⁷ may be halogen. R¹⁷ may be —CF₃. R¹⁷ may be —OR^(17A).R^(17A) may be hydrogen or unsubstituted C₁-C₅ alkyl. In embodiments, Xis —C(O)—. R² may be R¹⁷-substituted or unsubstituted alkyl, orR¹⁷-substituted or unsubstituted aryl, where R¹⁷ is —CF₃, OR^(17A).R^(17A) may be hydrogen or unsubstituted C₁-C₅ alkyl. In embodiments, R²is R¹⁷-substituted or unsubstituted aryl, where R¹⁷ is R¹⁸-substitutedor unsubstituted alkyl (e.g. C₁-C₅ alkyl), —OR^(17A), or —CF₃. R^(17A)may be hydrogen or substituted or unsubstituted alkyl (e.g. C₁-C₅alkyl). R¹⁷ may be methyl. R^(17A) may be methyl.

In embodiments, R² is R¹⁷-substituted or unsubstituted alkyl orR¹⁷-substituted or unsubstituted aryl and R¹ is R¹⁰-substituted orunsubstituted alkyl, unsubstituted cycloalkyl, or R¹⁰-substituted orunsubstituted aryl. R¹⁷ and R¹⁰ are as described herein, includingembodiments thereof. L¹ and L² may independently be a bond, —C(O)—,substituted or unsubstituted alkylene, substituted or unsubstitutedheteroarylene, or substituted or unsubstituted arylene. In embodiments,L¹ and L² are a bond. L¹ and L² are substituted or unsubstitutedalkylene. In embodiments, L¹ is substituted or unsubstituted alkyleneand L² is a bond.

In embodiments, the compound of the method has formula:

In embodiments, the compound herein (e.g. formula (I), (II), or (III))has formula 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 4j, 4k, 4l, 4m, 4n, 4o,4p, 4q, 4r, 4s, 8-1, 8-2, 8-3, 9-1, 9-2, 9-3, Z533, Z201, Z380, Z254,Z991, E7, Z993, Z990, Z098, Z992, Z047, Z873, or Z26476908. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula 4a. In embodiments, the compound herein (e.g. formula (I), (II),or (III)) has formula 4b. In embodiments, the compound herein (e.g.formula (I), (II), or (III)) has formula 4c. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula 4d. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula 4e. In embodiments, the compound herein (e.g. formula (I), (II),or (III)) has formula 4f. In embodiments, the compound herein (e.g.formula (I), (II), or (III)) has formula 4g. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula 4h. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula 4i. In embodiments, the compound herein (e.g. formula (I), (II),or (III)) has formula 4j. In embodiments, the compound herein (e.g.formula (I), (II), or (III)) has formula 4k. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula 4l. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula 4m. In embodiments, the compound herein (e.g. formula (I), (II),or (III)) has formula 4n. In embodiments, the compound herein (e.g.formula (I), (II), or (III)) has formula 4o. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula 4p. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula 4q. In embodiments, the compound herein (e.g. formula (I), (II),or (III)) has formula 4r. In embodiments, the compound herein (e.g.formula (I), (II), or (III)) has formula 4s. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula 8-1. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula 8-2. In embodiments, the compound herein (e.g. formula (I),(II), or (III)) has formula 8-3. In embodiments, the compound herein(e.g. formula (I), (II), or (III)) has formula 9-1. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula 9-2. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula 9-3. In embodiments, the compound herein (e.g. formula (I),(II), or (III)) has formula Z533. In embodiments, the compound herein(e.g. formula (I), (II), or (III)) has formula Z201. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula Z380. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula Z254. In embodiments, the compound herein (e.g. formula (I),(II), or (III)) has formula Z991. In embodiments, the compound herein(e.g. formula (I), (II), or (III)) has formula E7. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula Z993. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula Z990. In embodiments, the compound herein (e.g. formula (I),(II), or (III)) has formula Z098. In embodiments, the compound herein(e.g. formula (I), (II), or (III)) has formula Z992. In embodiments, thecompound herein (e.g. formula (I), (II), or (III)) has formula Z047. Inembodiments, the compound herein (e.g. formula (I), (II), or (III)) hasformula Z873. In embodiments, the compound herein (e.g. formula (I),(II), or (III)) has formula Z26476908.

The metabolic disease may be dyslipidemia, insulin-resistance, increasedblood pressure, visceral obesity, cholestasis, or hypercoagubility. Themetabolic disease may be dyslipidemia. The metabolic disease may beinsulin-resistance. The metabolic disease may be increased bloodpressure. The metabolic disease may be visceral obesity. The metabolicdisease may be cholestasis. The metabolic disease may behypercoagubility. In embodiments, the metabolic diseases includes atleast one of dyslipidemia, insulin-resistance, increased blood pressure,visceral obesity, cholestasis, or hypercoagubility. In embodiments, themetabolic disease includes at least cholestasis or at leastdyslipidemia. In embodiments the dyslipidemia is hypertriglyceridemia.

In another aspect is provided a method of antagonizing an FXR protein.The method includes contacting an FXR protein with a compound disclosedherein (e.g. formula (I), (II), or (III)), thereby antagonizing the FXRprotein.

In embodiments, X, Y, L¹, L², z1, z2, n, n3, n6, n7, n8, n10, n11, R¹,R², R³, R^(4A), R^(4B), R⁵, R⁶, R⁷, R⁸, R^(9A), R^(9B), R^(9C), R¹⁰,R^(10A), R^(10B), R^(10C), ROD, R¹¹, R^(11A), R^(11B), R^(11C), andR^(11D), are as described herein, including embodiments thereof. Inembodiments, the method includes administering a pharmaceuticallycomposition as described herein, including embodiments thereof. Inembodiments, a compound disclosed herein is a compound described herein(e.g., a compound described in another aspect or embodiment herein, forexample, in a compound aspect or embodiment or a pharmaceuticalcomposition aspect or embodiment or in another method aspect orembodiment).

ADDITIONAL EMBODIMENTS

1. A compound having the formula:

(I) wherein, X is —CH₂— or —C(O)— or —CY(OH)—; Y is hydrogen, halogen,—N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OR^(9A), —NHR^(9A),—COOR^(9A), —CONHR^(9A), —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂,—OCH₃, —NHC(O)NHNH₂, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl; L¹ isindependently a bond, —C(O)—, —C(O)—O, —O—, —S—, —NR^(9B)—,—C(O)NR^(9B)—, —S(O)_(n)—, —S(O)NR^(9B)—, substituted or unsubstitutedalkylene, substituted or unsubstituted heteroalkylene, substituted orunsubstituted cycloalkylene, substituted or unsubstitutedheterocycloalkylene, substituted or unsubstituted arylene, orsubstituted or unsubstituted heteroarylene; L² is independently a bond,—C(O)—, —C(O)—O, —O—, —S—, —NR^(9C)—, —C(O)NR^(9C)—, —S(O)_(n)—,—S(O)NR^(9C)—, substituted or unsubstituted alkylene, substituted orunsubstituted heteroalkylene, substituted or unsubstitutedcycloalkylene, substituted or unsubstituted heterocycloalkylene,substituted or unsubstituted arylene, or substituted or unsubstitutedheteroarylene; R¹ and R² are independently substituted or unsubstitutedalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl; R³ is hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN,—CHO, —OR^(3A), —NR^(3B)R^(3C), —COOR^(3A), —C(O)NR^(3B)R^(3C), —NO₂,—SR^(3D), —S(O)_(n3)R^(3B), —S(O)_(n3)OR^(3B), —S(O)_(n3)NR^(3B)R^(3C),—NHNR^(3B)R^(3C), —ONR^(3B)R^(3C), —NHC(O)NHNR^(3B)R^(3C), orsubstituted or unsubstituted alkyl, R⁵ is hydrogen or substituted orunsubstituted alkyl; R⁶ is halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN,—CHO, —OR^(6A), —NR^(6B)R^(6C), —COOR^(6A), —CONR^(6B)R^(6C), —NO₂,—SR^(6D), —SO_(n6)R^(6B), —SO_(n60)R^(6B), —SO_(n6)NR^(6B)R^(6C),—NHNR^(6B)R^(6C), —ONR^(6B)R^(6C), —NHC(O)NHNR^(6B)R^(6C), substitutedor unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; R⁷is independently hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN,—CHO, —OR^(7A), —NR^(7B)R^(7C), —COOR^(7A), —C(O)NR^(7B)R^(7C), —NO₂,—SR^(7D), —S(O)_(n7)R^(7B), —S(O)_(n7)OR^(7B), —S(O)_(n7)NR^(7B)R^(7C),—NHNR^(7B)R^(7C), —ONR^(7B)R^(7D), —NHC(O)NHNR^(7B)R^(7C), substitutedor unsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl; R⁸ is independently hydrogen, halogen, —N₃,—CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(8A), —NR^(8B)R^(8C),—COOR^(8A), —C(O)NR^(8B)R^(8C), —NO₂, —SR^(8D), —S(O)_(n8)R^(8B),—S(O)_(n8)OR^(8B), —S(O)_(n8)NR^(8B)R^(8C), —NHNR^(8B)R^(8C),—ONR^(8B)R^(8C), —NHC(O)NHNR^(8B)R^(8C), substituted or unsubstitutedalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl; R^(9A), R^(9B), R^(9C) are independently hydrogen, halogen,—N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂, —COOH, —CONH₂, —SH,—SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂, substitutedor unsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl; R^(3A), R^(6A), R^(7A), and R^(8A) areindependently hydrogen or unsubstituted alkyl; R^(3B), R^(6B), R^(7B),R^(8B), R^(3C), R^(6C), R^(7C), R^(8C), R^(3D), R^(6D), R^(7D), andR^(8D) are independently hydrogen, substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted aryl, or substituted or unsubstituted heteroaryl; z1 is1, 2, 3, 4, 5 or 6; z2 is 1, 2, 3, 4, 5, 6, 7 or 8; n, n3, n6, n7, andn8 are independently 1 or 2; and wherein if X is —C(O)— and -L¹-R¹ isunsubstituted phenyl, then -L²-R² is not methyl, p-substituted orunsubstituted phenyl, or unsubstituted pyridine.

2. The compound of embodiment, wherein R⁶ is substituted orunsubstituted C₁-C₅ alkyl.

3. The compound of embodiment 1 or 2, wherein X is —C(O)—.

4. The compound of any one of embodiments 1 to 3, wherein L¹ is a bond,substituted or unsubstituted alkylene, substituted or unsubstitutedheteroalkylene, substituted or unsubstituted cycloalkylene, substitutedor unsubstituted heterocycloalkylene, substituted or unsubstitutedarylene, or substituted or unsubstituted heteroarylene.

5. The compound of any one of embodiments 1 to 4, wherein L¹ issubstituted or unsubstituted C₁-C₅ alkylene.

6. The compound of any one of embodiments 1 to 5, wherein L² is a bond,substituted or unsubstituted alkylene, substituted or unsubstitutedheteroalkylene, substituted or unsubstituted cycloalkylene, substitutedor unsubstituted heterocycloalkylene, substituted or unsubstitutedarylene, or substituted or unsubstituted heteroarylene.

7. The compound of any one of embodiments 1 to 6, wherein L² is a bondor substituted or unsubstituted alkylene.

8. The compound of any one of embodiments 1 to 7, wherein R¹ isunsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,or substituted or unsubstituted aryl.

9. The compound of embodiment 1, having formula:

10. The compound of embodiment 9, wherein R¹ is R¹⁰-substituted orunsubstituted alkyl, R¹⁰-substituted or unsubstituted cycloalkyl, orR¹⁰-substituted or unsubstituted aryl, wherein R¹⁰ is independentlyhydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(10A),—NR^(10B)R^(10C), —COOR^(10A), —C(O)NR^(10B)R^(10C), —NO₂, —SR^(10D),—S(O)_(n10)R^(10B), —S(O)_(n10)OR^(10B), —S(O)_(n10)NR^(10B)R^(10C),—NHNR^(10B)R^(10C), —ONR^(10B)R^(10C), —NHC(O)NHNR^(10B)R^(10C),substituted or unsubstituted alkyl, substituted or unsubstitutedheteroalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl; R^(10A), R^(10B), R^(10C), andR^(10D) are independently hydrogen, substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted aryl, or substituted or unsubstituted heteroaryl; andn10 is 1 or 2.

11. The compound of embodiment 9 or 10, wherein R¹ is R¹⁰-substituted orunsubstituted alkyl, unsubstituted cycloalkyl, or R¹⁰-substituted orunsubstituted aryl; R¹⁰ is hydrogen, halogen, CF₃, OR¹⁰A; and R^(10A) ishydrogen or unsubstituted C₁-C₅ alkyl.

12. The compound of embodiment 1 having formula:

(II).

13. The compound of embodiment 12, wherein R¹ is substituted orunsubstituted alkyl, substituted or unsubstituted aryl or substituted orunsubstituted heteroaryl.

14. The compound of embodiment 12 or 13, wherein R¹ is R¹⁰-substitutedor unsubstituted alkyl, R¹⁰-substituted or unsubstituted aryl, orR¹⁰-substituted or unsubstituted heteroaryl, wherein R¹⁰ isindependently halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO,—OR^(10A), substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl; and R^(10A) is independentlyhydrogen or substituted or unsubstituted alkyl.

15. The compound of any one of embodiments 12 to 14, wherein R¹ isR¹⁰-substituted or unsubstituted alkyl, R¹⁰-substituted or unsubstitutedaryl, or R¹⁰-substituted or unsubstituted heteroaryl; R¹⁰ is halogen,—CF₃, OR^(10A), substituted or unsubstituted C₁-C₅ alkyl, or substitutedor unsubstituted aryl; and R^(10A) is hydrogen or methyl.

16. The compound of any one of embodiments 1 to 15, wherein R² ishydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl.

17. The compound of any one of embodiments 1 to 16, wherein R² ishydrogen, R¹⁷-substituted or unsubstituted alkyl or R¹⁷-substituted orunsubstituted aryl, wherein R¹⁷ is independently halogen, —N₃, —CF₃,—CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(17A), —NR^(17B)R^(17C), —COOR^(17A),—C(O)NR^(17B)R^(17C), —NO₂, —SR^(17D), —S(O)_(n17)R^(7B),—S(O)_(n17)OR^(17B), —S(O)_(n17)NR^(17B)R^(17C), —NHNR^(17B)R^(7C),—ONR^(17B)R^(17C), —NHC(O)NHNR^(17B)R^(17C), R¹⁸-substituted orunsubstituted alkyl, R¹⁸-substituted or unsubstituted heteroalkyl,R¹⁸-substituted or unsubstituted cycloalkyl, R¹⁸-substituted orunsubstituted heterocycloalkyl, R¹⁸-substituted or unsubstituted aryl,or R¹⁸-substituted or unsubstituted heteroaryl; R^(17A), R^(17B),R^(17C), and R^(17D) are independently hydrogen, substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl; and n17 is 1 or 2.

18. The compound of any one of embodiments 1 to 17, wherein R² ishydrogen, R¹⁷-substituted or unsubstituted alkyl, R¹⁷-substituted orunsubstituted aryl, or R¹⁷-substituted or unsubstituted heteroaryl; R¹⁷is substituted or unsubstituted alkyl, halogen, —CF₃, —OR^(17A); andR^(17A) is hydrogen or unsubstituted C₁-C₅ alkyl.

19. The compound of any one of embodiments 1 to 18, wherein R³ ishydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(3A),or substituted or unsubstituted alkyl, wherein R^(3A) is hydrogen orunsubstituted C₁-C₅ alkyl.

20. The compound of any one of embodiments 1 to 19, wherein R³ ishydrogen, halogen, —CF₃, —OH, or substituted or unsubstituted alkyl.

21. The compound of any one of embodiments 1 to 20, wherein R⁵ ishydrogen or methyl.

22. The compound of any one of embodiments 1 to 21, wherein R⁷ and R⁸are independently hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN,—CHO, —OH, —OCH₃, or substituted or unsubstituted alkyl.

23. The compound of any one of embodiments 1 to 22, having the formula:

24. A pharmaceutical composition comprising a pharmaceuticallyacceptable excipient and a compound having formula:

wherein, X is —C(R^(4A))(R^(4B))—, —C(O)— or —CY(OH)—; Y is hydrogen,halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OR^(9A), —NHR^(9A),—COOR^(9A), —CONHR^(9A), —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂,—OCH₃, —NHC(O)NHNH₂, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl; L¹ isindependently a bond, —C(O)—, —C(O)O—, —O—, —S—, —NR^(9B)—,—C(O)NR^(9B)—, —S(O)_(n)—, —S(O)NR^(9B)—, substituted or unsubstitutedalkylene, substituted or unsubstituted heteroalkylene, substituted orunsubstituted cycloalkylene, substituted or unsubstitutedheterocycloalkylene, substituted or unsubstituted arylene, orsubstituted or unsubstituted heteroarylene; L² is independently a bond,—C(O)—, —C(O)O—, —O—, —S—, —NR^(9C)—, —C(O)NR^(9C)—, —S(O)_(n)—,—S(O)NR^(9C)—, substituted or unsubstituted alkylene, substituted orunsubstituted heteroalkylene, substituted or unsubstitutedcycloalkylene, substituted or unsubstituted heterocycloalkylene,substituted or unsubstituted arylene, or substituted or unsubstitutedheteroarylene; R¹, R², R³, R^(4A), R^(4B), R⁵, R⁶, R⁷, and R⁸ areindependently hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN,—CHO, —OR^(11A), —NR^(11B)R^(11C), —COOR^(11A), —C(O)NR^(11B)R^(11C),—NO₂, —SR^(11D), —S(O)_(n11)R^(11B), —S(O)_(n111)OR^(11B),—S(O)_(n11)NR^(11B)R^(11C), —NHNR^(11B)R^(11C), —ONR^(11B)R^(11C),—NHC(O)NHNR^(11B)R^(11C), substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted aryl, or substituted or unsubstituted heteroaryl;R^(9A), R^(9B), R^(9C) are independently hydrogen, halogen, —N₃, —NO₂,—CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂, —COOH, —CONH₂, —SH, —SO₃H,—SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂, substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl; n11 is 1 or 2; z1 is 1, 2, 3, 4, 5, or 6; z2is 1, 2, 3, 4, 5, 6, 7, or 8; and R^(11A), R^(11B), R^(11C) and R^(11D)are independently hydrogen, substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted aryl, or substituted or unsubstituted heteroaryl.

25. A method of antagonizing Famesoid X Receptor (FXR) protein, saidmethod comprising contacting a FXR protein with a compound of any one ofembodiments 1 to 23 the pharmaceutical composition of claim 24.

26. A method of treating metabolic disease, said method comprisingadministering to a subject in need thereof a compound having theformula:

wherein, X is —C(R^(4A))(R^(4B))—, —C(O)— or —CY(OH)—; Y is hydrogen,halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OR^(9A), —NHR^(9A),—COOR^(9A), —CONHR^(9A), —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂,—OCH₃, —NHC(O)NHNH₂, substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl; L¹ isindependently a bond, —C(O)—, —C(O)O—, —O—, —S—, —NR^(9B)—,—C(O)NR^(9B)—, —S(O)_(n)—, —S(O)NR^(9B)—, substituted or unsubstitutedalkylene, substituted or unsubstituted heteroalkylene, substituted orunsubstituted cycloalkylene, substituted or unsubstitutedheterocycloalkylene, substituted or unsubstituted arylene, orsubstituted or unsubstituted heteroarylene; L² is independently a bond,—C(O)—, —C(O)O—, —O—, —S—, —NR^(9C)—, —C(O)NR^(9C)—, —S(O)_(n)—,—S(O)NR^(9C)—, substituted or unsubstituted alkylene, substituted orunsubstituted heteroalkylene, substituted or unsubstitutedcycloalkylene, substituted or unsubstituted heterocycloalkylene,substituted or unsubstituted arylene, or substituted or unsubstitutedheteroarylene; R¹, R², R³, R^(4A), R^(4B), R⁵, R⁶, R⁷, and R⁸ areindependently hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN,—CHO, —OR^(11A), —NR^(11B)R^(11C), —COOR^(11A), —C(O)NR^(11B)R^(11C),—NO₂, —SR^(11D), —S(O)_(n11)R^(11B), —S(O)_(n11)R^(11B),—S(O)_(n111)NR^(11B)R^(11C), —NHNR^(11B)R^(11C), —ONR^(11B)R^(11C),—NHC(O)NHNR^(11B)R^(11C), substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted aryl, or substituted or unsubstituted heteroaryl;R^(9A), R^(9B), R^(9C) are independently hydrogen, halogen, —N₃, —NO₂,—CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂, —COOH, —CONH₂, —SH, —SO₃H,—SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂, substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl; n11 is 1 or 2; z1 is 1, 2, 3, 4, 5, or 6; z2is 1, 2, 3, 4, 5, 6, 7, or 8; and R^(11A), R^(11B), R^(1C), and R^(11D)are independently hydrogen, substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted aryl, or substituted or unsubstituted heteroaryl,thereby treating said metabolic disease.

27. The method of embodiment 26, wherein X is —C(O)—.

28. The method of embodiment 26 or 27, wherein L¹ is a bond, substitutedor unsubstituted alkylene, substituted or unsubstituted heteroalkylene,substituted or unsubstituted cycloalkylene, substituted or unsubstitutedheterocycloalkylene, substituted or unsubstituted arylene, orsubstituted or unsubstituted heteroarylene.

29. The method of any one of embodiments 26 to 28, wherein L¹ issubstituted or unsubstituted C₁-C₅ alkylene.

30. The method of any one of embodiments 26 to 29, wherein L² is a bond,substituted or unsubstituted alkylene, substituted or unsubstitutedheteroalkylene, substituted or unsubstituted cycloalkylene, substitutedor unsubstituted heterocycloalkylene, substituted or unsubstitutedarylene, or substituted or unsubstituted heteroarylene

31. The method of any one of embodiments 26 to 30, wherein L² is a bondor substituted or unsubstituted alkylene.

32. The method of any one of embodiments 26 to 31, wherein R¹ and R² areindependently substituted or unsubstituted alkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl.

33. The method of embodiment 26, having formula:

34. The method of embodiment 33, wherein R¹ is R¹⁰-substituted orunsubstituted alkyl, R¹⁰-substituted or unsubstituted cycloalkyl, orR¹⁰-substituted or unsubstituted aryl, wherein R¹⁰ is independentlyhydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(10A),—NR^(10B)R^(10C), —COOR^(10A), —C(O)NR^(10B)R^(10C), —NO₂, —SR^(10D),—S(O)_(n10)R^(10B), —S(O)_(n10)OR^(10B), S(O)_(n10)NR^(11B)R^(10C),—NHNR^(10B)R^(10C), —ONR^(10B)R^(10C), —NHC(O)NHNR^(10B)R^(10C),substituted or unsubstituted alkyl, substituted or unsubstitutedheteroalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl; R^(10A), R^(10B), R^(10C), andR^(10D) are independently hydrogen, substituted or unsubstituted alkyl,substituted or unsubstituted heteroalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted heterocycloalkyl, substitutedor unsubstituted aryl, or substituted or unsubstituted heteroaryl; andn10 is 1 or 2.

35. The method of embodiment 33 or 34, wherein R¹ is R¹⁰-substituted orunsubstituted alkyl, unsubstituted cycloalkyl, or R¹-substituted orunsubstituted aryl; R¹⁰ is hydrogen, halogen, CF₃, OR^(10A); and R^(10A)is hydrogen or unsubstituted C₁-C₅ alkyl.

36. The method of embodiment 26 having formula:

37. The method of embodiment 36, wherein R¹ is substituted orunsubstituted alkyl, substituted or unsubstituted aryl or substituted orunsubstituted heteroaryl.

38. The method of embodiment 36 or 37, wherein R¹ is R¹⁰-substituted orunsubstituted alkyl, R¹⁰-substituted or unsubstituted aryl, orR¹⁰-substituted or unsubstituted heteroaryl, wherein R¹⁰ isindependently halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO,—OR^(10A), substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl; and R^(10A) is independentlyhydrogen or substituted or unsubstituted alkyl.

39. The method of any one of embodiments 36 to 38, wherein R¹ isR¹-substituted or unsubstituted alkyl, R¹-substituted or unsubstitutedaryl, or R¹⁰-substituted or unsubstituted heteroaryl; R¹⁰ is halogen,—CF₃, OR^(10A), substituted or unsubstituted C₁-C₅ alkyl, or substitutedor unsubstituted aryl; and R^(10A) is hydrogen or methyl.

40. The method of any one of embodiments 26 to 39, wherein R² ishydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl.

41. The method of any one of embodiments 26 to 40, wherein R² ishydrogen, R¹⁷-substituted or unsubstituted alkyl or R¹⁷-substituted orunsubstituted aryl, wherein R¹⁷ is independently halogen, —N₃, —CF₃,—CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(17A), —NR^(17B)R^(17C), —COOR^(17A),—C(O)NR^(17B)R^(17C), —NO₂, —SR^(17D), —S(O)_(n17)R^(17B),—S(O)_(n17)OR^(17B), —S(O)_(n17)NR^(17B)R^(17C), —NHNR^(17B)R^(7C),—ONR^(17B)R^(7C), —NHC(O)NHNR^(17B)R^(7C), R¹⁸-substituted orunsubstituted alkyl, R¹⁸-substituted or unsubstituted heteroalkyl,R¹⁸-substituted or unsubstituted cycloalkyl, R¹⁸-substituted orunsubstituted heterocycloalkyl, R¹⁸-substituted or unsubstituted aryl,or R⁸-substituted or unsubstituted heteroaryl; R^(17A), R^(17B),R^(17C), and R^(17D) are independently hydrogen, substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl; and n17 is 1 or 2.

42. The method of any one of embodiments 26 to 41, wherein R² ishydrogen, R¹⁷-substituted or unsubstituted alkyl, R¹⁷-substituted orunsubstituted aryl, or R¹⁷-substituted or unsubstituted heteroaryl; R¹⁷is substituted or unsubstituted alkyl, halogen, —CF₃, —OR^(17A); andR^(17A) is hydrogen or unsubstituted C₁-C₅ alkyl.

43. The method of any one of embodiments 26 to 42, wherein R³ ishydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(3A),or substituted or unsubstituted alkyl, wherein R^(3A) is hydrogen orunsubstituted C₁-C₅ alkyl.

44. The method of any one of embodiments 26 to 43, wherein R³ ishydrogen, halogen, —CF₃, —OH, or substituted or unsubstituted alkyl.

45. The method of any one of embodiments 26 to 44, wherein R⁵ ishydrogen or methyl.

46. The method of any one of embodiments 26 to 45, wherein R⁷ and R⁸ areindependently hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN,—CHO, —OH, —OCH₃, substituted or unsubstituted alkyl, or substituted orunsubstituted heterocycloalkyl.

47. The method of embodiment 26 to 46, wherein the compound has theformula:

48. The method of any one of embodiments 26 to 47, wherein saidmetabolic disease comprises dyslipidemia, insulin-resistance, increasedblood pressure, visceral obesity, cholestasis, or hypercoagubility.

49. The method of any one of embodiments 26 to 48, wherein saidmetabolic disease comprises at least cholestasis or at leastdyslipidemia.

50. The method of embodiment 48 or 49, wherein said dyslipidemia ishypertriglyceridemia.

EXAMPLES

Modulating FXR may be beneficial for treating all aspects of themetabolic syndrome, a complex cluster of cardiovascular disease withrisk factors including dyslipidemia, insulin-resistance, increased bloodpressure, visceral obesity and hypercoagubility.⁵ Recent findings alsosuggest that FXR may act as a key metabolic regulator in the liver tomaintain the homeostasis of liver metabolites.⁶ Synthetic and naturalligands that have either agonistic or antagonistic activity against FXRare powerful chemical tools for controlling the activity of FXR andmanaging various clinical conditions. FXR ligands have been investigatedin preclinical studies for targeted therapy of metabolic diseases, buthave shown many limitations.⁷ There is, therefore, a need for novelpotent and selective modulators as agonists or antagonists of FXR, bothfor potential clinical applications, as well as for further studies tobetter understand its biological functions.

Several potent and selective FXR agonists have been reported, such asGW4064 and 6α-ethylchenodeoxycholic acid (6-ECDCA).⁸ These agonists havebeen shown to decrease plasma triglyceride (TG) levels and increase thesynthesis of high-density lipoprotein cholesterol.⁹ However, preclinicaldevelopment of FXR agonists is limited by the complex response,including undesirable effects, triggered by activation of FXR in theliver. For example, FXR activation inhibits bile acid synthesis andbasolateral efflux of bile by indirectly repressing the expression ofcholesterol 7 alpha-hydroxylase, or cytochrome P450 7A1 (CYP7A1), therate-limiting enzyme of the bile acid synthesis pathway.¹⁰ In addition,activation of FXR, while reducing TG levels in hypertriglyceridemicpatients, would also decrease levels of high density lipoprotein (HDL)and lead to accumulation of cholesterol in the body as a consequence ofthe inhibited bile acid synthesis. Furthermore, FXR agonists interferewith the ability of constitutive androstane receptor (CAR) to regulatebasolateral transporters in hepatocytes. These effects might worsenliver injury in a subset of patients with obstructive cholestasis (asevere liver disease that impairs bile flow and causes irreversibleliver damage), thereby limiting the preclinical development and possibleclinical use of FXR agonists. In contrast, FXR antagonists might beuseful for understanding the function of FXR and ultimately for treatingliver disorders, if they targeted a specific cluster of genes and thusavoided the detrimental side effects mediated by FXR agonists. Thedevelopment of a FXR-specific antagonist is needed to possibly validatethe clinical relevance of antagonizing FXR.¹¹

An antagonist of FXR, if selective for upregulating CYP7A1 expression,may be useful as a therapeutic agent to increase the conversion ofcholesterol to bile acids, resulting in lower low density lipoprotein(LDL) levels in hyperlipidemic patients. This activity may occur throughFXR's regulation of the expression of small heterodimer partner (SHP).²SHP attenuates the expression of CYP7A1 by inhibiting the activity ofliver receptor homologue 1 (LRH-1), which augments CYP7A1 expression.Antagonizing FXR decreases SHP levels, which, in turn, would increaseCYP7A1 activity, enhance cholesterol metabolism in vivo and reduce serumlevels of total cholesterol. In addition, FXR can promote expression ofan intestinal bile acid-binding protein (I-BABP) gene.¹² When expressionof I-BABP is repressed by an antagonist of FXR, re-absorption of bileacids in the ileum is repressed, which may reduce the amount of bileacid that returns to the liver, and, therefore, promote the expressionof CYP7A1. Thus, an FXR antagonist could potentially induce repressionof I-BABP expression in the ileum, leading to reduced levels of serumcholesterol, and suggesting potential as a therapeutic agent forhypercholesterolemia in humans.¹¹

Despite the potential of FXR as a therapeutic target for metabolicdiseases, few FXR antagonists (synthetic small molecules or naturalproducts) are described. Recently, the natural product guggulsterone wasidentified as the first putative FXR antagonist.¹³ However,guggulsterone is not a specific FXR antagonist with low FXR antagonisticpotency (ICso of 12-25 μM).¹⁴ In addition, its mechanism of antagonismfor FXR is unclear. Thus, rather than being a true antagonist of FXR,guggulsterone is a unique FXR ligand that has antagonistic activity incoactivator association assays and can enhance the action of FXRagonists in vivo.¹⁵

Furthermore, nonsteroidal antagonists have been reported in theliterature, which antagonizes FXR in in vitro reporter assays but actsin a gene-selective manner in vivo; it has an agonistic effect on theexpression of CYP7A1, antagonistic effect on the expression of I-BABP,and does not affect SHP expression, the best-characterized FXR targetgene.²⁰ Recent ligand-based virtual screening identified other potentialFXR antagonists.²¹ However, these antagonists lack potency. 22

FXR antagonists may be discoverable through the use of a time-resolvedfluorescence resonance energy transfer (TR-FRET) assay.²³ Identifiedchemotypes include heterocyclic amide compounds.²⁴ The pyrazoleheterocycle has long been considered a privileged scaffold in drugdiscovery on the basis of its wide-ranging biological activities,including modulating G-protein coupled receptor modulators, inhibitingcyclooxygenase-2 (COX-2), and p38 MAP kinase.²⁵ However, investigatingpyrazole heterocycles is challenging given the breadth of biologicalactivity. Thus identification of potential FXR antagonists meansselecting a structural motif to serve as the scaffold of a focusedlibrary, and optimizing to develop more potent and selective FXRantagonists. The antagonistic effect of a substituted pyrazolecarboxamide (Z26476908) was examined against FXR. Synthesizing1,3,4-trisubstituted-pyrazole carboxamides as lead to the development ofseveral novel compounds, exemplified by 4j or1-(3-Methoxybenzyl)-3-(3-methoxyphenyl)-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-1H-pyrazole-4-carboxamide) with significantly FXR antagonisticactivities compared to Z26476908. 4j is the most potent FXR antagonistto date.

Example 2

Identification of a Substituted Pyrazole-4-Carboxamide Z26476908 as aTemplate for Designing Novel FXR Antagonists

Sixteen (16) substituted pyrazole carboxamides were examined for anyactivity through FXR biochemical TR-FRET binding, FXR cell-basedagonistic and antagonistic, and cytotoxicity assays. Among thecarboxamide analogs, Z26476908, a 1,3,4-trisubstituted-pyrazolecarboxamide analog, had the highest FXR binding affinity (IC₅₀=47 nM)and appeared as a relatively potent FXR antagonist (IC₅₀ of 2.62 μM)(FIG. 2).

Example 3

Design and Synthesis of 1,3,4-Trisubstituted Pyrazole Nonsteroidal FXRAntagonists

With the novel substituted pyrazole-4-carboxamide framework in hand, aseries of trisubstituted-pyrazole carboxamide analogs were synthesizedand evaluated for their receptor binding affinity and antagonisticpotency in modulating the transcriptional activity of FXR. No structuralinformation was available on the binding mode of FXR antagonists nor wasa co-crystal structure of substituted pyrazole carboxamide frameworkcomplexed with the LBD of FXR available. Without being bound by anytheory, the flexible nature of FXR side chains suggests the FXR LBD mayhave considerable flexibility to accommodate ligands of different shapesby changing its conformation in response to ligand binding.²⁸

On the basis of the detailed analysis of the synthesized 16 substitutedpyrazole carboxamides as described herein, the substitutedmorpholinosulfonyl moiety of aniline on the 4-position may be importantto improve the antagonistic activity against FXR. The alternativedeconstructive hypothesis for fragment binding was investigated the1,3,4-trisubstituted pyrazole-based molecules.²⁹ Retrospectively,1,3,4-trisubstituted-pyrazole carboxamides can be considered formed bytwo fragments: the substituted-N¹—C3-pyrazole core (herein “F1”) andsubstituted morpholinosulfonyl aniline moiety chain (herein “F2”) (FIG.3).

We identified that the substituted N¹—C3-pyrazole moiety is sensitive tomodifications. Thus various hydrophobic residues, such as alkyl ormethoxy residues, substituted in the in R₁ or R₂ positions of thephenyl-ring significantly improve antagonistic activity. We alsodetermined that the substituted N¹—C3-pyrazole core (F1) andmorpholinosulfonyl) aniline (F2) could bind separately to FXR by using2- or 4-methyl-3-(morpholinosulfonyl)aniline and3-(morpholinosulfonyl)aniline as F2 functionalities. A series ofsubstituted F1 fragments was prepared as described in the ExperimentalSection (See 3a-3e). The antagonistic effect of F1 fragments and F2fragments were tested in a cell-based transient transfection assay. F1failed to show an antagonistic effect against FXR, while F2 had an lowantagonistic effect against FXR. However, by connecting F1 moieties toF2 moieties through a linker of just one covalent bond by an amidebridge, the resulting carboxamide compounds had dramatically improvedantagonistic activity against FXR, exemplified by compounds 4 series(FIG. 4).

The F2 fragments have a hydrophobic region centered on the doublehydrogen bond acceptor (sulfone) and had very weak antagonistic activityagainst FXR. Such fragments may provide considerable conformationalrigidity to the receptor recognition after joining with F1 fragments.Analysis indicated that the position of the morpholinosulfonyl moiety ofthe F2 phenyl ring is sensitive to modifications. Further analysis ofthe structural requirements as effective FXR antagonists showed that themeta-position-substituted morpholinosulfonyl moiety on the aniline amidemoiety influences the antagonistic activity. Thus the3-(morpholinosulfonyl)aniline moiety of the amide moiety was fixed toact as a specific anchor in FXR binding recognition.

Variations of R³ on the F2 fragments also affected the antagonisticpotency. For example, replacing the 3-(morpholinosulfonyl) aniline with4-methyl-3-(morpholinosulfonyl) aniline in the final conjugation withselected F1 resulted in higher antagonistic activity. Additionally,replacing the 4-methyl substituent on the aniline ring with a 2-methylsubstituent conjugated with the same F1 resulted in lower antagonisticactivities. Inclusion of an unmethylated 3-morpholinosulfonyl anilinesubstantially decreased the antagonistic potency. Taken together, thispreliminary analysis provided insight into the structural requirementsfor effective FXR antagonists—indicating that4-methyl-3-(morpholinosulfonyl) aniline in the F2 functionality isappropriate factor.

Example 4

F2 fragments were considered as a key pharmacophoric region where asubstituent, such as 4-methyl substituted aniline, may be crucial forhydrophobic interaction with FXR. The 4-methyl-3-(morpholinosulfonyl)aniline was fixed and two regions of F1 fragments modified. It wasdiscovered that a subtle optimization between steric/hydrophobic effectsof the R¹ substituents and fine-tuning of the hydrogen-bondingcapability of R² substituents, resulted in novel FXR antagonistsdisplaying high FXR binding affinity and potent cellular antagonisticeffects against FXR.

As indicated in FIG. 5, the N¹- and C3-pyrazole moieties on the pyrazolecore were explored with various electronic and hydrophobic substitutedalkyls and phenyls. Without being bound by any particular theory, wereasoned that potent analogs of 1,3,4-trisubstituted-pyrazolecarboxamides may have structural features in common. From a parallellibrary synthesis perspective, compounds of this type are attractivebecause they contain only two vectors (denoted R¹ and R²) that allow theintroduction of significant structural diversity. A synthetic strategywas developed to optimize the N¹—C3-pyrazole core structure throughsubstitutions at R¹ and R² as a focused two-component small array ofpyrazole. Combining structural considerations and chemical feasibility,the initial strategy included a medicinal chemistry parallel approachinvolving variations in both the electronic and steric properties of theappendages of the central pyrazole nucleus. A scaffold expansion basedon two diverse points given by the substituents and their positions onthe pyrazole ring, as well as the substituents (R¹ and R²) on theN¹,C3-pyrazole rings, was therefore designed (FIGS. 5 and 6).

On the basis of the above design, two protocols for preparing the1,3,4-trisubstituted-pyrazole carboxamides were developed to optimizethe synthesis of compounds 4. These protocols included preparing variousstructural isomers to determine whether the positions of the R₁ and R₂could affect compound activity. The intermediates 3 and 7 (FIGS. 5 and6) were prepared via two possible routes to allow access to finalfunctional analogs. In the first route, lead optimization was initiatedthrough exploration of the phenyl functionality located on theN¹-position. A series of para- and meta-substitutions on the N¹-pyrazolering was investigated (FIG. 5). Condensation between substitutedacetophenones and substituted phenylhydrazines provides hydrazones 1. AVilsmeier-Haack reaction assembles the pyrazole nucleus templates.³⁰However, these conditions either do not form key aldehydes or have pooryields. The Vilsmeier-Haack reaction was modified by adding thecorresponding phenylhydrazones to an excess equivalence of POCl₃ and DMFat 0° C., then heated to 60-70° C. with stirring over 18 h under N₂ toafford the desired key cyclized aldehydes 2 at a 70-90% yield afterhydrolysis. Oxidation of the pyrazole-4-carboxaldehydes with a Jones'reagent³¹ yielded the corresponding pyrazole-4-carboxylic acids 3.Finally, the corresponding acids 3 were subsequently coupled with4-methyl-3-(morpholinosulfonyl) aniline through a Mitsunobu reaction³²in the presence of an activating coupling agent (i.e., HOBt and EDCI) toproduce the desired 4 with amide side bond properly constructed. Thesynthetic pathways used to obtain the 5 analogs of1,3,4-trisubstituted-1H-pyrazoles 4 are illustrated in FIG. 5.

R² functional groups were investigated for the structure requirementsfor FXR antagonistic activity as shown in FIG. 6. The introduction of R₂groups was carried out by treating β-keto esters with triethylorthoformate in the presence of Ac₂O as a catalyst to provide thecorresponding ethoxymethylene intermediate 5. Cyclization of 5 withhydrazine in dry ethanol afforded the pyrazole core 6. The N¹-alkylationreaction of 6 with excess appropriate bromoalkyl and bromobenzyl wasperformed in the presence of cesium carbonate as the base andacetonitrile as solvent. The ethyl esters 6 were hydrolyzed under basicconditions to afford the corresponding carboxylic acid 7. This wasfollowed by a Mitsunobu coupling with4-methyl-3-(morpholinosulfonyl)aniline in the presence of EDCI/DMAP as afixed coupling reagent to produce the desired 12 products 4f-4s.

The amide moiety was examined to determine if the amide bridge wassensitive to modifications. Three amides of series 4 were varied togenerate compounds 8. Compounds 4f, 4m, and 4o were chosen to react withiodomethane in the presence of sodium hydride to give N-alkylationcompounds 8 (FIG. 7). The amide position was considered to be a site ofpotential metabolism.³³ Accordingly, derivatives containing reducedamides were synthesized to investigate. The amide groups in 4f, 4m, and4o were reduced to corresponding amines with 1N borane-THF complex toyield compounds 9, illustrated in FIG. 7.

Example 5

FXR TR-FRET Binding Assay.

The FXR binding affinities of Z26476908 and the 23 synthesized1,3,4-trisubstituted-pyrazol-4-carboxamide analogs is shown in FIGS.5-7, along with control compounds GW4064 and lithocholic acid (LCA). Allcompounds were tested through an in vitro FXR TR-FRET binding assayusing DY246 as the fluorescent probe.²³ TR-FRET assays were chosen duetheir advantages of low background fluorescence interference andincreased sensitivity compared to other fluorescence-based assays, suchas FI, FP and FRET assays.³⁴ DY246 is a derivative of GW4064, which is apotent FXR agonist. DY246 also acts as a potent FXR agonist (ECso of 550nM) and has successfully been used as a fluorescent probe in a highthroughput screening campaign to identify FXR antagonists.²³ In arepresentative assay, DMSO (vehicle and negative control), 10 μM GW4064(positive control), and titrations of GW4064, lithocholic acid or otherchemicals were incubated for 20 minutes with appropriate mixture ofGST-FXR-LBD, Tb-anti-GST and DY246, after which the TR-FRET signals werecollected and activity for each chemical was normalized to DMSO negativecontrol (0% inhibition) and 10 μM GW4064 positive control (100%inhibition). The activities of compounds that displayed inhibitoryeffects in a dose-dependent manner were fit into a one-site competitivebinding equation to derive individual IC₅₀ values. The TR-FRET bindingactivities were summarized in Tables 1, 2, and 3. Many of thesecompounds had significantly improved FXR binding affinity when comparedto Z6908. Noticeably, 4j had an IC₅₀ of 7.5 nM in the FXR TR-FRETbinding assay, which was 5.26-fold more potent than the control chemicalZ26476908 (IC₅₀ of 47 nM) (Tables 1, 2, and 3; FIG. 8A).

TABLE 1 The effect of varying the substitution pattern of the1,3,4-substituted-pyrazole- 4-carboxamide derivatives on theirbiological activities (scaffold A). Scaffold A

FXR TR-FRET GB FXR Cell Binding GB FXR Cell Anta. Cyto Compound R¹ R² %Inh. IC₅₀ ^(a) % Inh. IC₅₀ ^(a) % Inh. IC₅₀ GW4064   100 ± 4.3 19.8 ±2.5  NA NA NT NA  (10 μM) nM Lithocholic  82.3 ± 0.9 18.3 ± 1.2   16.1 ±0.5 NA NT NA Acid  (40 μM) (40 μM) Z26476908 Ph 4-CH₃—Ph 100.2 ± 5.247.0 ± 5.1   77.2 ± 2.2 2.62 ± 0.13 17.9 ± 0.5 NA (164 nM) nM (40 μM) μM(40 μM) 4a 4-F—Ph 4-CH₃—Ph  95.0 ± 1.2 24.3 ± 0.6   72.0 ± 2.2  2.49 ±0.006 18.5 ± 1.0 (493 nM) nM (40 μM) μM (40 μM) 4b 3-Cl—Ph 4-CH₃—Ph 99.3 ± 1.1 10.4 ± 0.9   60.6 ± 0.9 5.91 ± 0.15 NT NA (164 nM) nM (40μM) μM 4c 2,4-Di-Cl—Ph 4-CH₃—Ph 119.8 ± 7.8 14.1 ± 0.3   89.9 ± 1.9 1.24± 0.12 NT NA (164 nM) nM (40 μM) μM 4d 3-CF₃—Ph 4-CH₃—Ph  77.5 ± 4.323.9 ± 2.1   54.8 ± 1.3 22.29 ± 1.14   7.3 ± 0.2 NA (164 nM) nM (40 μM)μM (40 μM) 4e

4-CH₃—Ph 101.8 ± 2.8 (164 nM) 17.7 ± 0.4  nM  79.1 ± 2.4 (40 μM) 7.91 ±1.16 μM 11.5 ± 0.2 (13.3 μM)   NA 4f (CH₃)₂CH 4-CH₃—Ph 130.6 ± 3.8 49.1± 9.9   99.1 ± 4.4 1.69 ± 0.18 NT NA  (4.4 μM) nM (40 μM) μM 4gCH₃(CH₂)₃ 4-CH₃—Ph 130.1 ± 0.7 52.5 ± 4.1   97.9 ± 8.1 11.51 ± 0.07 10.3 ± 0.3 NA  (1.5 μM) nM (20 μM) μM (4.4 μM)  4h

4-CH₃—Ph  97.8 ± 1.2 (164 nM) 10.2 ± 1.6  nM  84.4 ± 4.1 (40 μM) 844.1 ±10.3  nM  7.9 ± 0.3 (4.4 μM)  NA 4i

4-CH₃—Ph 105.0 ± 4.9  (1.5 μM) 76.9 ± 2.7  nM 100.1 ± 3.2 (40 μM) 848.8± 69.0  nM NT NA 4j

4-CH₃—Ph 130.1 ± 5.4 (164 nM) 7.5 ± 0.8 nM  98.9 ± 4.3 (40 μM) 468.5 ±8.4   nM NT NA 4k

4-CH₃—Ph  99.2 ± 6.4 (164 nM) 18.4 ± 1.2  nM  93.4 ± 3.9 (40 μM) 515.0 ±25.4  nM NT NA 41 HO(CH₂)₄ 4-CH₃—Ph  89.3 ± 0.1 130.3 ± 16     97.6 ±3.7 2.61 ± 0.29  5.9 ± 0.2 NA (493 nM) nM (40 μM) μM (40 μM) 4m

CH(CH₃)₂ 100.6 ± 5.6  (4.4 μM) 199.4 ± 21.2  nM  99.2 ± 2.7 (40 μM) 3.11± 0.58 μM NT NA 4n (CH₃)₂CH 3-CH₃O—Ph 149.8 ± 6.9 159.7 ± 22.6   97.8 ±1.5 3.49 ± 0.64 10.8 ± 0.2 (13.3 μM)  nM (40 μM) μM (4.4 μM)  4o

3-CH₃O—Ph 114.1 ± 3.3 (493 nM) 42.8 ± 0.5  nM  89.4 ± 4.2 (40 μM) 1.24 ±0.09 μM NT NA 4p (CH₃)₂CH 4-CH₃—Ph 133.2 ± 5.3 77.5 ± 3.7   100.0 ± 3.71.95 ± 0.28 19.5 ± 1.1 NA  (4.4 μM) nM (40 μM) μM (40 μM) 4q

4-CH₃—Ph 109.1 ± 3.6 (164 nM) 30.9 ± 3.6  nM  97.6 ± 0.9 (40 μM) 592.7 ±3.0   nM NT NA 4r (CH₃)₂CH CH₃O(CH₂)₂  98.2 ± 3.8 3.42 ± 0.19  62.5 ±0.8 29.58 ± 1.75  NT NA  (40 μM) μM (40 μM) μM 4s

CH₃O(CH₂)₂ 113.5 ± 0.8 (13.3 μM)  389.5 ± 9.4   nM  95.9 ± 2.4 (40 μM)11.1 ± 0.64 μM NT NA NA: not applicable; NT: Not toxic (toxicity lessthan 5%); GB FXR Cell Anta: GeneBLAzer FXR cell-based antagonisticassay; GB FXR Cell Cyto: Cytotoxicity assay performed in the GeneBLAzerFXR cells; ^(a)IC50 values represent the means ± SE of at least threeindependent experiments derived as described in the herein; % Inh: %Inhibition is presented as the means ± SE of at least three independentexperiments calculated as described in the herein, at the hereinspecified compound concentration.

TABLE 2 The effect of varying the substitution pattern of the1,3,4-substituted-pyrazole- 4-carboxamide derivatives on theirbiological activities (scaffold B). Scaffold B

FXR TR-FRET GB FXR Cell GB FXR Cell Binding Anta. Cyto Compound R¹ R² %Inh. IC₅₀ % Inh. IC₅₀ % Inh. IC₅₀ 8-1 (CH₃)₂CH 4-CH₃—Ph 132.9 ± 6.2489.4 ± 21.2  86.4 ± 2.8  16.16 ± 15.0 ± 0.7 NA (40 μM) nM (40 μM) 0.28μM (40 μM) 8-2

(CH₃)₂CH  80.3 ± 5.2 (40 μM) 5.33 ± 0.24 μM 2.4 ± 0.1 (20 μM) NA 13.5 ±0.4 (40 μM) NA 8-3

3-CH₃O—Ph  69.7 ± 3.5 (40 μM) 3.81 ± 0.20 μM 23.8 ± 0.4  (40 μM) NA 19.7± 0.4 (40 μM) NA

TABLE 3 The effect of varying the substitution pattern of the1,3,4-substituted-pyrazole- 4-carboxamide derivatives on theirbiological activities (scaffold C). Scaffold C

FXR TR-FRET GB FXR Cell GB FXR Cell Binding Anta. Cyto Compound R¹ R² %Inh. IC₅₀ % Inh. IC₅₀ % Inh. IC₅₀ 9-1 (CH₃)₂CH 4-CH₃—Ph 99.5 ± 2.6 2.04± 0.02 36.8 ± 0.3 NA 10.5 ± 0.3 NA (13.3 μM) μM (40 μM) (40 μM) 9-2

(CH₃)₂CH 72.5 ± 2.7  (4.4 μM) 2.31 ± 0.32 μM 64.8 ± 1.9 (40 μM) 27.83 ±1.54 μM 13.9 ± 0.6 (40 μM) NA 9-3

3-CH₃O—Ph 39.8 ± 1.8 (1.48 μM) NA  3.1 ± 0.1 (40 μM) NA NT NA

Example 6

Cell-Based FXR Transactivation Assay.

A GeneBLAzer FXR cell-based assay was used to investigate the cellularactivities of the 1,3,4-trisubstituted-pyrazol-4-carboxamide analogs.The assay detects the levels of a 3-lactamase reporter controlled by apromoter containing the binding site of the DNA binding domain (DBD) ofthe GAL4 transcription factor; the Gal4 DBD was fused to the LBD of FXRin this assay.³⁵

In typical agonistic tests, DMSO (vehicle and negative control), 10 gtMGW4064 (positive control), and titrations of GW4064, LCA or the 23synthesized 1,3,4-trisubstituted-pyrazol-4-carboxamide analogs weremixed with GeneBLAzer FXR-UAS-bla HEK 293T cells. The reporter assayswere performed after a16 h incubation. No agonistic activities wereobserved for all the synthesized compounds.

For the antagonistic tests, titrations of compounds were tested in thepresence of 400 nM GW4064. Assay controls included: DMSO alone (100%inhibition), 400 nM GW4064 alone (0% inhibition), and titrations of LCAin the presence of 400 nM GW4064 (as an assay reference). Activities ofcompounds that displayed activation or inhibitory activities in adose-dependent manner were fit into a sigmoidal dose-response equationto derive individual EC₅₀ or ICso values. The tested chemicals' FXRactivities are summarized in Tables 1, 2, and 3. Many of these compoundshad significantly improved antagonistic activity when compared toZ26476908. 4j had an IC₅₀ of 468.5 nM, which was 4.59-fold more potentthan that of Z26476908 (IC₅₀ of 2.62 μM) (Tables 1, 2, and 3; FIG. 8).Without being bound by any particular theory, we hypothesized that theincreased antagonistic potency of 4j arose from a hydrophobic grouplinked to the N¹-position of the pyrazole core.

Example 7

Cytotoxicity Assay.

Generally if a tested chemical in the FXR cell-based antagonistic assayscaused a signal reduction, it was considered an antagonist. However,signal reduction could also be caused non-specifically if a chemical wascytotoxic (although GeneBLAzer assays are relatively insensitive tocytotoxicity because of their use of ratiometric reading). To examine ifcertain chemical antagonistic effect was caused by cytotoxicity, thesame GeneBLAzer FXR cells were used to perform cytotoxicity assay. Thisassay was set up like the FXR agonistic assay, with the exception ofsignal reading. Instead of detecting the reporter activities,CellTiter-Glo® assay was used to detect cell viability. DMSO with cellsor without cells group were served as negative (0% Inhibition) orpositive (100% Inhibition), respectively. Cytotoxic activities aresummarized in Tables 1, 2, and 3. All chemicals tested showed marginaltoxicity (% inhibition <5%), therefore the antagonistic effect of thecompounds was not caused by non-specific cytotoxicity.

Example 8

The effect of introducing electron withdrawing groups, such as afluorine, chlorine, dichlorines, and trifluoromethyl atoms, at ortho,meta, or para positions of the N¹-phenyl was examined. All of thesederivatives (4a, 4b, 4c, 4d, and 4e) improved FXR antagonistic activityby about 3- to 4-fold as compared to Z26476908 (Table 1), indicatingthat the electron withdrawing groups were well tolerated forantagonistic activity. Without being bound by any particular theory,this observation may be attributed to the higher interaction strength offluorine or chlorine atoms compared to hydrogen or the slightly largervolume of heterogen which enables a tighter fit. Based on this initialfinding, longer benzyl chains or small alkyl groups were introduced toreplace the N¹-phenyl of the pyrazole moiety. The synthetic methodologyfor constructing the corresponding pyrazole-4-carboxylic acids was used.Replacing the phenyl ring with small hydrophobic substituents such asisopropyl (4f) or n-butyl (4g) allowed retention of the antagonisticactivity toward FXR. Substituting with a methylcyclopropane (4i)decreased the activity by 2-fold for hFXR as compared to Z26476908.Incorporating a bulkier group, such as benzo[d]thiazole (4e), led tohigher potency in hFXR by 3-fold. Other substitutions, including longerand bulkier benzyl aromatic substituents such as 2-naphthyl (4h) andbenzyl with an electron donating group m-methoxy (4j), enhancedantagonistic activity. Among the N¹-alkylated analogs, 4j exhibited themost potent FXR-antagonistic activity, with IC₅₀ values of 7.5 nM and468.5 nM in a FXR TR-FRET binding assay and a FXR cell-basedantagonistic assay, respectively. In addition, compound 4j had no FXRagonistic activity and no cytotoxicity.

An expanded hydrophobic moiety at the N¹-position and the positiveinfluence of the benzyl-m-methoxy group may be generally preferred atthe N¹-position of the pyrazole ring. Replacing the original C3-p-methylphenyl of 4j with the stronger electron-donating m-methoxy phenyl groupresulted in analog 4o, which had slightly decreased antagonisticactivity (Table 1) compared to 4j. This suggests that the binding pocketof FXR that hosted the m-methoxy phenyl group on the C3 position ofpyrazole is not sufficiently wide to accept larger substituents forhydrogen bond interactions with FXR. Replacing the original ofC3-p-methyl phenyl (R₂) of 4j with a smaller isopropyl group (analog 4m)decreased the potency and affinity, demonstrating that the C3 moiety maybe sensitive in terms of steric bulkiness and/or hydrophobicity. Forinstance, introducing ap-trifluoromethyl phenyl with electronwithdrawing properties at the C3 position of the pyrazole ring gaveproducts 4p and 4q which had nanomolar IC₅₀ values for in vitro potency.4p and 4q appeared to have similar antagonistic activities as theirparent compounds 4f and 4o. Replacing the p-trifluoromethyl phenyl atthe C3 position of the pyrazole ring with a linear 2-methoxy-ethyl groupto obtain compounds 4r and 4s, resulted in loss of potency relative tothat of 4f and 4o.

In addition to physical and chemical properties, metabolic instability(hydrolysis) of the amide bridge in the carboxamide analogs couldcontribute to a poor pharmacokinetical profile.³³ The carboxamidenitrogen was methylated to form a tertiary amine 8 and reduction of theamide linker to form a secondary amine 9, was performed. The routedescribed in FIG. 7 rapidly synthesized compounds 4f, 4m, and 4o withamide moieties. The carboxamide nitrogens of 4f, 4m, and 4o weremethylated to form N-methyl analogs 8-1, 8-2, and 8-3 (FIG. 7).N-methylation of the amide compounds 8 decreased the antagonisticactivity (Table 2 and 3). When compared to the activity of the originalamides, 8-1, 8-2, and 8-3 had weak activity at 1 μM against FXR.Similarly, compounds 9 had weak activity at 1 μM. Compound 9demonstrated more than 300-fold loss in affinity and potency as comparedwith 4j.

FXR is a nuclear receptor that functions as a physiological receptor forbile acids. A highly potent and selective antagonist of FXR wouldrepresent an important novel option that could prove useful for treatingdyslipidemia and cholestasis. Thus, there is considerable need toidentify lead structures and pharmacorphones in this relativelyunexplored area. The strategies and results herein led to optimizationof 1,3,4-trisubstituted-pyrazole carboxamides as FXR antagonists. Theseries of 1,3,4-trisubstituted-pyrazole carboxamide analogues weredeveloped herein and analyzed for physicochemical properties based on invitro data. All of these compounds were evaluated for FXR bindingaffinities in biochemical assay and antagonistic activity in cell-basedtransactivation assays. All amide compounds reported here behaved aspotent FXR antagonists, and showed no FXR agonistic activity. Compound4j was identified as a promising candidate that had IC₅₀ values of 7.5nM and 468.5 nM in FXR TR-FRET binding assays and FXR cell-basedantagonistic assay, respectively.

Example 9

General Procedures:

Organic reagents were purchased from commercial suppliers unlessotherwise noted and were used without further purification. All solventswere analytical or reagent grade. All reactions were carried out inflame-dried glassware under argon or nitrogen. Melting points weredetermined and reported automatically by an optoelectronic sensor inopen capillary tubes and were uncorrected. ¹H NMR and ¹³C NMR spectrawere measured at 500 MHz and 125 MHz, respectively, using CDCl₃ or CD₃ODas solvents and tetramethylsilane (Me₄Si) as the internal standard.Flash column chromatography was performed using Sigma-Aldrich silica gel60 (200-400 mesh), carried out under moderate pressure with columns ofan appropriate size packed and eluted with appropriate eluents. Allreactions were monitored by thin layer chromatography (TLC) on precoatedplates (silica gel HLF). TLC spots were visualized either by exposure toiodine vapor or by irradiation with UV light. Organic solvents wereremoved under vacuum by a rotary evaporator. Elemental analyses wereperformed by Columbia Analytical Services Inc, Tucson, Ariz.

(E)-1-(4-fluorophenyl)-2-(1-p-tolylethylidene)hydrazine (1a). To asolution of 4′-methylacetophenone (0.5 g, 3.73 mmol) in 8 mL of aceticacid and 5 mL of water/MeOH, 4-fluorophenylhydrazine hydrochloride (0.6g, 3.73 mmol) was added. The reaction mixture was stirred at roomtemperature for 18 h. The reaction mixture was diluted with anadditional 30 mL of water and subsequently filtered and the solid wasdried in vacuo to afford 0.63 g of beige solid 1a (70% yield): mp 101.8°C. ¹H NMR (CDCl₃) δ 7.68 (d, 2H), 7.19 (d, 3H), 7.07 (t, 2H), 6.98 (d,2H), 2.37 (s, 3H), 2.23 (s, 3H).

(E)-1-(3-Chlorophenyl)-2-(1-p-tolylethylidene)hydrazine (1b). To asolution of 4′-methylacetophenone (0.5 g, 3.73 mmol) in 8 mL of aceticacid and 5 mL of water/MeOH, 3-chlorophenylhydrazine hydrochloride (0.67g, 3.73 mmol) was added. The reaction mixture was stirred at roomtemperature for 18 h. The reaction mixture was diluted with anadditional 30 mL of water and subsequently filtered and the solid wasdried in vacuo to afford 0.58 g of beige solid 1b (60% yield): mp 100.5°C. ¹H NMR (CDCl₃) δ 7.68 (t, 2H), 7.20 (t, 5H), 6.98 (s, 1H), 6.83 (d,1H), 2.38 (s, 3H), 2.28 (s, 3H).

(E)-1-(2,4-dichlorophenyl)-2-(1-p-tolylethylidene)hydrazine (1c). To asolution of 4′-methylacetophenone (0.5 g, 3.73 mmol) in 8 mL of aceticacid and 5 mL of water/MeOH, 2,4-dichlorophenylhydrazine hydrochloride(0.8 g, 3.73 mmol) was added. The reaction mixture was stirred at roomtemperature for 18 h. The reaction mixture was diluted with anadditional 30 mL of water and subsequently filtered and the solid wasdried in vacuo to afford 0.98 g of beige solid 1c (90% yield): mp 122.7°C. ¹H NMR (CDCl₃) δ 7.71 (t, 2H), 7.61 (d, 2H), 7.29 (s, 1H), 7.021 (d,3H), 2.38 (s, 3H), 2.28 (s, 3H).

(E)-1-(3-Trifluromethylphenyl)-2-(1-p-tolylethylidene)hydrazine (1d). Toa solution of 4′-methylacetophenone (0.5 g, 3.73 mmol) in 8 mL of aceticacid and 5 mL of water/MeOH, 3-trifluoromethylphenylhydrazinehydrochloride (0.66 g, 3.73 mmol) was added. The reaction mixture wasstirred at room temperature for 18 h. The reaction mixture was dilutedwith an additional 30 mL of water and subsequently filtered and thesolid was dried in vacuo to afford 1.01 g of beige solid 1d (93% yield):mp 103.7° C. ¹H NMR (CDCl₃) δ 7.72 (d, 2H), 7.44 (m, 4H), 7.28 (d, 2H),7.14 (s, 1H), 2.41 (s, 3H), 2.27 (s, 3H).

(E)-2-(2-(1-(p-tolyl)ethylidene)hydrazinyl)benzo[d]thiazole (1e). To asolution of 4′-methylacetophenone (0.5 g, 3.73 mmol) in 8 mL of aceticacid and 1 mL of water, 2-hydrazinobenthiazole (0.62 g, 3.73 mmol) wasadded. The reaction mixture was stirred at room temperature for 18 h.The reaction mixture was diluted with an additional 20 mL of water andsubsequently filtered and the solid was dried in vacuo to afford 1 g ofbeige solid 1e (99% yield): mp 112.6° C. ¹H NMR (CDCl₃) δ 7.74 (d, 2H),7.68 (d, 1H), 7.53 (d, 1H), 7.36 (d, 1H), 7.25 (d, 2H), 7.16 (d, 1H),2.41 (s, 3H), 2.17 (s, 3H).

1-(4-fluorophenyl)-3-p-tolyl-1H-pyrazole-4-carbaldehyde (2a). To asolution of a mixture of DMF (3 mL) and POCl₃ (1.5 mL, 16.4 mmol) in anice bath under argon which was stirred for 10 min, was added 1a (0.21 g,0.87 mmol) dissolved in dichloroethane (5 mL); the mixture was raised to70° C. and stirred for an additional 18 h. The reaction mixture was thencooled to room temperature, slowly poured into saturated aqueous NaHCO₃(200 mL) under ice cold conditions, and then warmed to room temperatureand stirred for 3 h. The aqueous layer was extracted with EtOAc. Theorganic layers were washed with water and brine, dried over Na₂SO₄ andconcentrated in vacuo to yield 0.21 g (88%) of the title compound: mp143.8° C., which was used without further purification. ¹H NMR (CDCl₃) δ10.05 (s, 1H), 8.47 (s, 1H), 7.78 (m, 1H), 7.71 (d, 2H), 7.33 (d, 2H),7.19 (m, 3H), 2.44 (s, 3H). ¹³C NMR (CDCl₃) δ 187.0, 156.5, 132.7,130.9, 130.2, 129.8, 123.9, 123.1, 118.1, 117.8, 23.3.

1-(3-Chlorophenyl)-3-p-tolyl-1H-pyrazole-4-carbaldehyde (2b). To asolution of a mixture of DMF (5 mL) and POCl₃ (1.5 mL, 16.4 mmol) in anice bath under argon which was stirred for 10 min, was added 1b (0.58 g,2.24 mmol) dissolved in dichloroethane (5 mL); the mixture was raised to70° C. and stirred for an additional 18 h. The reaction mixture was thencooled to room temperature and slowly poured into saturated aqueousNaHCO₃ (200 mL) under ice cold conditions which was warmed to roomtemperature and stirred for 3 h. The aqueous layer was extracted withEtOAc. The organic layers were washed with water, brine, dried overNa₂SO₄ and concentrated in vacuo to yield 0.64 g (88%) of the titlecompound: mp 118.7° C., which was used without further purification. ¹HNMR (CDCl₃) δ 10.05 (s, 1H), 8.53 (s, 1H), 7.88 (s, 1H), 7.67 (d, 3H),7.46 (t, 1H), 7.31 (d, 3H), 2.44 (s, 3H). ¹³C NMR (CDCl₃) δ 186.5,159.3, 141.1, 132.1, 130.9, 130.2, 129.3, 121.6, 118.8, 23.0.

1-(2,4-Dichlorophenyl)-3-p-tolyl-1H-pyrazole-4-carbaldehyde (2c). To asolution of a mixture of DMF (5 mL) and POCl₃ (1.5 mL, 16.4 mmol) in anice bath under argon which was stirred for 10 min, was added 1c (0.61 g,2.08 mmol) dissolved in dichloroethane (5 mL); the mixture was raised to70° C. and stirred for an additional 18 h. The reaction mixture was thencooled to room temperature and slowly poured into saturated aqueousNaHCO₃ (200 mL) under ice cold conditions which was warmed to roomtemperature and stirred for 3 h. The aqueous layer was extracted withEtOAc. The organic layers were washed with water, brine, dried overNa₂SO₄ and concentrated in vacuo to yield 0.53 g (78%) of the titlecompound: mp 85.8° C., which was used without further purification. ¹HNMR (CDCl₃) δ 10.05 (s, 1H), 8.48 (s, 1H), 7.66 (m, 3H), 7.54 (s, 1H),7.42 (d, 1H), 7.37 (d, 2H), 2.38 (s, 3H). ¹³C NMR (CDCl₃) δ 186.6,156.59 140.9, 137.4, 136.8, 134.1, 132.0, 131.7, 130.8, 129.4, 127.2,105.7, 22.7.

3-p-Tolyl-1-(3-(trifluoromethyl)phenyl)-1H-pyrazole-4-carbaldehyde (2d).To a solution of a mixture of DMF (5 mL) and POCl₃ (1.5 mL, 16.4 mmol)in an ice bath under argon which was stirred for 20 min, was added 1d(0.75 g, 2.56 mmol) dissolved in dichloroethane (7 mL); the mixture wasraised to 70° C. and stirred for an additional 18 h. The reactionmixture was then cooled to room temperature and slowly poured intosaturated aqueous NaHCO₃ (200 mL) under ice cold conditions which waswarmed to room temperature and stirred for 3 h. The aqueous layer wasextracted with EtOAc. The organic layers were washed with water andbrine, dried over Na₂SO₄ and concentrated in vacuo to yield 0.79 g (93%)of the title compound (mp 155.1° C.), which was used without furtherpurification. ¹H NMR (CDCl₃) δ 10.08 (s, 1H), 8.60 (s, 1H), 8.13 (s,1H), 7.99 (q, 1H), 7.74 (d, 2H), 7.67 (d, 2H), 7.35 (d, 2H), 2.45 (s,3H). ¹³C NMR (CDCl₃) δ 186.6, 157.3, 141.7, 140.8, 132.3, 131.8, 130.9,130.3, 126.6, 126.2, 123.8, 22.8.

1-(2,3-Dihydro-1H-inden-1-yl)-3-(p-tolyl)-1H-pyrazole-4-carbaldehyde(2f). To a solution of a mixture of DMF (5 mL) and POCl₃ (1.5 mL, 16.4mmol) in an ice bath under argon which was stirred for 20 min, was added1f (1.0 g, 3.55 mmol) dissolved in dichloroethane (5 mL); the mixturewas raised to 60° C. and stirred for an additional 18 h. The reactionmixture was then cooled to room temperature and slowly poured intosaturated aqueous NaHCO₃ (200 mL) under ice cold conditions which waswarmed to room temperature and stirred for an additional 5 h. Theaqueous layer was extracted with EtOAc. The organic layers were washedwith water, brine, dried over Na₂SO₄ and concentrated in vacuo to yield0.74 g (70%) of the title compound: mp 145.3° C., which was used withoutfurther purification. ¹H NMR (CDCl₃) δ 10.11 (s, 1H), 9.08 (s, 1H), 7.98(d, 1H), 7.89 (d, 1H), 7.79 (d, 2H), 7.55 (t, 1H), 7.44 (t, 1H), 7.35(d, 2H), 2.41 (s, 3H). ¹³C NMR (CDCl₃) δ 186.0, 157.1, 152.0, 141.5,134.0, 130.9, 130.3, 128.3, 124.4, 123.2, 23.4.

1-(4-fluorophenyl)-3-p-tolyl-1H-pyrazole-4-carboxylic acid (3a). To asolution of 2a (0.21 g, 0.75 mmol) dissolved in 16 mL of acetone, 5 mLof Jones' reagent was added. The reaction mixture was stirred at roomtemperature and monitored by TLC. The reaction mixture was poured intowater and extracted with EtOAc. The combined organic layers were washedwith water and brine, dried over Na₂SO₄, and concentrated in vacuo toafford 0.16 g (72%) of the title acid: mp 202.0° C. ¹H NMR (CDCl₃) δ8.51 (s, 1H), 7.75 (m, 3H), 7.32 (d, 2H), 7.18 (t, 4H), 2.41 (s, 3H).¹³C NMR (CDCl₃) δ 170.7, 164.5, 155.9, 140.6, 135.1, 132.6, 130.9,130.6, 130.2, 130.1, 122.8, 118.2, 22.7. Anal. Calcd for C₁₇H₁₃FN₂O₂: C,68.91; H, 4.41; N, 9.45. Found: C, 68.13; H, 4.43; N, 8.94.

1-(3-Chlorophenyl)-3-p-tolyl-1H-pyrazole-4-carboxylic acid (3b). To asolution of 2b (0.51 g, 1.72 mmol) dissolved in 16 mL of acetone, 5 mLof Jones' reagent was added. The reaction mixture was stirred at roomtemperature and monitored by TLC. The reaction mixture was poured intowater and extracted with EtOAc. The combined organic layers were washedwith water and brine, dried over Na₂SO₄, and concentrated in vacuo toafford 0.51 g (95%) of the title acid: mp 194.4° C. ¹H NMR (CDCl₃) δ8.57 (s, 1H), 7.86 (d, 1H), 7.77 (t, 2H), 7.66 (d, 1H), 7.44 (t, 1H),7.34 (d, 1H), 7.28 (m, 2H), 2.41 (s, 3H). ¹³C NMR (CDCl₃) δ 168.8,156.9, 147.7, 141.6, 140.3, 137.2, 134.7, 132.1, 130.6, 129.1, 121.3,118.7, 22.8. Anal. Calcd for C₁₇H₁₃FC₁N₂O₂: C, 65.29; H, 4.19; N, 8.96.Found: C, 64.65; H, 3.37; N, 8.80.

1-(2,4-Dichlorophenyl)-3-p-tolyl-1H-pyrazole-4-carboxylic acid (3c). Toa solution of 2c (0.53 g, 1.6 mmol) dissolved in 16 mL of acetone, 5 mLof Jones' reagent was added. The reaction mixture was stirred at roomtemperature and monitored by TLC. The reaction mixture was poured intowater and extracted with EtOAc. The combined organic layers were washedwith water and brine, dried over Na₂SO₄, and concentrated in vacuo toafford 0.51 g (91%) of the title acid: mp 211.7° C. ¹H NMR (CDCl₃) δ8.52 (s, 1H), 7.75 (d, 2H), 7.66 (d, 1H), 7.58 (s, 1H), 7.41 (d, 1H),7.24 (d, 2H), 2.43 (s, 3H). ¹³C NMR (CDCl₃) δ 171.6, 155.7, 139.3,131.9, 130.6, 130.2, 134.7, 132.1, 130.6, 129.8, 22.7. Anal. Calcd forC₁₇H₁₂C₁₂N₂O₂: C, 58.81; H, 3.48, N, 8.07. Found: C, 58.46; H, 3.40, N,7.68.

3-(p-Tolyl)-1-(3-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxylic acid(3d). To a solution of 2d (0.79 g, 2.39 mmol) dissolved in 16 mL ofacetone, 5 mL of Jones' reagent was added. The reaction mixture wasstirred at room temperature and monitored by TLC. The reaction mixturewas poured into water and extracted with EtOAc. The combined organiclayers were washed with water and brine, dried over Na₂SO₄, andconcentrated in vacuo to afford 0.81 g (98%) of the title acid: mp181.8° C. ¹H NMR (CDCl₃) δ 8.64 (s, 1H), 8.09 (s, 1H), 7.98 (d, 1H),7.79 (d, 2H), 7.63 (d, 2H), 7.31 (t, 2H), 2.45 (s, 3H). ¹³C NMR (CDCl₃)δ 168.2, 155.7, 140.8, 140.5, 134.8, 131.7, 130.7, 130.2, 129.8, 125.5,123.7, 117.9, 114.5, 22.8. Anal. Calcd for C₁₈H₁₃F₃N₂O₂: C, 62.43; H,3.78; N, 8.09. Found: C, 61.95; H, 3.74; N, 7.62.

1-(Benzo[d]thiazol-2-yl)-3-(p-tolyl)-1H-pyrazole-4-carboxylic acid (3e).To a solution of 2e (0.71 g, 2.31 mmol) dissolved in 16 mL of acetone, 5mL of Jones' reagent was added. The reaction mixture was stirred at roomtemperature and monitored by TLC. The reaction mixture was poured intowater and extracted with EtOAc. The combined organic layers were washedwith water and brine, dried over Na₂SO₄, and concentrated in vacuo toafford 0.41 g (57%) of the title acid: mp 208.0° C. ¹H NMR (CDCl₃) δ9.09 (s, 1H), 7.98 (d, 1H), 7.90 (d, 1H), 7.81 (d, 2H), 7.54 (d, 1H),7.43 (d, 1H), 7.35 (d, 2H), 2.45 (s, 3H). ¹³C NMR (CDCl₃) δ 171.2,160.1, 151.6, 141.3, 134.0, 131.3, 130.3, 129.0, 126.9, 124.2, 123.5,23.0.

General Procedure of Mitsunobu Reaction

To a solution of 3 in CH₂Cl₂ was added EDCI and HOBT. The reactionmixture was stirred for 1-2 h. To the reaction were added4-methyl-3-(morpholinosulfonyl)aniline and the reaction mixture wasstirred at room temperature for overnight and quenched with water.Layers were separated and the aqueous layer was extracted with EtOAc.The combined organic solution was dried over Na₂SO₄ and then evaporatedunder a vacuum. The resulting yellow solids were purified by flashcolumn chromatography to afford 4a-4e.

1-(4-fluorophenyl)-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-3-p-tolyl-1H-pyrarazole-4-carboxamide(4a). To a solution of 3a (0.2 g, 0.67 mmol) in CH₂Cl₂ (10 mL) was addedEDCI (0.22 g, 1.16 mmol) and HOBT (0.16 g, 1.16 mmol). The reactionmixture was stirred for 1 h. To the reaction were added4-methyl-3-(morpholinosulfonyl)aniline (0.17 g, 0.68 mmol) and thereaction mixture was stirred at room temperature for 12 h and quenchedwith water. Layers were separated and the aqueous layer was extractedwith EtOAc. The combined organic solution was dried over Na₂SO₄ and thenevaporated under a vacuum. The resulting yellow solid was purified byflash column chromatography (H/EtOAc 1:1) to afford 4a as a white solid(0.09 g, 26% yield), mp 95.9° C. ¹H NMR (CDCl₃) δ 8.52 (s, 1H), 7.73 (s,1H), 7.72 (d, 2H), 7.64 (t, 2H), 7.54 (d, 2H), 7.36 (d, 2H), 7.27 (d,3H), 3.72 (d, 4H), 3.17 (d, 4H), 2.57 (s, 3H), 2.47 (s, 3H). ¹³C NMR(CDCl₃) δ 162.1, 152.6, 141.4, 137.5, 137.4, 134.8, 134.6, 132.7, 131.2,130.7, 130.2, 125.2, 122.7, 122.3, 119.5, 117.9, 117.7, 67.7, 46.8,23.9, 22.6. Anal. Calcd for C₂₈H₂₇FN₄O₄S: C, 62.91; H, 5.09; N, 10.48;F, 3.55. Found: C, 62.75; H, 4.57; N, 10.46; F, 3.4.

1-(3-Chlorophenyl)-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-3-(p-tolyl)-1H-pyrazole-4-carboxamide(4b). To a solution of 3b (0.2 g, 0.67 mmol) in CH₂Cl₂ (10 mL) was addedEDCI (0.22 g, 1.16 mmol) and HOBT (0.15 g, 1.16 mmol). The reactionmixture was stirred for 1 h. To the reaction were added4-methyl-3-(morpholinosulfonyl)aniline (0.17 g, 0.68 mmol) and thereaction mixture was stirred at room temperature for 12 h and quenchedwith water. The organic layer was collected and the aqueous layer wasextracted with EtoAc. The combined organic solution was dried overNa₂SO₄, evaporated under a vacuum. The resulting yellow solid waspurified by flash column chromatography (H/EtOAc 1:1) to afford 4b as awhite solid (0.07 g, 19% yield), mp 204.9° C. ¹H NMR (CDCl₃) δ 8.60 (s,1H), 7.88 (s, 1H), 7.72 (d, 1H), 7.62 (m, 3H), 7.45 (d, 2H), 7.41 (m,3H), 7.24 (d, 2H), 3.75 (d, 4H), 3.21 (d, 4H), 2.59 (s, 3H), 2.50 (s,3H). ¹³C NMR (CDCl₃) δ 162.1, 152.7, 147.6, 141.7, 137.9, 134.8, 132.8,132.0, 131.3, 130.7, 128.9, 125.1, 122.3, 121.3, 118.5, 67.7, 64.9,23.0, 21.5, Anal. Calcd for C₂₈H₂₇ClN₄O₄S: C, 61.03; H, 4.94; N, 10.17;Cl, 6.43. Found: C, 60.78; H, 4.61; N, 9.94; Cl, 6.7.

1-(2,4-Dichlorophenyl)-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-3-(p-tolyl)-1H-pyrazole-4-carboxamide(4c). To a solution of 3c (0.2 g, 0.58 mmol) in CH₂Cl₂ (5 mL) was addedEDCI (0.22 g, 1.16 mmol) and HOBT (0.16 g, 1.16 mmol). The reactionmixture was stirred for 1 h. To the reaction were added4-methyl-3-(morpholinosulfonyl)aniline (0.15 g, 0.58 mmol) and thereaction mixture was stirred at room temperature for 12 h and quenchedwith water. The organic layer was collected and the aqueous layer wasextracted with EtoAc. The combined organic solution was dried overNa₂SO₄, evaporated under a vacuum. The resulting yellow solid waspurified by flash column chromatography (H/EtOAc 1:1) to afford 4c as awhite solid (0.06 g, 20% yield), mp 99.8° C. ¹H NMR (CDCl₃) δ 8.52 (s,1H), 7.73 (s, 1H), 7.62 (m, 3H), 7.45 (d, 2H), 7.38 (m, 3H), 7.24 (d,2H), 3.73 (d, 4H), 3.19 (d, 4H), 2.57 (s, 3H), 2.46 (s, 3H). ¹³C NMR(CDCl₃) δ 162.0, 152.6, 141.9, 139.9, 137.7, 134.7, 134.3, 132.0, 131.3,130.8, 129.5, 127.4, 125.2, 122.0, 118.3, 116.6, 67.7, 46.8, 22.9, 21.8.Anal. Calcd for C₂₈H₂₆Cl₂N₄O₄S: C, 57.44; H, 4.48; N, 9.57; Cl, 12.22.Found: C, 57.11; H, 4.27; N, 8.91; Cl, 12.2.

N-(4-Methyl-3-(morpholinosulfonyl)phenyl)-3-(p-tolyl)-1-(3-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxamide (4d). To a solution of 3d (0.2 g, 0.58mmol) in CH₂Cl₂ (10 mL) was added EDCI (0.34 g, 1.76 mmol) and HOBT(0.24 g, 1.76 mmol). The reaction mixture was stirred for 1 h. To thereaction were added 4-methyl-3-(morpholinosulfonyl)aniline (0.2 g, 0.78mmol) and the reaction mixture was stirred at room temperature for 16 hand quenched with water. The organic layer was collected and the aqueouslayer was extracted with EtOAc. The combined organic solution was driedover Na₂SO₄, evaporated under a vacuum. The resulting yellow solid waspurified by flash column chromatography (H/EtOAc 1:1) to afford 4d as awhite solid (0.1 g, 31% yield), mp 192.7° C. ¹H NMR (CDCl₃) δ 8.67 (s,1H), 8.12 (s, 1H), 7.92 (d, 1H), 7.72 (s, 1H), 7.64 (d, 4H), 7.51 (t,3H), 7.41 (d, 2H), 3.74 (d, 4H), 3.19 (d, 4H), 2.58 (s, 3H), 2.50 (s,3H). ¹³C NMR (CDCl₃) δ 165.0, 151.6, 141.9, 139.9, 137.7, 134.7, 134.3,132.0, 131.3, 130.8, 129.5, 127.4, 125.2, 124.1, 118.3, 116.6, 67.8,46.9, 23.9, 23.6. Anal. Calcd for C₂₉H₂₇F₃N₄O₄S: C, 59.58; H, 4.66; N,9.58; F, 9.75. Found: C, 60.07; H, 4.38; N, 9.53; F, 10.

1-(Benzo[d]thiazol-2-yl)-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-3-(p-tolyl)-1H-pyrazole-4-carboxamide(4e). To a solution of 3e (0.2 g, 0.59 mmol) in CH₂Cl₂ (5 mL) was addedEDCI (0.14 g, 0.71 mmol) and HOBT (0.1 g, 0.7 mmol). The reactionmixture was stirred for 1 h. To the reaction were added4-methyl-3-(morpholinosulfonyl)aniline (0.15 g, 0.59 mmol) and thereaction mixture was stirred at room temperature for 12 h and quenchedwith water. The organic layer was collected and the aqueous layer wasextracted with EtOAc. The combined organic solution was dried overNa₂SO₄, evaporated under a vacuum. The resulting yellow oil was purifiedby flash column chromatography (H/EtOAc 1:1) to afford 4e as apale-yellow solid (0.07 g, 21% yield), mp 153.1° C. ¹H NMR (CDCl₃) δ8.51 (s, 1H), 8.02 (s, 1H), 7.97 (d, 2H), 7.79 (d, 1H), 7.71 (t, 2H),7.55 (t, 1H), 7.40 (dd, 4H), 3.74 (d, 4H), 3.19 (d, 4H), 2.63 (s, 3H),2.44 (s, 3H). ¹³C NMR (CDCl₃) δ 165.0, 159.6, 144.5, 135.4, 137.7,131.3, 131.0, 130.7, 130.2, 128.5, 126.1, 123.1, 123.0, 67.7, 47.7,23.0, 21.7. Anal. Calcd for C₂₉H₂₇N₅O₄S₂: C, 60.71; H, 4.74; N, 12.21.Found: C, 60.57; H, 4.2; N, 12.6.

General Procedure of Mitsunobu Reaction for Producing 4f-4s

To a solution of 7 in CH₂Cl₂ was added EDCI and DMAP. To the reactionwas added 4-methyl-3-(morpholinosulfonyl)aniline and the reactionmixture was stirred at room temperature for 6 h and quenched with waterand then treated with 10% HCl. The organic layer was collected and theaqueous layer was extracted with EtOAc. The combined organic solutionwas dried over Na₂SO₄, evaporated under a vacuum. The resulting yellowoil was purified by flash column chromatography to afford 4f-4s.

1-Isopropyl-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-3-(p-tolyl)-1H-pyrazole-4-carboxamide(4f). To a solution of 7-1 (0.11 g, 0.43 mmol) in CH₂Cl₂ (5 mL) wasadded EDCI (0.14 g, 0.73 mmol) and DMAP (0.09 g, 0.73 mmol). To thereaction was added 4-methyl-3-(morpholinosulfonyl)aniline (0.11 g, 0.43mmol) and the reaction mixture was stirred at room temperature for 6 hand quenched with water and then treated with 10% HCl. The organic layerwas collected and the aqueous layer was extracted with EtOAc. Thecombined organic solution was dried over Na₂SO₄, evaporated under avacuum. The resulting yellow oil was purified by flash columnchromatography (H/EtOAc 1:1) to afford 4f as a white solid (0.11 g, 50%yield), mp 198.2° C. ¹H NMR (CDCl₃) δ 8.13 (s, 1H), 7.69 (s, 1H), 7.54(d, 2H), 7.44 (d, 2H), 7.35 (d, 2H), 7.26 (d, 1H), 4.55 (m, 1H), 3.74(d, 4H), 3.17 (d, 4H), 2.56 (s, 3H), 2.46 (s, 3H), 1.59 (d, 6H). ¹³C NMR(CDCl₃) δ 163.2, 145.3, 140.8, 135.2, 134.7, 130.3, 130.1, 126.1, 121.8,120.9, 117.9, 109.9, 67.7, 56.5, 46.7, 24.1, 22.9, 21.1. Anal. Calcd forC₂₅H₃₀N₄O₄S. ½ H2O: C, 61.07; H, 6.15; N, 11.39. Found: C, 61.26; H,6.31; N, 11.29.

1-Butyl-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-3-(p-tolyl)-1H-pyrazole-4-carboxamide(4g). To a solution of 7-2 (0.2 g, 0.77 mmol) in CH₂Cl₂ (10 mL) wasadded EDCI (0.18 g, 0.92 mmol) and HOBT (0.12 g, 0.92 mmol). Thereaction mixture was stirred for 1 h. To the reaction were added4-methyl-3-(morpholinosulfonyl)aniline (0.2 g, 0.77 mmol) and thereaction mixture was stirred at room temperature for 12 h and quenchedwith water. The organic layer was collected and the aqueous layer wasextracted with EtOAc. The combined organic solution was dried overNa₂SO₄, evaporated under a vacuum. The resulting yellow oil was purifiedby flash column chromatography (H/EtOAc 1:1) to afford 4g as a whitesolid (0.2 g, 53% yield), mp 177.4° C. ¹H NMR (CDCl₃) δ 8.07 (s, 1H),7.69 (s, 1H), 7.54 (d, 2H), 7.44 (d, 2H), 7.35 (d, 2H), 7.23 (s, 1H),4.18 (m, 2H), 3.74 (d, 4H), 3.17 (d, 4H), 2.56 (s, 3H), 2.46 (s, 3H),1.92 (t, 2H), 1.41 (t, 2H), 0.98 (t, 3H). ¹³C NMR (CDCl₃) δ 162.7,151.3, 140.9, 137.6, 134.8, 131.7, 131.5, 130.7, 125.2, 122.1, 120.9,116.9, 67.7, 53.9, 46.8, 33.5, 22.8, 21.4, 21.1, 14.9. Anal. Calcd forC₂₆H₃₂N₄O₄S: C, 62.88; H, 6.49; N, 11.28. Found: C, 62.65; H, 6.27; N,11.08.

N-(4-Methyl-3-(morpholinosulfonyl)phenyl)-1-(naphthalen-2-ylmethyl)-3-(p-tolyl)-1H-pyrazole-4-carboxamide(4h). To a solution of 7-3 (0.2 g, 0.78 mmol) in CH₂Cl₂ (10 mL) wasadded EDCI (0.18 g, 0.94 mmol) and DMAP (0.11 g, 0.94 mmol). To thereaction was added 4-methyl-3-(morpholinosulfonyl)aniline (0.2 g, 0.78mmol) in one portion and the reaction mixture was stirred at roomtemperature for 6 h and then treated with 10% HCl. The organic layer wascollected and the aqueous layer was extracted with EtOAc. The combinedorganic solution was dried over Na₂SO₄, evaporated under a vacuum. Theresulting yellow oil was purified by flash column chromatography(H/EtOAc 1:1) to afford 4g as a white solid (0.2 g, 50% yield), mp144.9° C. ¹H NMR (CDCl₃) δ 8.13 (s, 1H), 7.85 (m, 4H), 7.68 (s, 1H),7.53 (m, 4H), 7.45 (m, 2H), 7.35 (d, 2H), 7.20 (d, 2H), 5.51 (s, 2H),3.72 (t, 4H), 3.15 (t, 4H), 2.51 (s, 3H), 2.46 (s, 3H). ¹³C NMR (CDCl₃)δ 162.2, 151.2, 141.2, 137.4, 136.9, 135.6, 134.8, 133.7, 131.3, 130.8,130.4, 129.4, 129.2, 129.1, 128.1, 127.1, 125.1, 122.1, 67.8, 58.4,46.9, 22.9, 21.6. Anal. Calcd for C₃₃H₃₂N₄O₄S: C, 68.25; H, 5.55; N,9.65. Found: C, 68.00; H, 6.04; N, 9.48.

1-(Cyclopropylmethyl)-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-3-(p-tolyl)-1H-pyrazole-4-carboxamide(4i). To a solution of 7-4 (0.2 g, 0.78 mmol) in CH₂Cl₂ (10 mL) wasadded EDCI (0.18 g, 0.94 mmol) and DMAP (0.11 g, 0.94 mmol). To thereaction was added 4-methyl-3-(morpholinosulfonyl)aniline (0.2 g, 0.78mmol) in one portion and the reaction mixture was stirred at roomtemperature for 6 h and then treated with 10% HCl. The organic layer wascollected and the aqueous layer was extracted with EtOAc. The combinedorganic solution was dried over Na₂SO₄, evaporated under a vacuum. Theresulting yellow solid was purified by crystallization from EtOAc gave4i as a white solid (0.3 g, 78% yield), mp 210.0° C. ¹H NMR (CDCl₃) δ8.23 (s, 1H), 7.71 (d, 1H), 7.54 (d, 2H), 7.46 (d, 2H), 7.35 (d, 2H),7.21 (d, 1H), 4.05 (d, 2H), 3.74 (t, 4H), 3.17 (t, 4H), 2.51 (s, 3H),1.36 (brs, 1H), 0.74 (q, 2H), 0.45 (t, 2H). ¹³C NMR (CDCl₃) δ 162.5,150.8, 141.0, 137.6, 137.1, 131.3, 130.8, 125.0, 122.1, 67.8, 58.9,46.9, 23.2, 21.9, 12.0, 5.6. Anal. Calcd for C₂₆H₃₀N₄O₄S.¼ H₂O: C,61.98; H, 6.00; N, 11.02. Found: C, 61.63; H, 5.82; N, 10.84.

1-(3-Methoxybenzyl)-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-3-(p-tolyl)-1H-pyrazole-4-carboxamide(4j, DY268). To a solution of 7-5 (0.1 g, 0.31 mmol) in CH₂Cl₂ (8 mL)was added EDCI (0.071 g, 0.37 mmol) and DMAP (0.045 g, 0.37 mmol). Tothe reaction was added 4-methyl-3-(morpholinosulfonyl)aniline (0.08 g,0.31 mmol) in one portion and the reaction mixture was stirred at roomtemperature for 6 h and then treated with 10% HCl. The organic layer wascollected and the aqueous layer was extracted with EtOAc. The combinedorganic solution was dried over Na₂SO₄, evaporated under a vacuum. Theresulting yellow oil was purified by flash column chromatography(H/EtOAc 1:1) to afford 4j as a white solid (0.08 g, 47% yield), mp183.3° C. ¹H NMR (CDCl₃) δ 8.01 (s, 1H), 7.69 (s, 1H), 7.55 (d, 2H),7.44 (d, 2H), 7.34 (m, 3H), 7.22 (d, 2H), 6.93 (d, 1H), 6.87 (s, 1H),5.32 (s, 2H), 3.85 (s, 3H), 3.74 (t, 4H), 3.17 (t, 4H), 2.56 (s, 3H),2.46 (s, 3H). ¹³C NMR (CDCl₃) δ 162.6, 160.0, 141.4, 137.1, 135.5,134.8, 131.5, 131.3, 130.8, 125.1, 122.1, 115.5, 115.4, 67.7, 58.0,56.7, 46.8, 22.8, 21.6. Anal. Calcd for C₃₀H₃₂N₄O₅S: C, 64.27; H, 5.75;N, 9.99. Found: C, 64.01; H, 5.77; N, 9.63.

N-(4-methyl-3-(morpholinosulfonyl)phenyl)-3-(p-tolyl)-1-(3-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide(4k). To a solution of 7-6 (0.11 g, 0.34 mmol) in CH₂Cl₂ (5 mL) wasadded EDCI (0.078 g, 0.41 mmol) and DMAP (0.05 g, 0.41 mmol). To thereaction was added 4-methyl-3-(morpholinosulfonyl)aniline (0.087 g, 0.34mmol) in one portion and the reaction mixture was stirred at roomtemperature for 6 h and then treated with 10% HCl. The organic layer wascollected and the aqueous layer was extracted with EtOAc. The combinedorganic solution was dried over Na₂SO₄, evaporated under a vacuum. Theresulting yellow solid was purified by crystallization from EtOAc gave4k as a white solid (0.1 g, 56% yield), mp 179.3° C. ¹H NMR (CDCl₃) δ8.07 (s, 1H), 7.68 (s, 1H), 7.59 (s, 1H), 7.51 (t, 4H), 7.45 (t, 2H),7.43 (d, 2H), 7.21 (d, 2H), 5.41 (s, 2H), 3.72 (t, 4H), 3.15 (t, 4H),2.51 (s, 3H), 2.46 (s, 3H). ¹³C NMR (CDCl₃) δ 162.4, 151.6, 141.4,137.3, 135.7, 134.8, 134.6, 132.8, 131.3, 130.8, 126.2, 125.1, 122.2,118.4, 67.7, 57.4, 46.8, 22.8, 21.6. Anal. Calcd for C₃₀H₂₉F₃N₄O₄S: C,60.19; H, 4.88; N, 9.36, F, 9.52. Found: C, 60.45; H, 4.70; N, 9.15, F,9.20.

1-(4-Hydroxybutyl)-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-3-(p-tolyl)-1H-pyrazole-4-carboxamide(4l). To a solution of 7-7 (0.09 g, 0.34 mmol) in CH₂Cl₂ (5 mL) wasadded EDCI (0.078 g, 0.41 mmol) and DMAP (0.05 g, 0.41 mmol). To thereaction was added 4-methyl-3-(morpholinosulfonyl)aniline (0.087 g, 0.34mmol) in one portion and the reaction mixture was stirred at roomtemperature for 6 h and then treated with 10% HCl. The organic layer wascollected and the aqueous layer was extracted with EtOAc. The combinedorganic solution was dried over Na₂SO₄, evaporated under a vacuum. Theresulting yellow oil was purified by flash column chromatography(CHCl₃/MeOH 95:5) to afford 4l as a white solid (0.05 g, 27% yield), mp57.8° C. ¹H NMR (CDCl₃) δ 8.01 (s, 1H), 7.68 (s, 1H), 7.50 (d, 2H), 7.49(t, 1H), 7.15 (t, 4H), 4.21 (d, 2H), 4.20 (d, 2H), 3.72 (t, 4H), 3.11(t, 4H), 2.51 (s, 3H), 2.46 (s, 3H), 1.94 (t, 2H), 1.26 (t, 2H). ¹³C NMR(CDCl₃) δ 162.2, 154.9, 141.3, 139.8, 137.6, 135.2, 134.8, 131.8, 131.3,130.6, 129.9, 125.2, 122.3, 67.7, 63.3, 53.8, 46.8, 30.7, 27.2, 21.6.Anal. Calcd for C₂₆H₃₂N₄O₄S: C, 60.71; H, 4.74; N, 12.21. Found: C,60.57; H, 4.2; N, 12.26.

(Z)-Ethyl 3-ethoxy-2-(4-methylbenzoyl)acrylate (5-1)

Ethyl 3-oxo-3-(p-tolyl)propanoate (1.0 g, 4.85 mmol) andtriethylorthoformate (1.15 g, 7.76 mmol) were heated to reflux andstirred for 30 min. Acetic anhydride (1.5 g, 14.55 mmol) was then added,and refluxing continued for about 12 h. Then the mixture was cooled anddiluted with EtOAc and water was added to the solution, which was thenstirred for 10 min to decompose excess triethylorthoformate. The aqueouslayer was extracted with EtOAc. The organic layers were washed withwater, brine, dried over Na₂SO₄ and concentrated in vacuo to yield 1.21g (94%) of the title compound which was used without furtherpurification. ¹H NMR (CDCl₃) δ 7.82 (d, 2H), 7.69 (s, 1H), 7.27 (d, 2H),4.17 (q, 2H), 4.11 (q, 2H), 2.40 (s, 3H), 1.28 (t, 3H), 1.17 (t, 3H).¹³C NMR (CDCl₃) δ 192.9, 162.7, 145.5, 136.2, 130.8, 130.5, 130.3,113.7, 73.1, 61.9, 23.1, 16.6, 15.6.

(Z)-Ethyl 2-(ethoxymethylene)-4-methyl-3-oxopentanoate (5-2)

Ethyl isobutyryl acetate (2.0 g, 12.64 mmol) and triethylorthoformate(3.0 g, 20.22 mmol) were heated to reflux for 30 min. Acetic anhydride(3.8 g, 37.92 mmol) was then added, and refluxing continued for about 12h. The reaction mixture was cooled and diluted with EtOAc and water wasadded to the solution, which was then stirred for 10 min to decomposeexcess triethylorthoformate. The aqueous layer was extracted with EtOAc.The organic layers were washed with water, brine, dried over Na₂SO₄ andconcentrated in vacuo to yield 2.49 g (92%) of the title compound whichwas used without further purification. ¹H NMR (CDCl₃) δ 7.52 (s, 1H),4.29 (q, 2H), 4.19 (q, 2H), 3.14 (m, 1H), 1.37 (t, 3H), 1.32 (t, 3H),1.16 (s, 3H), 1.11 (s, 3H). ¹³C NMR (CDCl₃) δ 203.4, 165.8, 163.1,114.7, 73.4, 62.2, 42.1, 20.2, 19.3, 16.6, 15.6.

(Z)-Ethyl 3-ethoxy-2-(3-methoxybenzoyl)acrylate (5-3)

Ethyl (3-methoxybenzoyl) acetate (1.0 g, 4.5 mmol) andtriethylorthoformate (1.07 g, 7.2 mmol) were heated to reflux for 30min. Acetic anhydride (1.37 g, 13.5 mmol) was then added, and refluxingcontinued for about 12 h. The reaction mixture was cooled and dilutedwith EtOAc and water was added to the solution, which was then stirredfor 10 min to decompose excess triethylorthoformate. The aqueous layerwas extracted with EtOAc. The organic layers were washed with water,brine, dried over Na₂SO₄ and concentrated in vacuo to yield 1.1 g (88%)of the title compound which was used without further purification. ¹HNMR (CDCl₃) δ 7.68 (s, 1H), 7.47 (t, 2H), 7.35 (t, 1H), 7.11 (t, 1H),4.17 (q, 2H), 4.11 (q, 2H), 1.16 (t, 3H), 1.06 (t, 3H). ¹³C NMR (CDCl₃)δ 193.3, 167.1, 162.9, 161.2, 140.1, 130.7, 130.5, 123.7, 121.4, 114.1,73.2, 62.0, 56.8, 16.6, 15.6.

(Z)-Ethyl 3-ethoxy-2-(3-(trifluoromethyl)benzoyl)acrylate (5-4). Ethyl(4-trifluoromethylbenzoyl) acetate (1.0 g, 3.84 mmol) andtriethylorthoformate (0.91 g, 6.15 mmol) were heated to reflux for 30min. Acetic anhydride (1.18 g, 11.53 mmol) was then added, and refluxingcontinued for about 12 h. The reaction mixture was cooled and dilutedwith EtOAc and water was added to the solution, which was then stirredfor 10 min to decompose excess triethylorthoformate. The aqueous layerwas extracted with EtOAc. The organic layers were washed with water,brine, dried over Na₂SO₄ and concentrated in vacuo to yield 1.08 g (89%)of the title compound which was used without further purification. ¹HNMR (CDCl₃) δ 8.06 (d, 1H), 7.97 (d, 1H), 7.87 (s, 1H), 7.74 (d, 2H),4.16 (q, 2H), 4.11 (q, 2H), 1.27 (t, 6H). ¹³C NMR (CDCl₃) δ 193.2,164.1, 130.7, 130.3, 127.8, 127.3, 126.8, 114.1, 73.6, 62.1, 16.6, 15.5.

(Z)-Methyl 2-(ethoxymethylene)-5-methoxy-3-oxopentanoate (5-5). Methyl5-methoxy-3-oxovalerate (2.0 g, 12.48 mmol) and triethylorthoformate(3.0 g, 19.96 mmol) were heated to reflux for 30 min. Acetic anhydride(3.82 g, 37.44 mmol) was then added, and refluxing continued for about 6h. The reaction mixture was cooled and diluted with EtOAc and water wasadded to the solution, which was then stirred for 10 min to decomposeexcess triethylorthoformate. The aqueous layer was extracted with EtOAc.The organic layers were washed with water, brine, dried over Na₂SO₄ andconcentrated in vacuo to yield 2.27 g (84%) of the title compound whichwas used without further purification. ¹H NMR (CDCl₃) δ 7.90 (s, 1H),4.25 (q, 2H), 3.66 (t, 2H), 3.35 (s, 3H), 3.23 (t, 2H), 1.31 (t, 3H).¹³C NMR (CDCl₃) δ 200.5, 185.9, 165.7, 108.1, 67.7, 67.6, 60.3, 51.4,38.8, 15.2.

Ethyl 3-(p-tolyl)-1H-pyrazole-4-carboxylate (6-1)

A solution of hydrazine monohydrate (0.2 ml, 4.2 mmol) in dry ethanol (1ml) was added dropwise at 0° C. to a solution of (Z)-Ethyl3-ethoxy-2-(4-methylbenzoyl)acrylate (5-1) (1.0 g, 3.81 mmol) in ethanol(5 ml). The reaction mixture was stirred at rt for 12 h and theresulting solid was filtered, washed with water and cold ethanol, anddried to afford 0.77 g (88%) of 6-1 as a white solid, mp 83.5° C. ¹H NMR(CDCl₃) δ 8.04 (s, 1H), 7.59 (d, 2H), 7.27 (d, 2H), 4.27 (q, 2H), 2.40(s, 3H), 1.31 (t, 3H). ¹³C NMR (CDCl₃) δ 164.8, 149.3, 142.8, 140.8,130.4, 130.3, 127.9, 113.1, 61.6, 22.8, 15.7.

Ethyl 3-isopropyl-1H-pyrazole-4-carboxylate (6-2)

A solution of hydrazine monohydrate (0.67 g, 13.40 mmol) in dry ethanol(1 ml) was added dropwise at 0° C. to a solution of (Z)-ethyl2-(ethoxymethylene)-4-methyl-3-oxopentanoate (5-2) (2.49 g, 11.62 mmol)in ethanol (10 ml). The reaction mixture was stirred at rt for 12 h andthe solvent was removed, solidified by pet. ether to afford 1.28 g (61%)of 6-2 as a white solid, mp 71.5° C. ¹H NMR (CDCl₃) δ 11.46 (brs, 1H),7.96 (s, 1H), 4.32 (q, 2H), 3.69 (m, 1H), 1.36 (s, 6H), 1.33 (t, 3H).¹³C NMR (CDCl₃) δ 165.1, 142.1, 111.6, 61.3, 27.1, 22.9, 15.8.

Ethyl 3-(3-methoxyphenyl)-1H-pyrazole-4-carboxylate (6-3)

A solution of hydrazine monohydrate (0.22 g, 4.35 mmol) in dry ethanol(1 ml) was added dropwise at 0° C. to a solution of (Z)-ethyl3-ethoxy-2-(3-methoxybenzoyl)acrylate (5-3) (1.1 g, 3.95 mmol) inethanol (5 ml). The reaction mixture was stirred at rt for 12 h and thesolvent was removed. The crude was resolved in EtOAc, washed with water,and concentrated to afford 0.97 g (98%) of 6-3 as a red oil which wasused without further purification. ¹H NMR (CDCl₃) δ 8.05 (s, 1H), 7.36(t, 1H), 7.29 (t, 3H), 6.98 (d, 1H), 4.28 (q, 2H), 3.81 (s, 3H), 1.30(t, 3H). ¹³C NMR (CDCl₃) δ 164.6, 160.7, 141.6, 132.2, 130.7, 122.8,116.5, 116.2, 112.8, 61.6, 56.8, 15.7.

Ethyl 3-(4-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxylate (6-4). Asolution of hydrazine monohydrate (0.22 g, 4.35 mmol) in dry ethanol (1ml) was added dropwise at 0° C. to a solution of (Z)-ethyl3-ethoxy-2-(3-methoxybenzoyl)acrylate (5-4) (1.08 g, 3.41 mmol) inethanol (5 ml). The reaction mixture was stirred at rt for 12 h and thesolvent was removed. The crude was resolved in EtOAc, washed with water,and concentrated to afford a red oil which was solidified by EtOAc togive 0.79 g (82%) of 6-4 as a pale red solid, mp 177.2° C. ¹H NMR (MeOD)δ 8.12 (s, 1H), 7.84 (d, 2H), 7.67 (d, 2H), 4.28 (q, 2H), 1.29 (t, 3H).¹³C NMR (MeOD) δ 164.7, 136.1, 131.2, 131.1, 130.7, 127.4, 126.7, 126.2,125.7, 112.6, 61.4, 14.4.

Methyl 3-(2-methoxyethyl)-1H-pyrazole-4-carboxylate (6-5). A solution ofhydrazine monohydrate (0.57 g, 11.54 mmol) in dry ethanol (1 ml) wasadded dropwise at 0° C. to a solution of (Z)-methyl2-(ethoxymethylene)-5-methoxy-3-oxopentanoate (5-5) (2.27 g, 10.49 mmol)in ethanol (7 ml). The reaction mixture was stirred at rt for 12 h andthe solvent was removed. The crude was resolved in EtOAc, washed withwater, and concentrated to afford a red oil which was solidified byEtOAc to give 1.72 g (89%) of 6-5 as a yellow oil. ¹H NMR (CDCl₃) δ 7.90(s, 1H), 4.24 (q, 2H), 3.76 (s, 1H), 3.65 (t, 2H), 3.33 (s, 3H), 1.28(t, 3H). ¹³C NMR (CDCl₃) δ 165.2, 148.3, 141.5, 122.4, 72.1, 60.3, 52.5,27.3.

1-Isopropyl-3-(p-tolyl)-1H-pyrazole-4-carboxylic acid (7-1). A solutionof 6-1 (0.5 g, 2.17 mmol), 1-Bromo-2-methyl-propane (0.55 g, 3.25 mmol)and cesium carbonate (2.12 g, 6.51 mmol) in acetonitrile (10 ml) wasstirred at room temperature for 16 hrs and the reaction was stopped.Water (10 ml) was added into the reaction mixture and the aqueous layerwas extracted with ethyl acetate (3×15 ml). The combined organic layerswere washed with brine (3×10 ml), dried over Na₂SO₄, filtered andconcentrated to give crude. ¹H NMR (CDCl₃) δ 8.00 (s, 1H), 7.67 (d, 2H),7.22 (d, 2H), 4.54 (m, 1H), 4.25 (q, 2H), 2.38 (s, 3H), 1.56 (d, 6H),1.31 (t, 3H). The crude residue in ethanol (12 mL) was treated with 1Naqueous potassium hydroxide (7.5 mL) at 75° C. for 2.5 hours. Thereaction was cooled, acidified with 5N HCl and the ethanol removed invacuo. The solids were filtered, washed with water, hexanes and dried invacuo to afford 0.31 g (58%) of 7-1 as a beige powder, mp 129.0° C. ¹HNMR (CDCl₃) δ 8.06 (s, 1H), 7.66 (d, 2H), 7.21 (d, 2H), 4.53 (m, 1H),2.38 (s, 3H), 1.56 (d, 6H). ¹³C NMR (CDCl₃) δ 169.8, 154.6, 139.7,134.6, 131.0, 130.6, 130.1, 55.9, 24.1, 24.0, 22.9.

1-Butyl-3-(p-tolyl)-1H-pyrazole-4-carboxylic acid (7-2). A solution of6-1 (0.5 g, 2.17 mmol), 1-Bromobutane (0.29 g, 3.25 mmol) and cesiumcarbonate (2.12 g, 6.51 mmol) in acetonitrile (10 ml) was stirred atroom temperature for 16 hrs and the reaction was stopped. Water (10 ml)was added into the reaction mixture and the aqueous layer was extractedwith ethyl acetate (3×15 ml). The combined organic layers were washedwith brine (3×10 ml), dried over Na₂SO₄, filtered and concentrated. Thecrude residue in ethanol (12 mL) was treated with 1N aqueous potassiumhydroxide (7.5 mL) at 75° C. for 3.5 hours. The reaction was cooled,acidified with 5N HCl and the ethanol removed in vacuo. Solvent wasremoved and the resulting yellow oil was purified by flash columnchromatography (CHCl₃/MeOH 9:1) to afford 7-2 as pale-yellow oil (0.5 g,50% yield). ¹H NMR (CDCl₃) δ 8.06 (s, 1H), 7.66 (d, 2H), 7.21 (d, 2H),4.53 (m, 1H), 2.38 (s, 3H), 1.56 (d, 6H). ¹³C NMR (CDCl₃) δ 169.8,154.6, 139.7, 134.6, 131.0, 130.6, 130.1, 55.9, 24.1, 24.0, 22.9.

1-(Naphthalen-2-ylmethyl)-3-(p-tolyl)-1H-pyrazole-4-carboxylic acid(7-3). A solution of 6-1 (0.18 g, 0.78 mmol), 2-(bromomethyl)naphthalene(0.26 g, 1.17 mmol) and cesium carbonate (0.76 g, 2.34 mmol) inacetonitrile (5 ml) was stirred at room temperature for 16 hrs and thereaction was stopped. Water (10 ml) was added into the reaction mixtureand the aqueous layer was extracted with ethyl acetate (3×15 ml). Thecombined organic layers were washed with brine (3×10 ml), dried overNa₂SO₄, filtered and concentrated. The crude residue in ethanol (10 mL)was treated with 1N aqueous potassium hydroxide (7.5 mL) at 75° C. for3.5 hours. The reaction was cooled, acidified with 5N HCl and theethanol removed in vacuo to afford 7-3 as a pale-yellow solid (0.2 g,77% yield), mp 151.2° C. ¹H NMR (CDCl₃) δ 8.06 (s, 1H), 7.75 (m, 3H),7.71 (d, 2H), 7.53 (d, 2H), 7.48 (m, 1H), 7.20 (m, 3H), 5.45 (s, 2H),2.40 (s, 3H). ¹³C NMR (CDCl₃) δ 169.3, 155.2, 139.8, 134.7, 131.3,130.6, 130.5, 130.4, 129.9, 129.7, 129.6, 129.3, 129.2, 129.1, 128.9,128.0, 59.9, 22.8.

1-(Cyclopropylmethyl)-3-(p-tolyl)-1H-pyrazole-4-carboxylic acid (7-4). Asolution of 6-1 (0.5 g, 2.17 mmol), bromomethylcyclopropane (0.43 g,3.25 mmol) and cesium carbonate (2.12 g, 6.51 mmol) in acetonitrile (10ml) was stirred at room temperature for 16 hrs and the reaction wasstopped. Water (10 ml) was added into the reaction mixture and theaqueous layer was extracted with ethyl acetate (3×15 ml). The combinedorganic layers were washed with brine (3×10 ml), dried over Na₂SO₄,filtered and concentrated to give the crude. ¹H NMR (CDCl₃) δ 8.09 (s,1H), 7.68 (d, 2H), 7.26 (d, 2H), 4.24 (q, 2H), 4.02 (t, 2H), 2.42 (s,3H), 1.33 (brs, 1H), 1.22 (t, 3H), 0.72 (t, 2H), 0.48 (t, 2H). The cruderesidue in ethanol (10 mL) was treated with 1N aqueous potassiumhydroxide (7.5 mL) at 75° C. for 3.5 hours. The reaction was cooled,acidified with 5N HCl and the ethanol removed in vacuo. The solids werefiltered, washed with water hexanes and dried over in vacuo to afford7-4 as a pale-yellow solid (0.3 g, 55% yield), mp 142.6° C. ¹H NMR(CDCl₃) δ 8.18 (s, 1H), 7.69 (d, 2H), 7.23 (d, 2H), 4.04 (d, 2H), 2.44(s, 3H), 1.36 (brs, 1H), 0.74 (t, 2H), 0.44 (t, 2H). ¹³C NMR (CDCl₃) δ169.7, 154.9, 143.7, 139.7, 136.6, 130.6, 130.5, 130.1, 112.0, 58.7,22.8, 12.0, 5.5, 5.3.

1-(3-Methoxybenzyl)-3-(p-tolyl)-1H-pyrazole-4-carboxylic acid (7-5). Asolution of 6-1 (0.1 g, 0.43 mmol), 3-methoxybenzyl bromide (0.13 g,0.65 mmol) and cesium carbonate (0.42 g, 1.29 mmol) in acetonitrile (5ml) was stirred at room temperature for 16 hrs and the reaction wasstopped. Water (10 ml) was added into the reaction mixture and theaqueous layer was extracted with ethyl acetate (3×15 ml). The combinedorganic layers were washed with brine (3×10 ml), dried over Na₂SO₄,filtered and concentrated to give the crude. ¹H NMR (CDCl₃) δ 8.05 (s,1H), 7.90 (d, 2H), 7.24 (m, 3H), 6.89 (d, 2H). 6.84 (s, 1H), 5.29 (s,2H), 4.21 (q, 2H), 3.75 (s, 3H), 2.41 (s, 3H), 1.21 (t, 3H). The cruderesidue in ethanol (5 mL) was treated with 1N aqueous potassiumhydroxide (3.5 mL) at 75° C. for 3.5 hours. The reaction was cooled,acidified with 5N HCl and the ethanol removed in vacuo. The solids werefiltered, washed with water hexanes and dried over in vacuo to afford 7eas a white solid (0.1 g, 77% yield), mp 169.6° C. ¹H NMR (CDCl₃) δ 7.95(s, 1H), 7.68 (d, 2H), 7.31 (t, 1H), 7.22 (t, 2H), 6.90 (d, 2H), 6.84(s, 1H), 5.29 (b, 2H), 3.73 (s, 3H), 2.41 (s, 3H). ¹³C NMR (CDCl₃) δ168.9, 155.2, 139.8, 137.3, 131.5, 131.2, 130.6, 130.5, 130.1, 121.8,115.4, 115.3, 57.8, 56.7, 22.7.

3-(p-Tolyl)-1-(3-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxylic acid(7-6). A solution of 6-1 (0.1 g, 0.43 mmol), 3-(trifluoromethyl)benzylbromide (0.15 g, 0.65 mmol) and cesium carbonate (0.42 g, 1.29 mmol) inacetonitrile (5 ml) was stirred at room temperature for 6 hrs and thereaction was stopped. Water (10 ml) was added into the reaction mixtureand the aqueous layer was extracted with ethyl acetate (3×15 ml). Thecombined organic layers were washed with brine (3×10 ml), dried overNa₂SO₄, filtered and concentrated to give the crude. ¹H NMR (CDCl₃) δ7.97 (s, 1H), 7.68 (d, 2H), 7.58 (s, 1H), 7.51 (m, 3H). 7.23 (d, 2H),5.39 (s, 2H), 4.26 (q, 2H), 2.41 (s, 3H), 1.26 (t, 3H). The cruderesidue in ethanol (5 mL) was treated with 1N aqueous potassiumhydroxide (3.5 mL) at 75° C. for 5.5 hours. The reaction was cooled,acidified with 5N HCl and the ethanol removed in vacuo. The solids werefiltered, washed with water hexanes and dried over in vacuo to afford 7fas a white solid (0.11 g, 77% yield), mp 149.9 OC. ¹H NMR (CDCl₃) δ 8.01(s, 1H), 7.67 (d, 2H), 7.52 (s, 1H), 7.49 (d, 2H), 7.21 (m, 3H), 5.39(s, 2H), 2.41 (s, 3H). ¹³C NMR (CDCl₃) δ 169.2, 156.4, 143.9, 140.1,137.65 132.7, 131.1, 130.7, 130.6, 130.1, 126.8, 126.2, 119.5, 118.5,57.2, 22.7.

1-(4-Hydroxybutyl)-3-(p-tolyl)-1H-pyrazole-4-carboxylic acid (7-7). Asolution of 6-1 (0.1 g, 0.43 mmol), 4-bromo-1-butanol (0.10 g, 0.65mmol) and cesium carbonate (0.42 g, 1.29 mmol) in acetonitrile (5 ml)was stirred at room temperature for 6 hrs and the reaction was stopped.Water (10 ml) was added into the reaction mixture and the aqueous layerwas extracted with ethyl acetate (3×15 ml). The combined organic layerswere washed with brine (3×10 ml), dried over Na₂SO₄, filtered andconcentrated to give the crude. ¹H NMR (CDCl₃) δ 7.98 (s, 1H), 7.65 (d,2H), 7.20 (d, 2H), 4.24 (q, 2H). 4.09 (t, 2H), 3.45 (t, 2H), 2.41 (s,3H), 1.67 (t, 2H), 1.57 (t, 2H), 1.42 (t, 3H). The crude residue inethanol (5 mL) was treated with 1N aqueous potassium hydroxide (3.5 mL)at 75° C. for 5.5 hours. The reaction was cooled; the ethanol wasremoved in vacuo, acidified with 5N HCl, and dried over in vacuo toafford 7-7 as an oil (0.09 g, 82% yield). ¹H NMR (CDCl₃) δ 7.99 (s, 1H),7.65 (d, 2H), 7.19 (d, 2H), 4.14 (q, 2H), 3.62 (t, 2H), 2.40 (s, 3H),1.96 (t, 2H), 1.55 (t, 2H). ¹³C NMR (CDCl₃) δ 168.8, 154.9, 139.7,137.3, 131.1, 130.6, 130.1, 130.7, 112.0, 63.1, 53.7, 30.5, 27.9, 22.8.

3-Isopropyl-1-(3-methoxybenzyl)-1H-pyrazole-4-carboxylic acid (7-8). Asolution of 6-2 (0.5 g, 2.74 mmol), 3-methoxybenzyl bromide (0.83 g,4.11 mmol) and cesium carbonate (2.68 g, 8.22 mmol) in acetonitrile (10ml) was stirred at room temperature for 16 hrs and the reaction wasstopped. Water (10 ml) was added into the reaction mixture and theaqueous layer was extracted with ethyl acetate (3×15 ml). The combinedorganic layers were washed with brine (3×10 ml), dried over Na₂SO₄,filtered and concentrated to give crude. ¹H NMR (CDCl₃) δ 7.73 (s, 1H),7.29 (d, 1H), 6.87 (t, 1H), 6.83 (d, 1H), 6.77 (s, 1H), 5.22 (s, 2H),4.26 (q, 2H), 3.82 (s, 3H), 3.54 (m, 1H), 1.35 (d, 6H), 1.26 (t, 3H).The crude residue in ethanol (12 mL) was treated with 1N aqueouspotassium hydroxide (7.5 mL) at 75° C. for 4.5 hours. The reaction wascooled, the ethanol was removed in vacuo, acidified with 5N HCl, anddried over in vacuo to afford 7-8 as an white solid (0.59 g, 78% yield),mp 111.9° C. ¹H NMR (CDCl₃) δ 7.79 (s, 1H), 7.29 (t, 1H), 6.88 (d, 1H),6.84 (d, 1H), 6.78 (s, 1H), 5.23 (s, 2H), 3.79 (s, 3H), 3.55 (m, 1H),1.32 (d, 6H). ¹³C NMR (CDCl₃) δ 169.6, 163.0, 161.5, 138.0, 136.4,131.4, 121.7, 115.3, 115.1, 111.8, 57.5, 56.7, 28.0, 23.3.

3-Isopropyl-1-(3-methoxybenzyl)-1H-pyrazole-4-carboxylic acid (7-9). Asolution of 6-3 (0.3 g, 1.22 mmol), 2-iododpropane (0.31 g, 1.83 mmol)and cesium carbonate (1.19 g, 3.66 mmol) in acetonitrile (5 ml) wasstirred at room temperature for 16 hrs and the reaction was stopped.Water (10 ml) was added into the reaction mixture and the aqueous layerwas extracted with ethyl acetate (3×15 ml). The combined organic layerswere washed with brine (3×10 ml), dried over Na₂SO₄, filtered andconcentrated to give crude. ¹H NMR (CDCl₃) δ 8.01 (s, 1H), 7.39 (d, 1H),7.32 (t, 2H), 6.92 (d, 1H), 4.26 (q, 2H), 4.14 (m, 1H), 3.85 (s, 3H),1.43 (d, 6H), 1.17 (t, 3H). ¹³C NMR (CDCl₃) δ 164.6, 161.6, 142.5,133.5, 130.8, 123.5, 117.0, 116.1, 61.4, 56.7, 55.8, 51.9, 24.2, 15.7.The crude residue in ethanol (12 mL) was treated with 1N aqueouspotassium hydroxide (7.5 mL) at 75° C. for 12 hours. The reaction wascooled; the ethanol was removed in vacuo, acidified with 5N HCl, anddried over in vacuo to afford 7-9 as a yellow oil (0.25 g, 78% yield).¹H NMR (CDCl₃) δ 8.08 (s, 1H), 7.39 (d, 2H), 7.32 (t, 1H), 6.95 (d, 1H),4.51 (m, 1H), 3.85 (s, 3H), 1.58 (d, 6H). ¹³C NMR (CDCl₃) δ 169.6,160.6, 154.3, 143.5, 134.9, 134.7, 130.9, 123.3, 116.9, 115.9, 56.7,55.9, 24.1, 24.0.

1-(3-Methoxybenzyl)-3-(3-methoxyphenyl)-1H-pyrazole-4-carboxylic acid(7-10). A solution of 6-3 (0.3 g, 1.22 mmol), benzyl-3-methoxybenzene(0.37 g, 1.83 mmol) and cesium carbonate (1.19 g, 3.66 mmol) inacetonitrile (5 ml) was stirred at room temperature for 6 hrs and thereaction was stopped. Water (10 ml) was added into the reaction mixtureand the aqueous layer was extracted with ethyl acetate (3×15 ml). Thecombined organic layers were washed with brine (3×10 ml), dried overNa₂SO₄, filtered and concentrated to give crude. ¹H NMR (CDCl₃) δ 7.92(s, 1H), 7.39 (s, 1H), 7.32 (t, 3H), 6.94 (d, 3H), 6.84 (s, 1H), 5.31(s, 2H), 4.24 (q, 2H), 3.85 (s, 3H), 3.76 (s, 3H), 1.86 (t, 3H). Thecrude residue in ethanol (12 mL) was treated with 1N aqueous potassiumhydroxide (7.5 mL) at 75° C. for 12 hours. The reaction was cooled; theethanol was removed in vacuo, acidified with 5N HCl, and dried over invacuo to afford 7-10 as a yellow oil (0.27 g, 66% yield). ¹H NMR (CDCl₃)δ 7.96 (s, 1H), 7.38 (d, 2H), 7.32 (t, 3H), 6.92 (d, 2H), 6.84 (s, 1H),5.29 (s, 2H), 3.83 (s, 3H), 3.73 (s, 3H). ¹³C NMR (CDCl₃) δ 168.7,160.6, 161.1, 143.5, 137.7, 137.4, 134.6, 131.5, 130.4, 123.2, 121.8,116.2, 115.9, 115.4, 115.3, 57.9, 56.7.

1-Isopropyl-3-(4-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxylic acid(7-11). A solution of 6-4 (0.3 g, 1.06 mmol), 2-iodopropane (0.36 g,1.83 mmol) and cesium carbonate (1.19 g, 3.66 mmol) in acetonitrile (5ml) was stirred at room temperature for 6 hrs and the reaction wasstopped. Water (10 ml) was added into the reaction mixture and theaqueous layer was extracted with ethyl acetate (3×15 ml). The combinedorganic layers were washed with brine (3×10 ml), dried over Na₂SO₄,filtered and concentrated to give crude. ¹H NMR (CDCl₃) δ 8.00 (s, 1H),7.92 (s, 1H), 7.93 (d, 2H), 7.64 (d, 2H), 4.25 (q, 2H), 4.10 (m, 1H),1.61 (d, 6H), 1.28 (t, 3H). The crude residue in ethanol (10 mL) wastreated with 2N aqueous potassium hydroxide (5.5 mL) at 75° C. for 12hours. The reaction was cooled; the ethanol was removed in vacuo. Theresidue was taken up with EtOAc/water and acidified with 5N HCl to PH3.Organic phases were dried over Na₂SO₄, filtered and concentrated invacuo to afford 7-11 as a yellow solid (0.21 g, 67% yield), mp 161.1° C.¹H NMR (CDCl₃) δ 10.17 (brs, 1H), 8.10 (s, 1H), 7.93 (d, 2H), 7.62 (d,2H), 4.51 (brs, 1H), 1.52 (s, 6H). ¹³C NMR (CDCl₃) δ 168.1, 151.5,143.9, 142.1, 135.9, 133.5, 132.7, 130.3, 129.6, 125.3, 54.7, 22.4,22.3.

1-(3-Methoxybenzyl)-3-(4-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxylicacid (7-12). A solution of 6-4 (0.2 g, 0.7 mmol), 3-methoxy benzylbromide (0.21 g, 1.05 mmol) and cesium carbonate (0.68 g, 2.1 mmol) inacetonitrile (5 ml) was stirred at room temperature for 12 hrs and thereaction was stopped. Water (10 ml) was added into the reaction mixtureand the aqueous layer was extracted with ethyl acetate (3×15 ml). Thecombined organic layers were washed with brine (3×10 ml), dried overNa₂SO₄, filtered and concentrated to give crude. ¹H NMR (CDCl₃) δ 7.96(t, 2H), 7.66 (d, 2H), 7.29 (d, 2H), 6.88 (d, 2H), 6.83 (s, 1H), 5.28(s, 2H), 4.23 (q, 2H), 3.79 (s, 3H), 1.26 (t, 3H). The crude residue inethanol (5 mL) was treated with 2N aqueous potassium hydroxide (4 mL) at75° C. for 12 hours. The reaction was cooled; the ethanol was removed invacuo. The residue was taken up with EtOAc/water and acidified with 5NHCl to PH3. Organic phases were dried over Na₂SO₄, filtered andconcentrated in vacuo to afford 7-12 as a yellow solid (0.21 g, 80%yield), mp 141.7° C. ¹H NMR (CDCl₃) δ 7.92 (s, 1H), 7.87 (d, 2H), 7.23(t, 1H), 6.84 (d, 2H), 6.77 (s, 1H), 5.24 (s, 2H), 3.74 (s, 3H). ¹³C NMR(CDCl₃) δ 166.1, 160.8, 159.6, 142.4, 139.2, 135.9, 135.6, 130.0, 129.5,129.1, 125.4, 119.8, 113.6, 113.0, 112.7, 64.8, 55.0.

3-Isopropyl-1-(3-methoxybenzyl)-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-1H-pyrazole-4-carboxamide(4m, DY271). To a solution of 7-8 (0.12 g, 0.44 mmol) in CH₂Cl₂ (5 mL)was added EDCI (0.1 g, 0.53 mmol) and DMAP (0.07 g, 0.53 mmol). To thereaction was added 4-methyl-3-(morpholinosulfonyl)aniline (0.11 g, 0.44mmol) in one portion and the reaction mixture was stirred at roomtemperature for 6 h and then treated with 10% HCl. The organic layer wascollected and the aqueous layer was extracted with EtOAc. The combinedorganic solution was dried over Na₂SO₄, evaporated under a vacuum. Theresulting yellow oil was purified by flash column chromatography(H/EtOAc 1:1) to afford 4m as a white solid (0.18 g, 83% yield), mp179.7° C. ¹H NMR (CDCl₃) δ 8.10 (s, 1H), 7.79 (dd, 3H), 7.31 (m, 2H),6.83 (t, 2H), 6.82 (s, 1H), 5.28 (s, 2H), 3.81 (s, 3H), 3.66 (t, 4H),3.59 (m, 1H), 3.11 (t, 4H), 2.60 (s, 3H), 1.39 (d, 6H). ¹³C NMR (CDCl₃)δ 163.2, 161.2, 160.0, 138.8, 138.5, 136.3, 134.5, 135.1, 131.8, 131.4,126.1, 122.6, 122.7, 121.7, 115.2, 115.1, 67.6, 57.4, 56.7, 46.8, 28.4,23.6, 21.5. Anal. Calcd for C₂₆H₃₂N₄O₅S: C, 60.92; H, 6.29; N, 10.93.Found: C, 60.45; H, 5.97; N, 10.51.

1-Isopropyl-3-(3-methoxyphenyl)-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-1H-pyrazole-4-carboxamide(4n). To a solution of 7-9 (0.25 g, 0.96 mmol) in CH₂Cl₂ (5 mL) wasadded EDCI (0.22 g, 1.15 mmol) and DMAP (1.15 g, 1.15 mmol). To thereaction was added 4-methyl-3-(morpholinosulfonyl)aniline (0.25 g, 0.96mmol) in one portion and the reaction mixture was stirred at roomtemperature for 12 h and then treated with 10% HCl. The organic layerwas collected and the aqueous layer was extracted with EtOAc. Thecombined organic solution was dried over Na₂SO₄, evaporated under avacuum. The resulting yellow oil was purified by flash columnchromatography (H/EtOAc 1:1) to afford 4n as a white solid (0.26 g, 55%yield), mp 158.0° C. ¹H NMR (CDCl₃) δ 8.15 (s, 1H), 7.72 (s, 1H), 7.53(s, 1H), 7.47 (d, 2H), 7.24 (d, 2H), 7.19 (s, 1H), 7.05 (m, 1H), 4.57(m, 1H), 3.86 (s, 3H), 3.74 (t, 4H), 3.17 (t, 4H), 2.57 (s, 3H), 1.61(s, 6H). ¹³C NMR (CDCl₃) δ 163.2, 161.7, 150.6, 142.2, 137.7, 136.9,134.8, 134.5, 132.9, 132.6, 131.7, 125.6, 123.6, 123.1, 122.0, 117.6,67.7, 56.8, 56.0, 46.9, 24.2, 21.7. Anal. Calcd for C₂₅H₃₀N₄O₅S.¼ H₂O:C, 59.53; H, 5.92; N, 11.10. Found: C, 59.76; H, 5.67; N, 11.10.

1-(3-Methoxybenzyl)-3-(3-methoxyphenyl)-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-1H-pyrazole-4-carboxamide(4o). To a solution of 7-10 (0.25 g, 0.73 mmol) in CH₂Cl₂ (5 mL) wasadded EDCI (0.17 g, 0.88 mmol) and DMAP (0.11 g, 0.88 mmol). To thereaction was added 4-methyl-3-(morpholinosulfonyl)aniline (0.19 g, 0.73mmol) in one portion and the reaction mixture was stirred at roomtemperature for 12 h and then treated with 10% HCl. The organic layerwas collected and the aqueous layer was extracted with EtOAc. Thecombined organic solution was dried over Na₂SO₄, evaporated under avacuum. The resulting yellow oil was solidified by MeOH to afford 4o asa white solid (0.31 g, 74% yield), mp 190.1° C. ¹H NMR (CDCl₃) δ 8.04(s, 1H), 7.72 (s, 1H), 7.54 (s, 1H), 7.48 (t, 2H), 7.34 (s, 1H), 7.28(m, 3H), 7.20 (d, 1H), 6.94 (t, 1H), 6.88 (s, 1H), 3.82 (s, 3H), 3.80(s, 3H), 3.74 (t, 4H), 3.17 (t, 4H), 2.57 (s, 3H). ¹³C NMR (CDCl₃) δ163.2, 161.6, 160.0, 151.4, 137.7, 137.4, 135.7, 134.9, 134.5, 131.7,131.6, 125.0, 123.1, 122.1, 122.0, 116.9, 116.2, 115.5, 115.4, 67.8,58.1, 56.9, 56.7, 46.9, 21.7. Anal. Calcd for C₃₀H₃₂N₄O₅S.½ H₂O: C,61.51; H, 5.50; N, 9.56. Found: C, 61.50; H, 5.28; N, 9.39.

1-Isopropyl-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-3-(4-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxamide(4p). To a solution of 7-11 (0.2 g, 0.67 mmol) in CH₂Cl₂ (5 mL) wasadded EDCI (0.15 g, 0.81 mmol) and DMAP (0.08 g, 0.81 mmol). To thereaction was added 4-methyl-3-(morpholinosulfonyl)aniline (0.17 g, 0.67mmol) and the reaction mixture was stirred at room temperature for 12 hand quenched with water and then treated with 10% HCl. The organic layerwas collected and the aqueous layer was extracted with EtOAc. Thecombined organic solution was dried over Na₂SO₄, evaporated under avacuum. The resulting yellow oil was purified by flash columnchromatography (H/EtOAc 1:1) to afford 4p as a yellow solid (0.18 g, 51%yield), mp 192.2° C. ¹H NMR (CDCl₃) δ 8.12 (s, 1H), 8.09 (s, 1H), 7.87(d, 2H), 7.81 (d, 2H), 7.65 (d, 2H), 7.24 (d, 1H), 4.53 (m, 1H), 3.64(t, 4H), 3.07 (t, 4H), 2.54 (s, 3H), 1.53 (s, 6H). ¹³C NMR (CDCl₃) δ161.5, 148.8, 138.6, 136.2, 134.9, 133.7, 133.3, 130.4, 129.3, 125.7,119.4, 66.2, 66.1, 45.3, 45.2, 22.5, 20.1, 20.0. Anal. Calcd forC₂₅H₂₇F₃N₄O₄S.½ H₂O: C, 55.03; H, 4.98; N, 10.44. Found: C, 55.23; H,5.03; N, 10.26.

1-(3-Methoxybenzyl)-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-3-(4-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxamide(4q). To a solution of 7-12 (0.06 g, 0.16 mmol) in CH₂Cl₂ (2 mL) wasadded EDCI (0.04 g, 0.019 mmol) and DMAP (0.02 g, 0.019 mmol). To thereaction was added 4-methyl-3-(morpholinosulfonyl)aniline (0.04 g, 0.16mmol) and the reaction mixture was stirred at room temperature for 12 hand quenched with water and then treated with 10% HCl. The organic layerwas collected and the aqueous layer was extracted with EtOAc. Thecombined organic solution was dried over Na₂SO₄, evaporated under avacuum. The resulting yellow oil was purified by flash columnchromatography (H/EtOAc 1:1) to afford 4q as a yellow solid (0.022 g,61% yield), mp 208.2° C. ¹H NMR (CDCl₃) δ 7.98 (s, 1H), 7.89 (d, 2H),7.81 (s, 1H), 7.74 (d, 2H), 7.62 (d, 1H), 7.47 (s, 1H), 7.27 (t, 1H),7.26 (t, 1H), 6.94 9m, 3H), 5.34 (s, 2H), 3.82 (s, 3H), 3.72 (t, 4H),3.15 (t, 4H), 2.58 (s, 3H). ¹³C NMR (CDCl₃) δ 161.5, 148.8, 138.6,136.2, 134.9, 133.7, 133.3, 130.4, 129.3, 125.7, 119.4, 66.2, 66.1,45.3, 45.2, 22.5, 20.1, 20.0. Anal. Calcd for C₃₀H₂₉F3N₄O₅S.½ H₂O: C,57.77; H, 4.68; N, 8.98. Found: C, 58.08; H, 4.64; N, 8.64.

1-Isopropyl-N-methyl-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-3-(p-tolyl)-1H-pyrazole-4-carboxamide(8-1). A mixture of 4f (0.1 g, 0.21 mmol), NaH (60% dispersion in oil)(0.018 g, 0.46 mmol) and anhydrous DMF (10 ml) was stirred at roomtemperature for 30 min. The reaction mixture was cooled to 0° C., andiodomethane (0.1 mL, 1.47 mmol) was added to it. The resulting mixturewas stirred at room temperature under an atmosphere of N₂ and monitoredby TLC. The reaction was stopped, water (30 ml) was added into thereaction mixture and the aqueous layer was extracted with ethyl acetate(3×15 ml). The combined organic layers were washed with water and brine(3×10 ml), dried over Na₂SO₄, filtered and concentrated. The resultingyellow oil was purified by flash column chromatography (H/EtOAc 1:1) toafford 8-1 as a clear oil (0.07 g, 70% yield). ¹H NMR (CDCl₃) δ 7.34 (s,1H), 7.15 (d, 2H), 7.09 (t, 2H), 6.94 (d, 2H), 6.87 (d, 1H), 4.26 (m,1H), 3.67 (t, 4H), 3.27 (s, 3H), 3.05 (t, 4H), 2.55 (s, 3H), 2.41 (s,3H), 1.31 (d, 6H). ¹³C NMR (CDCl₃) δ 166.5, 144.0, 140.8, 136.8, 134.4,131.6, 130.8, 130.7, 130.4, 129.6, 129.3, 128.5, 127.4, 67.6, 51.5,46.6, 39.0, 22.8, 22.7, 21.6. HRMS (ESI); Calcd for C₂₆H₃₂N₄O₄S (M+1):497.2217. Found: 497.2215.

3-Isopropyl-1-(3-methoxybenzyl)-N-methyl-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-1H-pyrazole-4-carboxamide(8-2). A mixture of 4m (0.3 g, 0.58 mmol), NaH (60% dispersion in oil)(0.046 g, 1.27 mmol) and anhydrous DMF (15 ml) was stirred at roomtemperature for 30 min. The reaction mixture was cooled to 0° C., andiodomethane (0.25 mL, 4.09 mmol) was added to it. The resulting mixturewas stirred at room temperature under an atmosphere of N₂ and monitoredby TLC. The reaction was stopped, water (50 ml) was added into thereaction mixture and the aqueous layer was extracted with ethyl acetate(3×25 ml). The combined organic layers were washed with water and brine(3×10 ml), dried over Na₂SO₄, filtered and concentrated. The resultingyellow oil was purified by flash column chromatography (H/EtOAc 1:1) toafford 8-2 as a clear oil (0.27 g, 87% yield). ¹H NMR (CDCl₃) δ 7.45 (s,1H), 7.18 (dd, 3H), 6.78 (d, 1H), 6.52 (d, 2H), 6.50 (d, 1H), 4.95 (s,2H), 3.71 (s, 3H), 3.63 (t, 4H), 3.34 (s, 3H), 3.31 (m, 1H), 2.82 (t,4H), 2.53 (s, 3H), 1.23 (d, 6H). ¹³C NMR (CDCl₃) δ 166.5, 144.0, 140.8,136.8, 134.4, 131.6, 130.8, 130.7, 130.4, 129.6, 129.3, 128.5, 127.4,67.6, 51.5, 46.6, 39.0, 22.8, 22.7, 21.6. HRMS (ESI); Calcd forC₂₇H₃₄N₄O₅S (M+1): 527.2323. Found: 527.2321.

1-(3-Methoxybenzyl)-3-(3-methoxyphenyl)-N-methyl-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-1H-pyrazole-4-carboxamide(8-3). A mixture of 4o (0.1 g, 0.17 mmol), NaH (60% dispersion in oil)(0.02 g, 0.51 mmol) and anhydrous DMF (10 ml) was stirred at roomtemperature for 30 min. The reaction mixture was cooled to 0° C., andiodomethane (0.075 mL, 1.21 mmol) was added to it. The resulting mixturewas stirred at room temperature under an atmosphere of N₂ and monitoredby TLC. The reaction was stopped, water (50 ml) was added into thereaction mixture and the aqueous layer was extracted with ethyl acetate(3×25 ml). The combined organic layers were washed with water and brine(3×10 ml), dried over Na₂SO₄, filtered and concentrated. The resultingyellow oil was purified by flash column chromatography (H/EtOAc 1:1) toafford 8-2 as a clear oil (0.08 g, 87% yield). ¹H NMR (CDCl₃) δ 7.45 (s,1H), 7.21 (t, 2H), 7.14 (t, 1H), 6.85 (d, 2H), 6.80 (t, 3H), 6.72 (d,2H), 6.70 (s, 1H), 5.12 (s, 2H), 3.72 (s, 6H), 3.58 (t, 4H), 3.26 (s,3H), 2.84 (t, 4H), 2.41 (s, 3H). ¹³C NMR (CDCl₃) δ 164.3, 159.0, 158.6,148.3, 140.8, 135.5, 134.4, 133.9, 132.6, 131.6, 131.3, 129.0, 128.3,127.0, 119.3, 118.8, 113.3, 112.8, 111.3, 65.2, 54.3, 54.2, 44.0, 19.0.HRMS (ESI); Calcd for C₃₁H₃₄N₄O₆S (M+1): 591.2272. Found: 591.2270.

N-((1-Isopropyl-3-(p-tolyl)-1H-pyrazol-4-yl)methyl)-4-methyl-3-(morpholinosulfonyl)aniline(9-1). To a solution of 4f (0.1 g, 0.21 mmol) in anhydrous THF (5 mL), 1N borane-THF complex (7 mL) was added at 0° C. under N₂. The reactionmixture was heated to reflux for 3 h. After it was cooled to 0° C., 1Nmethanolic HCl (3 ml) was very carefully added dropwise to quench excessborane reagent and addition MeOH was added. The reaction mixture washeated to reflux for 2 h. The solvent was evaporated at reducedpressure. The oily residue was dissolved in EtOAc and neutralized with2N NaOH. The resulting mixture was extracted with EtOAc (3×15 ml). Thecombined extracts were washed with 0.5 N KOH, dried over Na₂SO₄, andevaporated in vacuo. The resulting yellow oil was purified by flashcolumn chromatography (H/EtOAc 1:1) to afford 9-1 as colorless oil (0.08g, 81% yield). ¹H NMR (CDCl₃) δ 7.55 (d, 2H), 7.47 (s, 1H), 7.20 (d,2H), 7.14 (s, 1H), 7.10 (d, 1H), 6.72 (d, 1H), 4.52 (m, 1H), 4.27 (s,2H), 3.71 (t, 4H), 3.12 (t, 4H), 2.51 (s, 3H), 2.36 (s, 3H), 1.53 (d,6H), ¹³C NMR (CDCl₃) δ 150.5, 147.6, 138.8, 136.7, 135.1, 130.7, 128.8,128.5, 127.6, 118.7, 115.7, 69.0, 46.7, 33.1, 24.1, 24.0. HRMS (ESI);Calcd for C₂₅H₃₂N₄O₃S (M+1): 469.6116. Found: 469.2715.

N-((3-Isopropyl-1-(3-methoxybenzyl)-1H-pyrazol-4-yl)methyl)-4-methyl-3-(morpholinosulfonyl)aniline(9-2). To a solution of 4m (0.1 g, 0.19 mmol) in anhydrous THF (5 mL), 1N borane-THF complex (7 mL) was added at 0° C. under N₂. The reactionmixture was heated to reflux for 3 h. After it was cooled to 0° C., 1Nmethanolic HCl (3 ml) was very carefully added dropwise to quench excessborane reagent and additional MeOH was added. The reaction mixture washeated to reflux for 3 h. The solvent was evaporated at reducedpressure. The oily residue was dissolved in EtOAc and neutralized with2N NaOH. The resulting mixture was extracted with EtOAc (3×15 ml). Thecombined extracts were washed with 0.5 N KOH, dried over Na₂SO₄, andevaporated in vacuo. The resulting yellow oil was purified by flashcolumn chromatography (H/EtOAc 1:1) to afford 9-2 as colorless oil (0.07g, 77% yield). ¹H NMR (CDCl₃) δ 7.22 (d, 2H), 7.21 (s, 1H), 7.12 (s,1H), 7.10 (d, 1H), 6.83 (d, 1H), 6.77 (d, 1H), 6.72 (t, 2H), 5.18 (s,2H), 4.11 (t, 2H), 3.76 (s, 3H), 3.69 (t, 4H), 3.11 (t, 4H), 3.05 (m,1H), 2.48 (s, 3H), 1.26 (d, 6H). ¹³C NMR (CDCl₃) δ 161.3, 157.7, 147.6,139.6, 136.4, 135.1, 131.2, 130.5, 127.1, 121.3, 118.5, 116.6, 115.6,114.8, 114.7, 67.7, 57.1, 56.6, 46.7, 39.8, 26.5, 24.0, 23.6, 21.1. HRMS(ESI); Calcd for C₂₆H₃₄N₄O₄S (M+1): 499.6376. Found: 499.3676.

N-((1-(3-Methoxybenzyl)-3-(3-methoxyphenyl)-1H-pyrazol-4-yl)methyl)-4-methyl-3-(morpholinosulfonyl)aniline(9-3). To a solution of 4o (0.1 g, 0.17 mmol) in anhydrous THF (5 mL), 1N borane-THF complex (8 mL) was added at 0° C. under N₂. The reactionmixture was heated to reflux for 3 h. After it was cooled to 0° C., 1Nmethanolic HCl (3 ml) was very carefully added dropwise to quench excessborane reagent and additional MeOH was added. The reaction mixture washeated to reflux for 2 h. The solvent was evaporated at reducedpressure. The oily residue was dissolved in EtOAc and neutralized with2N NaOH. The resulting mixture was extracted with EtOAc (3×15 ml). Thecombined extracts were washed with 0.5 N KOH, dried over Na₂SO₄, andevaporated in vacuo. The resulting yellow oil was purified by flashcolumn chromatography (H/EtOAc 1:1) to afford 9-3 as colorless oil(0.065 g, 72% yield). ¹H NMR (CDCl₃) δ 7.38 (s, 1H), 7.32 (m, 5H), 7.18(d, 1H), 7.11 (s, 1H), 6.89 (t, 2H), 6.81 (d, 2H), 6.69 (t, 1H), 5.28(s, 2H), 4.26 (s, 2H), 3.81 (s, 3H), 3.76 (s, 3H), 3.71 (t, 4H), 3.11(t, 4H), 2.49 (s, 3H). ¹³C NMR (CDCl₃) δ 161.3, 161.2, 151.1, 147.3,139.1, 136.4, 135.1, 131.7, 131.3, 127.4, 121.5, 118.6, 117.7, 115.7,115.3, 115.1, 116.2, 114.8, 114.1, 67.7, 57.5, 56.6, 46.7, 40.5, 21.2.HRMS (ESI); Calcd for C₃₀H₃₄N₄O₅S (M+Na): 565.6798. Found: 585.2798.

Example 10

Biology

DMSO and charcoal/dextran-treated FBS were obtained from FisherScientific (Pittsburgh, Pa.). GW4064 was purchased from R&D Systems,Inc. (Minneapolis, Minn.); lithocholic acid and rifampicin werepurchased from Sigma-Aldrich (St. Louis, Mo.); TO901317 was obtainedfrom Cayman Chemical Company (Ann Arbor, Mich.); Z26476908 was purchasedfrom Enamine LLC (Monmouth Junction, N.J.). Black polypropylene 384-wellplates were purchased from Matrical Bioscience (Spokane, Wash.). Black384-well tissue culture-treated clear bottom plates were obtained fromCorning Incorporated (Corning, N.Y.). White tissue culture-treated384-well plates were purchased from PerkinElmer (Waltham, Mass.).GST-hFXR-LBD, Tb-anti-GST antibody, coregulator buffer G, 1 M DTT,GeneBLAzer FXR-UAS-bla HEK 293T cells, DMEM, phenol red-free DMEM,dialyzed FBS, non-essential amino acids, sodium pyruvate, HEPES,hygromycin B, zeocin, penicillin/streptomycin, G418 and CCF4-AMsubstrate were purchased from Invitrogen (Carlsbad, Calif.).

All chemicals were initially solubilized in DMSO as 10 mM stocks andthen diluted in corresponding assay buffer or medium to indicatedconcentrations. All experiments were repeated in triplicate andrepresentative results were reported.

FXR TR-FRET Binding Assay

The FXR TR-FRET binding assay was performed as previously described²³with modifications. Briefly, in a black polypropylene 384-well plate(Matrical Bioscience, Spokane, Wash.), DMSO, 10 μM GW4064, andtitrations of GW4064, lithocholic acid or the synthesized chemicals weremixed with 10 nM GST-hFXR-LBD, 1.5 nM Tb-anti-GST antibody (Invitrogen,Carlsbad, Calif.), and 10 nM DY246 in a 20 μl/well of coregulator bufferG supplemented with 10 mM DTT. The final DMSO concentration was 0.4% forall wells. The plate was spun down after a brief shake and incubated atroom temperature for 20 min. The TR-FRET emission signals at 520 nm and490 nm for each well was then collected using a PHERAstar plate reader(BMG LABTECH, Cary, N.C.) with an excitation wavelength of 337 nm,100-μs delay time, and 200-μs integration time. The 520 nm/490 nm ratiofrom each well was then calculated. The DMSO group and 10 μM GW4064group were served as negative (0% inhibition) and positive (100%inhibition) controls, respectively. The % inhibition of tested chemicalsat given concentration was calculated based on negative and positivecontrols using equation 1.

$\begin{matrix}{{\%{Inhibition}} = {{100\%} - {100\% \times \frac{\begin{matrix}{{Chemical}_{520\mspace{14mu}{nm}\text{/}490\mspace{14mu}{nm}} -} \\{10\mspace{14mu}\mu\; M\mspace{14mu}{GW}\mspace{14mu} 4064_{520\mspace{14mu}{nm}\text{/}490\mspace{14mu}{nm}}}\end{matrix}}{{DMSO}_{520\mspace{14mu}{nm}\text{/}490\mspace{14mu}{nm}} - {10\mspace{14mu}\mu\; M\mspace{14mu}{GW}\mspace{14mu} 4064_{520\mspace{14mu}{nm}\text{/}490\mspace{14mu}{nm}}}}}}} & {{Equation}\mspace{14mu} 1}\end{matrix}$

For those chemicals with a maximal % inhibition >50% and activities thatbehaved in a dose-dependent manner, their inhibitory activities atdifferent concentrations were fit into a one-site competitive bindingequation with GraphPad PRISM 6.01 (GraphPad Software, Inc., La Jolla,Calif.) to derive IC₅₀ values.

FXR Cell-Based Transactivation Assay

FXR transactivation assays were performed using GeneBLAzer FXR-UAS-blaHEK 293T cells (Invitrogen). Cells were maintained according to themanufacturer's instructions. Briefly, cells were grown in DMEMsupplemented with 10% dialyzed FBS, 0.1 mM non-essential amino acids, 25mM HEPES, 100 μg/ml of hygromycin B, 100 μg/ml of zeocin, 100 units/mlpenicillin and 100 μg/ml streptomycin in regular tissue culture flasks.Upon transactivation assay, DMSO, 400 nM GW4064, 10 μM GW4064, andtitrations of GW4064, LCA or chemicals without 400 nM GW4064 (for FXRagonistic activity determination) or with 400 nM GW4064 (for FXRantagonistic activity determination) were mixed with cells (20,000cells/well in a 30 μL) in assay medium (phenol red-free DMEMsupplemented with 2% charcoal/dextran-treated FBS, 0.1 mM non-essentialamino acids, 1 mM sodium pyruvate, 100 units/ml penicillin and 100 μg/mlstreptomycin) in black 384-well tissue culture-treated clear bottomplates (Corning Incorporated, Corning, N.Y.). As a background control,the wells in column 24 of each plate were filled with 30 μL assay mediumalong with 0.5% DMSO. The final DMSO concentration was 0.5% in eachassay well. After a 16 h incubation in a cell culture incubator at 37°C., 6 μl/well of loading solution with CCF4-AM substrate was added.Plates were then incubated in dark for 90 min at room temperature beforemeasuring the fluorescent emissions at 460 nm and 535 nm (usingexcitation at 400 nm) with an Envision plate reader with bottom readcapacity. After background signal subtraction for individual emissionchannels, emission signals at 460 and 535 nm from each well were used todetermine the ratio of 460 nm/535 nm. For agonist assays, the DMSO groupand 10 μM GW4064 group served as negative (0% activation) and positive(100% activation) controls, respectively. The % activation wascalculated using equation 2.

$\begin{matrix}{{\%{Activation}} = {100\% \times \frac{{Chemical}_{460\mspace{14mu}{nm}\text{/}535\mspace{14mu}{nm}} - {DMSO}_{460\mspace{14mu}{nm}\text{/}535\mspace{14mu}{nm}}}{{10\mspace{14mu}\mu\; M\mspace{14mu}{GW}\mspace{14mu} 4064_{460\mspace{14mu}{nm}\text{/}535\mspace{14mu}{nm}}} - {DMSO}_{460\mspace{14mu}{nm}\text{/}535\mspace{14mu}{nm}}}}} & {{Equation}\mspace{14mu} 2}\end{matrix}$

For antagonistic assay in which 400 nM GW4064 was included in the assayconditions, the DMSO group and 400 nM GW4064 group served as positive(100% inhibition) and negative (0% inhibition) controls, respectively.The % inhibition was calculated using equation 3.

$\begin{matrix}{{\%{Inhibition}} = {{100\%} - {100\% \times \frac{\begin{matrix}{( {{Chemical} + {400\mspace{14mu}{nM}\mspace{14mu}{GW}\mspace{14mu} 4064}} )_{460\mspace{14mu}{nm}\text{/}535\mspace{14mu}{nm}} -} \\{DMSO}_{460\mspace{14mu}{nm}\text{/}535\mspace{14mu}{nm}}\end{matrix}}{{400\mspace{14mu}{nM}\mspace{14mu}{GW}\mspace{14mu} 4064_{460\mspace{14mu}{nm}\text{/}535\mspace{14mu}{nm}}} - {DMSO}_{460\mspace{14mu}{nm}\text{/}535\mspace{14mu}{nm}}}}}} & {{Equation}\mspace{14mu} 3}\end{matrix}$

For those chemicals with a maximal % inhibition >50% and activities thatbehaved in a dose-dependent manner, their inhibitory activities atdifferent concentrations were fit into a sigmoidal dose-responseequation with GraphPad PRISM 6.01 (GraphPad Software, Inc., La Jolla,Calif.) to derive IC₅₀ values.

Cell-Based Cytotoxicity Assay

Cytotoxicity assays were performed side-by-side with the FXR agonisticassay using GeneBLAzer FXR-UAS-bla HEK 293T cells with CellTiter-Glo®Luminescent Cell Viability Assay reagent (Promega). Briefly, cells weremaintained in DMEM supplemented with 10% dialyzed FBS, 0.1 mMnon-essential amino acids, 25 mM HEPES, 100 μg/ml of hygromycin B, 100μg/ml of zeocin, 100 units/ml penicillin and 100 μg/ml streptomycin inregular tissue culture flasks. For the cytotoxicity assay, DMSO,titrations of GW4064, LCA or of chemicals were mixed with cells (20,000cells/well in a 30 μL) in assay medium (phenol red-free DMEMsupplemented with 2% charcoal/dextran-treated FBS, 0.1 mM non-essentialamino acids, 1 mM sodium pyruvate, 100 units/ml penicillin and 100 μg/mlstreptomycin) in black 384-well tissue culture-treated clear bottomplates (Corning Incorporated, Corning, N.Y.). As a positive control, thewells in column 24 of each plate were filled with 30 μL assay mediumalong with 0.5% DMSO. The final DMSO concentration was 0.5% in eachassay well. After a 16 h incubation in a cell culture incubator at 37°C., the cell plates were cooled at room temperature for 20 min and thenCellTiter-Glo® reagent 20 μl/well was added followed by an incubationfor 20 min in the dark to allow the development of optimal luminescencesignal. The luminescence signal from each well in plates was collectedwith an Envision plate reader equipped with Ultra-sensitive Luminescencedetector. The DMSO group and no cell group served as negative (0%activation) and positive (100% activation) controls, respectively. The %inhibition was calculated using equation 4 below.

$\begin{matrix}{{\%{Inhibition}} = {{100\%} - {100\% \times \frac{{Signal}_{compound} - {Signal}_{{No}\mspace{14mu}{Cell}}}{{Signal}_{DMSO} - {Signal}_{{No}\mspace{14mu}{Cell}}}}}} & {{Equation}\mspace{14mu} 4}\end{matrix}$

Abbreviations Used

HTS, High-Throughput Screen; FXR, famesoid X receptor; NRs, nuclearreceptors; Cyp7A1, cytochrome 7A1; BAs, bile acids; CDCA,chenodeoxycholic acid; BSEP, bile salt export pump; SHP, smallheterodimer partner; SAR, structure-activity relationship: LBD,ligand-binding domain.

It is understood that the examples and embodiments described herein arefor illustrative purposes only and that various modifications or changesin light thereof will be suggested to persons skilled in the art and areto be included within the spirit and purview of this application andscope of the appended claims. All publications, patents, and patentapplications cited herein are hereby incorporated by reference in theirentirety for all purposes.

REFERENCES

-   1. Nuclear Receptor Nomenclature Committee. A unified nomenclature    system for the nuclear receptor superfamily. Cell 1999, 97, 161-163.-   2. Forman, B. M.; Goode, E.; Chen, J.; Oro, A. E.; Bradley, D. J.;    Perlmann, T.; Noonan, D. J.; Burka, L. T.; McMorris, T.; Lamph, W.    W.; Evans, R. M.; Weinberger, C. Identification of a nuclear    receptor that is activated by farnesol metabolites. Cell 1995, 81,    687-693.-   3. Wang, H.; Chen, J.; Hollister, K.; Sower, L. C.; Forman, B. M.    Endogenous bile acids are ligands for the nuclear receptor FXR/BAR.    Mol. Cell 1999, 3, 543-553.-   4. Fiorucci, S.; Mencarelli, A.; Distrutti, E.; Palladino, G.;    Cipriani, S. Targeting famresoid-X-receptor: from medicinal    chemistry to disease treatment. Curr. Med. Chem. 2010, 17, 139-159.-   5. Fiorucci, S.; Cipriani, S.; Baldelli, F.; Mencarelli, A. Bile    acidactivated receptors in the treatment of dyslipidemia and related    disorders. Prog. Lipid Res. 2010, 49, 171-185.-   6. Chen, W. D; Wang, Y. D; Zhang, L; Shiah, S; Wang, M; Yang, F; Yu,    D; Forman, B. M; Huang, W. (2010). Famesoid X receptor alleviates    age-related proliferation defects in regenerating mouse livers by    activating forkhead box mlb transcription. Hepatology.    51(3):953-962.-   7. Fiorucci., S.; Baldelli, F. Famesoid X receptor agonists in    biliary tract disease. Curr. Opin. Gastroenterol. 2009, 25, 252-259.-   8. Donna Yu, Daniell L. Mattem, and Barry M. Forman. An improved    synthesis of 6α-ethyl chenodeoxycholic acid (6ECDCA), a potent and    selective agonist for the famesoid X receptor (FXR). Steroids, 2012,    77, 1335-1338.-   9. Modica, S.; Moschetta, A. Nuclear bile acid receptor FXR as    pharmacological target: are we there yet? FEBS Lett. 2006, 580,    5492-5499.-   10. Renga, B.; Migliorati, M.; Mencarelli, A.; Cipriani, S.;    D'Amore, C.; Distrutti, E.; Fiorucci, S. Famesoid X receptor    suppresses constitutive androstane receptor activity at the    multidrug resistance protein-4 promoter. Biochim. Biophys. Acta    2011, 1809, 157-165.-   11. Fiorucci, S.; Zampella, A. Distrutti E. Development of FXR, PXR    and CAR agonists and antagonists for treatment of liver disorders.    Curr Top Med Chem. 2012, 12, 605-24.-   12. Makishima, M.; Okamoto, A. Y.; Repa, J. J.; Tu, H.; Learned, R.    M.; Luk, A.; Hull, M. V.; Lustig, K. D.; Mangelsdorf, D. J.;    Shan, B. Identification of a nuclear receptor for bile acids.    Science 1999, 284, 1362-1365.-   13. Urizar, N. L.; Liverman, A. B.; Dodds, D. T.; Silva, F. V.;    Ordentlich, P.; Yan, Y. Z.; Gonzalez, F. J.; Heyman, R. A.;    Mangelsdorf, D. J.; Moore, D. D. A natural product that lowers    cholesterol as an antagonist ligand for FXR. Science 2002, 296,    1703-1706.-   14. Urizar, N. L.; Moore, D. D. Guggulipid: a natural    cholesterollowering agent. Annu. Rev. Nutr. 2003, 23, 303-313.-   15. Pellicciari, R.; Costantino, G.; Fiorucci, S. Famesoid X    Receptor: From Structure to Potential Clinical Applications. J. Med.    Chem. 2005. 17, 1-21.-   16. Sepe, V.; Bifulco, G.; Renga, B.; D'Amore, C.; Fiorucci, S.;    Zampella, A. Discovery of Sulfated Sterols from Marine Invertebrates    as a New Class of Marine Natural Antagonists of    Farnesoid-X-Receptor, J. Med. Chem., 2011, 54, 1314-1320.-   17. Rengal, B.; Mencarelli, A.; D'Amore, C.; Cipriani, S.;    D'Auria, M. V.; Sepe, V.; Chini, M. G.; Monti, M. C.; Bifulco, G.;    Zampella, A.; Fiorucci, S. Discovery that theonellasterol a marine    sponge sterol is a highly selective FXR antagonist that protects    against liver injury in cholestasis. PLoS ONE. 2012, 7, e30443.-   18. Nam, S. J.; Ko, H.; Shin, M.; Ham, J.; Chin, J.; Kim, Y.; Kim,    H.; Shin, K.; Choi, H.; Kang, H. Famesoid X-activated receptor    antagonists from a marine sponge Spongia sp. Bioorg. Med. Chem.    Lett. 2006, 16, 5398-5402.-   19. Di Leva, F. S.; Festa, C.; D'Amore, C.; De Marino, S.; Renga,    B.; D'Auria, M. V.; Novellino, E.; Limongelli, V.; Zampella, A.;    Fiorucci, S. Binding Mechanism of the Famesoid X Receptor Marine    Antagonist Suvanine Reveals a Strategy To Forestall Drug Modulation    on Nuclear Receptors. Design, Synthesis, and Biological Evaluation    of Novel Ligands. J. Med. Chem. 2013, 56, 4701-4717.-   20. Dussault, I.; Beard, R.; Lin, M.; Hollister, K.; Chen, J.;    Xiao, J. H.; Chandraratna, R.; Forman, B. M. Identification of gene    selective modulators of the bile acid receptor FXR. J. Biol. Chem.    2003, 278, 7027-7033.-   21. Huang, H.; Yu, Y.; Gao, Z.; Zhang, Y.; Li, C.; Xu, X.; Jin, H.;    Yan, W.; Ma, R.; Zhu, J. Shen, X.; Jiang, H.; Chen, L.; Li, J.    Discovery and Optimization of 1,3,4-Trisubstituted-pyrazolone    Derivatives as Novel, Potent, and Nonsteroidal Farnesoid X Receptor    (FXR) Selective Antagonists. J. Med. Chem. 2012, 55, 7037-7053.-   22. Sayin, S. I.; Wahlstroem, A.; Felin, J.; Jaentti, S.; Marschall,    H-U.; Bamberg, K.; Angelin, B.; Hyoetylaeinen, T.; Oresic, M.;    Baeckhed, F. Gut Microbiota Regulates Bile Acid Metabolism by    Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally    Occurring FXR Antagonist, Cell Metabolism, 2013, 17, 225-235.-   23. Yu, D. D., Lin, W., Chen, T., Forman, B. M. Development of Time    Resolved Fluorescence Resonance Energy Transfer-based Assay for FXR    Antagonist Discovery, Bioorganic & Medicinal Chemistry, 2013, 21,    4266-4278.-   24. Takeda Pharmaceutical Co. Ltd., Heterocyclic amide compound and    use thereof, WO/2007/052843, 2007.-   25. Lamberth, C. Pyrazole chemistry in crop protection.    Heterocycles, 2007, 71, 1467.-   26. Akwabi-Ameyaw, A.; Caravella, J. A.; Chen, L.; Creech, K. L.;    Deaton, D. N.; Madauss, K. P.; Marr, H. B.; Miller, A. B.; Navas,    F., III; Parks, D. J.; Spearing, P. K.; Todd, D.; Williams, S. P.;    Wisely, G. B. Conformationally constrained famesoid X receptor (FXR)    agonists: alternative replacements of the stilbene. Bioorg. Med.    Chem. Lett. 2011, 21, 6154-6160.-   27. Hashimoto, Y. Retinobenzoic acids and nuclear retinoic acid    receptors. Cell Struct. Funct. 1991, 16, 113-123.-   28. Soisson, S. M; Parthasarathy, G.; Adams, A. D.; Sahoo, S.;    Sitlani, A.; Sparrow, C; Cui, J; Becker, J. W. Identification of a    potent synthetic FXR agonist with an unexpected mode of binding and    activation. Proc Natl Acad Sci USA. 2008, 105, 5337-5342.-   29. Babaoglu, K.; Shoichet, B. K. Deconstructing fragment-based    inhibitor discovery. Nat. Chem. Biol. 2006, 2, 720-723.-   30. Bebemitz, G. R.; Argentieri, G.; Battle, B.; Brennan, C.;    Balkan, B.; Burkey, B. F.; Eckhardt, M.; Gao, J.; Kapa, P.;    Strohschein, R. J.; Schuster, H. F.; Wilson, M.; Xu, D. D. The    Effect of 1,3-Diaryl-[1H]-pyrazole-4-acetamides on Glucose    Utilization in ob/ob Mice. J Med. Chem. 2001, 44, 2601-2611.-   31. Baraldi, P. G.; Tabrizi, M. A.; Preti, D. Bovero, A.;    Fruttarolo, F.; Romagnoli, R.; Zaid, N. A.; Moorman, A. R.; Varani,    K.; Borea P. A. New 2-Arylpyrazolo[4,3-c]quinoline Derivatives as    Potent and Selective Human A₃ Adenosine Receptor Antagonists. J Med.    Chem. 2005. 48, 5001-5008.-   32. Lepore, S. D.; He, Y. Use of sonication for the coupling of    sterically hindered substrates in the phenolic Mitsunobu    reaction. J. Org. Chem. 2003, 68, 8261-8263.-   33. Petzinger, E.; Wickboldt, A.; Pagels, P.; Starke, D.; Kramer, W.    Hepatobiliary Transport of Bile Acid Amino Acid, Bile Acid Peptide,    and Bile Acid Oligonucleotide Conjugates in Rats. Hepatology 1999,    30, 1257-1268.-   34. Ozers, M. S.; Marks, B. D.; Gowda, K.; Kupcho, K. R.; Ervin, K.    M.; De Rosier, T.; Qadir, N.; Eliason, H. C.; Riddle, S. M.;    Shekhani, M. S. The Androgen Receptor T877A Mutant Recruits LXXLL    and FXXLF Peptides Differently than Wild-Type Androgen Receptor in a    Time-Resolved Fluorescence Resonance Energy Transfer Assay,    Biochemistry 2007, 46, 683-695.-   35. Li, G.; Lin, W.; Araya, J. J.; Chen, T.; Timmermann, B. N.;    Guo, G. L. A tea catechin, epigallocatechin-3-gallate, is a unique    modulator of the famesoid X receptor. Toxicol Appl Pharmacol. 2012,    258, 268-74.

What is claimed is:
 1. A method of antagonizing Farnesoid X Receptor(FXR) protein, said method comprising contacting a FXR protein with thecompound having formula (II):

wherein, X is —CH₂—, —C(O)— or —CY(OH)—; Y is hydrogen; R¹ isR¹⁰-substituted or unsubstituted alkyl, R¹⁰-substituted or unsubstitutedcycloalkyl, R¹⁰-substituted or unsubstituted aryl, or R¹⁰-substituted orunsubstituted heteroaryl; R¹⁰ is hydrogen, halogen, —N₃, —CF₃, —CCl₃,—CBr₃, —Cl₃, —CN, —CHO, —OR^(10A), —NR^(10B)R^(10C), —COOR^(10A),—C(O)NR^(10B)R^(10C), —NO₂, —S(O)_(n10)R^(10B), —S(O)_(n10)OR^(10B),—S(O)_(n10)NR^(10B)R^(10C), —NHNR^(10B)R^(10C), —ONR^(10B)R^(10C),—NHC(O)NHNR^(10B)R^(10C), R¹³-substituted or unsubstituted alkyl,R¹³-substituted or unsubstituted heteroalkyl, R¹³-substituted orunsubstituted cycloalkyl, R¹³-substituted or unsubstitutedheterocycloalkyl, R¹³-substituted or unsubstituted aryl, orR^(u)-substituted or unsubstituted heteroaryl; R¹³ is halogen, —N₃,—NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂, —COOH, —CONH₂, —SH,—SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂,R¹⁴-substituted or unsubstituted alkyl, R¹⁴-substituted or unsubstitutedheteroalkyl, R¹⁴-substituted or unsubstituted cycloalkyl,R¹⁴-substituted or unsubstituted heterocycloalkyl, R¹⁴-substituted orunsubstituted aryl, or R¹⁴-substituted or unsubstituted heteroary; R¹⁴is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂, —COOH,—CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂,R¹⁵-substituted or unsubstituted alkyl, R¹⁵-substituted or unsubstitutedheteroalkyl, R¹⁵-substituted or unsubstituted cycloalkyl,R¹⁵-substituted or unsubstituted heterocycloalkyl, R¹⁵-substituted orunsubstituted aryl, or R¹⁵-substituted or unsubstituted heteroaryl; R¹⁵is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂, —COOH,—CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂,R¹⁶-substituted or unsubstituted alkyl, R¹⁶-substituted or unsubstitutedheteroalkyl, R¹⁶-substituted or unsubstituted cycloalkyl,R¹⁶-substituted or unsubstituted heterocycloalkyl, R¹⁶-substituted orunsubstituted aryl, or R¹⁶-substituted or unsubstituted heteroaryl; R¹⁶is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂, —COOH,—CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂,R¹⁴-substituted or unsubstituted alkyl, unsubstituted heteroalkyl,unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstitutedaryl, or unsubstituted heteroaryl; R² is R¹⁷-substituted orunsubstituted alkyl, R¹⁷-substituted or unsubstituted aryl, orR¹⁷-substituted or unsubstituted heteroaryl; R¹⁷ is independentlyhalogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(17A),—NR^(17B)R^(17C), —COOR^(17A), —C(O)NR^(17B)R^(17C), —SR^(17D),—S(O)_(n17)R^(17B), —S(O)_(m17)OR^(17B), —S(O)_(n17)NR^(17B)R^(17C),—NHNR^(17B)R^(17C), —ONR^(17B)R^(17C), —NHC(O)NHNR^(17B)R^(17C),R¹⁸-substituted or unsubstituted alkyl, R¹⁸-substituted or unsubstitutedheteroalkyl, R¹⁸-substituted or unsubstituted cycloalkyl,R¹⁸-substituted or unsubstituted heterocycloalkyl, R¹⁸-substituted orunsubstituted aryl, or R¹⁸-substituted or unsubstituted heteroaryl; R¹⁸is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂, —COOH,—CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂,R¹⁹-substituted or unsubstituted alkyl, R¹⁹-substituted or unsubstitutedheteroalkyl, R¹⁹-substituted or unsubstituted cycloalkyl,R¹⁹-substituted or unsubstituted heterocycloalkyl, R¹⁹-substituted orunsubstituted aryl, or R¹⁹-substituted or unsubstituted heteroaryl; R¹⁹is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂, —COOH,—CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂,R²⁰-substituted or unsubstituted alkyl, R²⁰-substituted or unsubstitutedheteroalkyl, R²⁰-substituted or unsubstituted cycloalkyl,R²⁰-substituted or unsubstituted heterocycloalkyl, R²⁰-substituted orunsubstituted aryl, or R²⁰-substituted or unsubstituted heteroaryl; R²⁰is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —OH, —NH₂, —COOH,—CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂, —ONH₂, —OCH₃, —NHC(O)NHNH₂,unsubstituted alkyl, unsubstituted heteroalkyl, unsubstitutedcycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, orunsubstituted heteroaryl; R³ is hydrogen or R²¹-substituted orunsubstituted alkyl; R²¹ is is halogen, —N₃, —NO₂, —CF₃, —CCl₃, —CBr₃,—CI₃, —CN, —OH, —NH₂, —COOH, —CONH₂, —SH, —SO₃H, —SO₄H, —SO₂NH₂, —NHNH₂,—ONH₂, —OCH₃, —NHC(O)NHNH₂, unsubstituted alkyl, unsubstitutedheteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl,unsubstituted aryl, or unsubstituted heteroaryl; R⁵ is hydrogen, orunsubstituted alkyl; R⁶ is halogen, or unsubstituted alkyl; R^(10A),R^(10B), R^(10C), and R^(10D), are independently hydrogen,R¹³-substituted or unsubstituted alkyl, R¹³-substituted or unsubstitutedheteroalkyl, R¹³-substituted or unsubstituted cycloalkyl,R¹³-substituted or unsubstituted heterocycloalkyl, R¹³-substituted orunsubstituted aryl, or R¹³-substituted or unsubstituted heteroaryl;R^(17A), R^(17B), R^(17C), or R^(17D) are independently hydrogen,R¹⁸-substituted or unsubstituted alkyl, R¹⁸-substituted or unsubstitutedheteroalkyl, R¹⁸-substituted or unsubstituted cycloalkyl,R¹⁸-substituted or unsubstituted heterocycloalkyl, R¹⁸-substituted orunsubstituted aryl, or R¹⁸-substituted or unsubstituted heteroaryl; n10and n17 are independently 1 or 2; and wherein if X is —C(O)— and R¹ isunsubstituted phenyl, then R² is not methyl, p-substituted orunsubstituted phenyl, or unsubstituted pyridine.
 2. The method of claim1, wherein X is —C(O)—.
 3. The method of claim 1, wherein R¹ isR¹⁰-substituted or unsubstituted alkyl, R¹⁰-substituted or unsubstitutedaryl or R¹⁰-substituted or unsubstituted heteroaryl; wherein R¹⁰ isindependently hydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN,—CHO, —OR^(10A), substituted or unsubstituted alkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl; and R^(10A) is independentlyhydrogen or unsubstituted alkyl.
 4. The method of claim 3, wherein R¹ isR¹⁰-substituted or unsubstituted alkyl, R¹⁰-substituted or unsubstitutedaryl or R¹⁰-substituted or unsubstituted heteroaryl; wherein R¹⁰ isindependently halogen, —CF₃, —OR^(10A), substituted or unsubstitutedC₁-C₅-alkyl or substituted or unsubstituted aryl; and R^(10A) ishydrogen or methyl.
 5. The method of claim 1, wherein R² is hydrogen,R¹⁷-substituted or unsubstituted alkyl or R¹⁷-substituted orunsubstituted aryl, wherein R¹⁷ is independently halogen, —CF₃,—OR^(17A), or unsubstituted C₁-C₅-alkyl; and R^(17A) is hydrogen orunsubstituted C₁-C₅-alkyl.
 6. The method of claim 1, wherein R³ ishydrogen, halogen, —N₃, —CF₃, —CCl₃, —CBr₃, —CI₃, —CN, —CHO, —OR^(3A),or R²¹-substituted or unsubstituted alkyl, wherein R^(3A) is hydrogen orunsubstituted C₁-C₅ alkyl; and R²¹ is hydrogen or substituted orunsubstituted C₁-C₅ alkyl.
 7. The method of claim 6, wherein R³ ishydrogen, halogen, —CF₃, —OH, or substituted or unsubstituted alkyl. 8.The method of claim 1, wherein R⁵ is hydrogen or methyl.
 9. The methodof claim 1, wherein R⁶ is unsubstituted C₁-C₅ alkyl.
 10. The method ofclaim 1, wherein the compound is: